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4Abstract
The prevalence of insulin resistant syndromes is rising worldwide. Affected
individuals are at increased risk of morbidity and premature mortality, much
of which is driven by cardiovascular disease (CVD). Enhancement of
vascular regeneration, using pharmacological or cell-based therapies, has
been suggested as a strategy to help address these issues. Although many
pathophysiological processes associated with insulin resistant syndromes
are likely to impair vascular regeneration, the effect of insulin resistance per
se is not established.
South Asian (SA) ethnicity is associated with increased risk of CVD, and
insulin resistance is thought to be a major contributor to this. We compared
the angiogenic capacity of late outgrowth endothelial progenitor cells
(LEPCs) from young SA men, with those from a matched group white
European (WE) men. LEPC have previously been shown to offer potential as
an autologous cell therapy in preclinical models of ischaemic CVD. Both
groups were well matched, and free of classical cardiovascular risk factors,
but the SA group were relatively insulin resistant. SA LEPCs did not augment
vascular regeneration in a murine model of limb ischaemia, in contrast with
WE LEPC. Akt activity, a critical modulator of angiogenesis, was reduced in
SA LEPC, and we were able to rescue SA LEPC dysfunction by enhancing
Akt activity.
We then established the impact of insulin resistance per se on vascular
regeneration, using insulin receptor haploinsufficient mice (IRKO). Indices of
angiogenesis were reduced in isolated endothelial cells, aortic ring
5segments, and ischaemic hind limb muscle. Moreover, this was associated
with functional resistance to vascular endothelial growth factor (VEGF),
which may have mechanistically contributed to our observations.
Together, these data provide insight into how insulin resistance may promote
the development of premature CVD, and show that by manipulating key
growth factor signalling nodes, we can rescue impaired vascular
regeneration. Furthermore, we have established that insulin resistance
negatively impacts on the functional response to VEGF, and it will be
important to explore the mechanisms underlying this phenomenon in future
studies. It is hoped that these findings will help lead to the development of
strategies to mitigate the effects of CVD in individuals with insulin resistance.
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Chapter 1. Introduction
‘Insulin resistance’ is the impaired response to the metabolic actions of the
glucose lowering hormone, insulin, and plays a central role in a number of
overlapping clinical syndromes including obesity, pre-diabetes and diabetes
mellitus (DM). DM represents a major global health burden with an estimated
170 million individuals affected worldwide in the year 2000. There has been a
rapid rise in the prevalence of this disorder and estimates suggest that
increasing levels of obesity, coupled with an aging population, mean that the
number of people affected will continue to rise, and at least double by 2030
[1]. DM and its complications cause significant morbidity, with the potential
for patients to experience debilitating eye disease, peripheral vascular
disease (PVD), chronic kidney disease (CKD) and coronary artery disease
(CAD). Besides the complications that can significantly impact on a patient’s
quality of life, it has been established that DM is associated with premature
death. Population studies have demonstrated an increased risk of mortality
for nearly all causes of death in patients with DM, and there is therefore a
significant reduction in life expectancy [2, 3].
Cardiovascular disease is responsible for much of this excess mortality, with
major vascular events occurring in patients with DM approximately 15 years
prior to those without DM [2, 4]. In patients with established cardiovascular
disease, DM is an important independent risk factor for adverse outcomes
[5]. Preceding the onset of DM (heralded by sustained hyperglycaemia),
there is a well recognised ‘pre-diabetic’ period. This is typically characterised
by insulin resistance that can manifest clinically as impaired fasting
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glycaemia (IFG) or impaired glucose tolerance (IGT). Importantly, patients
exhibiting IFG or IGT have also been shown to experience increased
cardiovascular mortality [6]. Abnormal glucose handling (IGT, IFG and DM) is
associated, and commonly occurs in conjunction with, a cluster of classical
cardiovascular (CV) risk factors. Despite advances in the treatment for the
conditions that occur as part of this insulin resistant phenotype, such as
hypertension and dyslipidaemia, mortality remains disproportionately high in
patients with IFG, IGT and DM [7, 8]. Observations of trends in CV disease in
clinical practice show that the proportion of patients who experience CV
events with DM is increasing and these patients have double the mortality of
those without DM [5, 9]. Insulin resistance, and potentially treatments for this,
have been mooted as both the explanation for this increased risk, and also a
possible avenue by which CV mortality discrepancies between patients with
and without DM could be addressed.
The principle factor underlying the increased vascular risk associated with
pre-diabetes and DM is atherosclerosis. Atherosclerosis is a condition
characterised by arterial inflammation and lipid deposition, which over time
will progress, causing luminal obstruction of the affected vessel. These
atherosclerotic lesions are covered by a fibrous cap, which partitions the
thrombogenic material contained within from the circulation. In the case of
‘plaque rupture’ this fibrous cap is disrupted, triggering a cascade of platelet
aggregation, thrombus formation and acute luminal obstruction that
ultimately leads to major cardiovascular events. These events are defined by
the site of vascular compromise; in the cerebral circulation these processes
25
may result in a stroke, in the heart it may cause myocardial infarction, and in
the peripheral arterial circulation there may be limb ischaemia. A key
initiating step in the development of atherosclerosis is endothelial
dysfunction, which is manifested as a reduction in the bioavailability of nitric
oxide (NO). NO, which has a portfolio of anti-atherosclerotic properties [10],
is produced in the vascular endothelium and plays a crucial homeostatic role.
Human studies have demonstrated a correlation between insulin resistance
and endothelial dysfunction [11, 12]. NO production in the endothelium can
be triggered by the actions of insulin via signalling cascades similar to those
that result in glucose uptake in metabolic tissues. This therefore provides a
mechanistic link between endothelial dysfunction and metabolic insulin
resistance [13].
Endogenous vascular repair and regeneration is a process by which the
effects of endothelial injury and atherosclerosis may be mitigated.
Considering the prevalence of ischaemic disorders in patients with insulin
resistant disorders, advancing our understanding of how insulin resistance
impacts upon these autologous repair mechanisms is important. Ultimately,
this may lead to the identification of novel therapeutic targets, with the
potential to retard disease progression or revascularise ischaemic tissue.
This thesis will investigate how modified insulin signalling, and insulin
resistance, impact upon vascular regeneration.
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1.1 Insulin signalling
Insulin signals via binding its cognate tyrosine kinase receptor (IR). This is an
atypical tyrosine kinase in the sense that it exists as a homodimer, and binds
its ligand to induce autophosphorylation, as opposed to typical tyrosine
kinase receptors in which ligand binding triggers dimerisation and activation
[14]. Insulin receptor phosphorylation brings about recruitment and
subsequent tyrosine phosphorylation of docking proteins, including insulin
receptor substrates-1 and 2 (IRS-1 and IRS-2). Insulin signal transduction is
a complex process activating many cascades, with multiple regulatory
feedback loops, and cross talk with other receptor signalling pathways. A
number of downstream molecules have been shown to bind to IRS in
response to insulin stimulation, but for the sake of simplicity it is helpful to
consider the two principle signalling cascades: the PI3-kinase pathway and
the ERK MAP-kinase pathway.
Phosphorylated IRS binds the regulatory p85 subunit of PI3-kinase via its
SH2 domain, allowing activation of the p110 catalytic subunit. This results in
increased phosphatidylinositol 3-phosphate (PIP3) production, which is
localised in the plasma membrane. Akt then localises to the plasma
membrane, via interaction of its plekstrin homology domain with PIP3, and is
partially activated by threonine 308 phosphorylation by phosphoinositide
dependant protein kinase 1 (PDK1), which is itself activated by PIP3. Full
activation of Akt occurs after additional serine 473 phosphorylation by the
mTORC2 complex. In the classical metabolic tissues this cascade then
results in GLUT4 translocation to the cell membrane, consequently
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increasing glucose disposal into the cell. In vascular endothelium it results in
endothelial nitric oxide synthase (eNOS) activation, and nitric oxide (NO)
production [15]. Other signal transducing proteins interact with IRS, including
Grb2. This leads to a signalling cascade resulting in MAP kinase activation
and this pathway mediates the mitogenic actions of insulin [16].
1.1.1 Mechanisms of insulin resistance
The epidemic of insulin resistant syndromes, such as the metabolic
syndrome and type 2 DM are clearly linked with obesity, and indeed some of
the mechanisms responsible for insulin resistance are thought to relate to
adiposity and effects that this can have on intracellular lipids, their
metabolites, as well the accompanying environment of hyperglycaemia and
chronic, low grade inflammation. Murine models have helped elucidate the
effect that accumulation of lipid has in certain tissues. Mice with tissue
specific (muscle and liver) over-expression of lipoprotein lipase have
increased muscle and liver triglyceride content and consequently are insulin
resistant [17]. For instance, in skeletal muscle, where insulin resistance
ultimately leads to impaired glucose disposal, it has been shown that
diacylglycerols (DAG), a breakdown product of triglycerides, activate protein
kinase C isoforms. This in turn leads to serine phosphorylation of the insulin
receptor substrate 1 (IRS-1), which may have an inhibitory effect on signal
transduction by interfering with the tyrosine phosphorylation of IRS-1, which
in turn reduces PI3-kinase activity, and its downstream effects [18-20]. It has
also been shown that intramuscular levels of diacylglycerol (DAG) are higher
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in obese and diabetic subjects compared with lean individuals. There is also
a correlation between intramyocellular DAG and insulin resistance [21, 22].
Insulin resistance progresses after the onset of frank diabetes and this can
be partially attributed to the effects of sustained hyperglycaemia. This occurs
due to the molecular effects of advanced glycation end products (AGEs) and
oxidative stress, both of which are manifestations of hyperglycaemia.
Although precise mechanisms are not yet clear, hyperglycaemia has been
shown to increase reactive oxygen species (ROS) production, which in turn
can cause insulin resistance. The mechanisms by which ROS induce insulin
resistance are multiple and include the activation of serine/threonine kinases
c-Jun NH 2-terminal kinase (JNK), PKCs, and IĸB kinase complex ß (IKKß). 
These kinases induce serine phosphorylation of IRS-1, which reduces the
downstream activity of PI3-K/Akt and ultimately reduces GLUT4 translocation
[23-25]. This oxidative stress also leads to the activation of nuclear factor
(NF)-ĸB [26] and this complex of transcription factors regulates a host of 
inflammatory signalling pathways, most of which have been shown to induce
insulin resistance [27]. Hyperglycaemia increases the production of
advanced glycation end products (AGEs) [26], which induce insulin
resistance by inducing inhibitory phosphorylation of IRS-1 and IRS-2, thereby
reducing Akt/PI3-k signalling [28]. AGEs also increase oxidative stress [29],
which as outlined, induces insulin resistance. Hyperinsulinaemia has also
been shown to exacerbate insulin resistance and in vitro studies have shown
that insulin reduces IRS1 and IRS2 abundance via PI3-K/Akt signalling [30].
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Substances released from adipose tissue, including adipokines and
inflammatory mediators, have also been implicated in insulin resistance. For
example, tumour necrosis factor (TNF)-alpha, is released from visceral
adipose deposits, and studies in leptin deficient ob/ob mice crossed with
TNF-alpha deficient mice highlight this role for TNF-alpha in insulin
resistance. These leptin deficient/TNF-alpha deficient mice had rescued
insulin sensitivity in muscle and fat tissues [31]. Mechanistic insight is
provided by further studies in leptin deficient mice, which demonstrate that
increased levels of TNF-alpha result in up regulation of suppressor of
cytokine signalling proteins (SOCS), which interferes with the association of
IRS-1 and the p85 subunit of PI3-kinase by reducing IRS-1 tyrosine
phosphorylation.
This brief discussion highlights some of the mechanisms responsible for
insulin resistance and also serves to demonstrate that the pathways involved
are numerous and complex. It also highlights pathways and signalling nodes
that are commonly implicated, such as the insulin receptor and its substrates,
Akt and PI3-K. Although the balance of evidence suggest that defects at the
level of these critical signalling nodes are likely to be significant with regards
insulin resistance, it is important to note that conflicting data exists. For
example, experiments utilising in vitro models of insulin resistance to mimic
conditions described above suggest that aberrant signalling at the IR/IRS
level may not be so critical. Hoehn et al experimentally mimicked insulin
resistance in vitro using lipotoxicity, inflammation and hyperinsulinaemia
models, and found that platelet derived growth factor (PDGF) signalling was
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also impaired. This an important observation as PDGF bypasses the IRS
node, and therefore suggests that modifications to the insulin signalling
cascade below the IRS node are more important [32].
The origins of cellular insulin resistance have also been challenged in other
ways, with some authors suggesting that insulin resistance is, in fact,
necessary to protect the cell from further oxidative damage when nutrients
are in oversupply [33].
The mechanisms that result in perturbed insulin signalling and insulin
resistance remain debated, and the preceding explanation offers just a few
putative mechanisms; unfortunately, a complete review is beyond the scope
of this introduction. However, it does highlight that there is unlikely to be one
pathophysiological defect in insulin signalling responsible for the insulin
resistance seen clinically, but rather multi-level signalling defects.
Figure 1-1. Multiple facets of the
in the underlying mechanism of insulin resistance. Dyslipidaemia and
elevation in FFAs has been shown to induce a number of deleterious effects
on insulin signalling. Elevated levels of DAG leads to activation of PK
serine phosphorylation of IRS and decreased PI3
results in increased AGE and ROS production, which activate PKC, JNK,
IKKß and NFkB. This causes inhibitory phosphor
pro-inflammatory gene expression.
metabolic syndrome
as TNF, IL-6. These cause insulin resistance via SOCS3 and JNK. FFA
indicates free fatty acid; ROS, Reactive oxygen species; TNF, Tumour
necrosis factor; PKC, protein kinase C; JNK, c
IKK, IkB-kinase; NFkB, Nuclear factor kB; IR, Insulin receptor; IRS, insulin
receptor substrate; PIP
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metabolic syndrome have been implicated
-K activity. Hyperglycaemia
ylation of IRS and promotes
Inflammation, a common feature of the
, is characterised by increased levels of cytokines such
-Jun amino
2, Phosphatidylinositol 4,5-bisphosphate; PIP
C,
-terminal kinase;
3,
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Phosphatidylinositol 3, 4,5-triphosphate; mTOR, mammalian target of
Rapamycin; IL, interleukin; PDK1, phosphoinositide dependent protein
kinase-1; GLUT4, glucose transporter type 4.
1.2 Vascular regeneration
1.2.1 Vasculogenesis
The process by which blood vessels form de novo in the embryo is termed
vasculogenesis. Endothelial progenitor cells, angioblasts, arising from
embryonic mesoderm coalesce to form the vasculature [34]. Vasculogenesis
is principally restricted to the early stages of vascular development.
However, there is evidence that circulating progenitor cells may enhance
vascular regeneration and these cells have been shown to incorporate into
neovessels, highlighting the potential for post-natal vasculogenesis. The
notion that, beyond embryogenesis, new blood vessel formation is an
angiogenesis dependent process was initially challenged by the work of Shi
et al. These authors observed endothelialisation in non-marginal regions of
Dacron grafts that had been implanted in the thoracic aortic region of dogs.
This was an interesting observation as, if endothelialisation is indeed entirely
dependant on local endothelial cell migration, re-endothelialisation should
occur from the margins inward. Shi et al concluded therefore, that circulating
cells must have contributed [35]. Following this, Asahara et al published
seminal work providing further support for circulating cells contributing to
postnatal vasculogenesis [36]. However, controversy remains, and there is
work from other groups that contest these and subsequently published data.
For example, work from Hagensen et al, demonstrates that flanking
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endothelial cells, rather than bone marrow derived cells, contribute to re-
endothelialisation in the setting of atherosclerosis, vessel injury and allograft
vasculopathy respectively [37-39]. The putative circulating vasculogenic cells
proposed to contribute to post-natal vasculogenesis will be discussed later in
greater detail.
1.2.2 Angiogenesis
Angiogenesis is a term commonly used to denote new vessel growth, but
actually describes the process by which vessels sprout or intussuscept from
the existing vasculature [40]. It is a complex process, requiring the
orchestration of numerous processes including pericyte detachment,
endothelial cell migration, proliferation, tubule formation, anastamosis, and
subsequent vessel maturation with the recruitment of mural cells. Disordered
angiogenesis is central to the pathogenesis of a number of diseases.
Inadequate vessel formation is implicated in ischaemic disorders such as
myocardial infarction, stroke and peripheral vascular disease. Excessive or
unregulated vessel growth is a hallmark of tumour growth, diabetic
retinopathy and age-related ‘wet’ maculopathy.
Figure 1-2. Schema demonstrating involvement of resident endothe
and circulating angiogenic cells in proposed models of neovascularisation.
1.2.2.1 Sprouting angiogenesis
Hypoxic tissues release growth factors and chemokines that initiate the
formation of new vessels from
supply and demand back to equilibrium. In the quiescent state
cells line blood vessels in a monolayer and are surrounded by a supporting
network of pericytes
multifunctional and help mainta
proliferation and producing molecules that aid endothelial cell survival. This
provides stability, and together the two layers of cells share a basement
membrane forming a sleeve that encloses endothelial tubules
preventing endothelial cell
oxygen, hypoxia inducible factors (HIFs) are regul
sensing prolyl hydroxylase domain 1
conditions, these PHDs hydrox
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the existing plexus in an effort to restore
and vascular smooth muscle cells. These pericytes are
in quiescence by suppressing
migration [41]. In the presence of abundant
ated by the oxygen
-3 (PHD1-3) proteins
ylate HIFs and thereby target them for
lial cells
, endothelial
endothelial
, thereby
. In physiological
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preoteolytic degradation. In hypoxic situations, however, levels of HIF rise
and production of the prototypical angiogenic molecule, VEGF, is stimulated
[42]. In response to increased VEGF production, pericytes detach from the
endothelial tube and the basement membrane is degraded by matrix
metalloproteases. VEGF also makes endothelial junctions ‘leaky’ allowing
extravasation of plasma proteins and the establishment of an extracellular
matrix and pro-angiogenic milieu [40]. Once this environment has developed,
one tip cell is ‘selected’ to lead the newly forming sprout. Endothelial cells at
the angiogenic front have an advantage in terms of differentiation to tip cells
as they are exposed to higher concentrations of VEGFA, which up regulates
cell surface Delta-like 4 (DLL4) expression, then triggering Notch activity in
neighbouring cells. Studies have recently demonstrated an important role for
the DLL4/Notch signalling pathway in the differentiation of endothelial cells
into either tip or stalk cells, with blockade of DLL4 or Notch leading to
excessive sprouting and tip cell formation [43]. This suggests that the tip cell
phenotype is the default endothelial response to angiogenic stimuli. Notch
signalling in cells neighbouring those at the tip alters gene expression,
promoting the proliferative stalk cell phenotype, thereby leading to elongation
of the endothelial sprout [40]. Tip cells, under the influence of VEGF,
produce long, dynamic filopodia that have within them an abundance of
VEGFR2, and are capable of responding to directional cues. Stalk cells do
not produce filopodia and proliferate in response to VEGFA [44]. These
processes will continue until a vascular network is formed allowing the flow of
blood and consequently the resolution of hypoxia. It is important to note that
a properly functioning vessel requires not only a perfused vascular tube, but
also a plethora of supporting mural cells, including pericytes and vascular
smooth muscle cells. Endothelial cells actively partaking in angiogenesis
release platelet derived growth factor B (PDGF
receptor B expressing
process to vascular development is highlighted in animal studies
genetic ablation of PDGF
aneurysm formation and lethal bleeding in the late
Figure 1-3. Schema
angiogenic front are studded with VE
VEGFA, have higher levels of VEGFR2 activity, thereby upregulating DLL4
and inducing Notch signalling in neighbouring cells
in a number of transcriptional changes, including upregulation of VEGFR1
and downregulation of VEFR2/3, and this assigns the cell to a stalk cell fate.
Tip cells are characterised by high levels of DLL4 production and low levels
of Notch signalling. Stalk cells have lower levels of DLL4 production and
36
-B) and this attracts PDGF
(PDGF-B+) pericytes [45, 46]. The importance of this
-B in mice leading to vessel leakage, micro
embryonic
highlighting tip/stalk cell selection. Filopodia at the
GFR2. Cells exposed to higher levels of
. Notch signalling results
, with
-
stage [46].
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higher levels of Notch signalling. Tip/stalk cell fate are dynamic however and
alter according to changes in the described signalling pathways.
1.2.3 VEGF
As highlighted in the preceding discussion, vascular endothelial growth factor
(VEGF) plays a central role in the processes required to bring about
angiogenesis. The following discussion will expand on VEGF and its actions
in relation to neovascularisation. The VEGF family consists of 5 related
growth factors: VEGFA or vascular permeability factor (VPF), VEGFB,
VEGFC, VEGFD and placental growth factor (PlGF) [47-51]. All 5 of the
human VEGF proteins can be spliced to form multiple isoforms. VEGFA, the
first to be discovered, is thought to be the principal growth factor involved in
angiogenesis. It’s production is sensitive to hypoxia inducible factor (HIF)
and can be produced by almost any cell, including endothelial cells in both
healthy and disease states [52, 53].
The family of VEGFs exert their effects via binding to their cognate tyrosine
kinase receptors. Principally, VEGFR1 (or FLT1), VEFGR2 (or FLK1 in the
mouse, and KDR in the human) and VEGFR3 (or FLT4) [54-56]. VEGFA, -B
and PlGF bind to VEGFR1, VEGFA binds to VEGFR2, and VEGFC and D
bind to VEGFR3 [57]. The effects of VEGFs are multiple and complex. They
share many similar regulatory functions such as cell survival, proliferation
and migration with other growth factors, including platelet derived growth
factor (PDGF) and epidermal growth factor (EGF) [57]. In other respects
however, they are unique, as they are able to transmit signals that bring
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about angiogenesis and regulate vascular permeability. VEGFR1 is a
regulator of macrophage and monocyte migration; its role in the endothelium
is more controversial, as is discussed later. VEGFR2 is important in all
aspects of endothelial cell biology, and VEGFR3 is important in lymphatic
and endothelial cell development, along with tip cell activity in all sprouting
endothelial cells [57, 58].
The main biological actions of VEGFA are its ability to stimulate endothelial
cell migration and proliferation [59-61], and to increase vascular permeability
[47, 62]. VEGFA exists in at least 9 nine different isoforms that are brought
about by alternate splicing of the VEGFA gene. These are VEGF121,
VEGF145, VEGF148, VEGF162, VEGF165, VEGF165b, VEGF183, VEGF189 and
VEGF206 [63, 64]. VEGF165b is an endogenous isoform that exerts an
inhibitory effect on VEGFR2 and does not trigger the intracellular signalling
cascade. This splicing affects the ability of certain isoforms to bind to
heparan sulphate and neuropilins (discussed later), and also dictates their
solubility and temporo-spatial distribution [65].
1.2.4 VEGF signalling
There are three structurally related VEGF receptor tyrosine kinases found in
humans - VEGFR1, VEGFR2 and VEGFR3. These VEGF receptors all share
a similar structure with an extracellular, ligand-binding domain composed of
immunoglobulin-like loops, a transmembrane domain, a juxtamembrane
domain, a split tyrosine kinase domain, and a c-terminal tail [66]. Binding of
VEGF to its receptor tyrosine kinase occurs at the N-terminal part of the
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extracellular domain. This ligand binding can occur by freely diffusible VEGF,
and also by the presentation of VEGF whilst bound to a co-receptor [66].
These co-receptors, chiefly Heparan Sulphate (HS) and Neuropilins 1 and 2
(NRP1, NRP2), can modulate VEGF action in several ways. For instance,
HS binding to various VEGFA isoforms impacts on solubility, signalling
amplitude and duration as wells as acting as a ‘reservoir’ for VEGFA and can
aid in the creation of VEGF gradients, important to processes such as
endothelial cell migration. NRP1 modulates VEGFR signalling and enhances
endothelial cell migration and survival. Although molecular mechanisms are
not fully understood, it is clear that these co-receptors play a crucial role in
vascular development. Murine models with over- and under-expression of
NRP1 are not viable, with embryonic lethality due to vascular abnormality
observed at E12.5-13.5 [67, 68]. The knockout of NRP2 seems to have
greater impact on small capillary and lymphatic development, whereas
arterial and venous development is preserved [69].
1.2.4.1 VEGFR1
VEGFR1 expression is abundant in vascular endothelial cells, monocytes,
macrophages, vascular smooth cells and many other cell types. VEGFR1
binds VEGFA with higher affinity than VEGFR2, but this induces weak
tyrosine kinase activity only [66]. The exact role for VEGFR1 in endothelial
cells is disputed, but animal models have helped elucidate its role. Mice with
holoinsufficiency of VEGFR1 (VEGFR1-/-) experience embryonic lethality at
E9. This is due to increased proliferation of endothelial cells, and severe
disorganisation of the vascular system [70]. However, targeted deletion of
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the intracellular domain of VEGFR1, rather than the whole receptor, is
compatible with vascular development [70]. This supports the notion that
VEGFR1 acts as a ‘reservoir’ to reduce VEGFA activity, and plays an
important regulatory role in tip cell selection via its Notch dependent
upregulation in stalk cells [71]. In addition to this negative regulatory role in
angiogenesis, VEGFR1 is important in mounting immune responses and
inflammatory angiogenesis. Mice expressing tyrosine kinase deficient
VEGFR1 (VEGFR TK-/-) exhibit impaired angiogenesis in a number of
pathological conditions, including malignancy [72] and cerebral ischaemia
[73].
1.2.4.2 VEGFR2
VEGFR2, is also known as the kinase insert domain receptor (KDR) in
humans, and foetal liver kinase-1 (Flk-1) in mice. Although primarily
expressed in vascular endothelial cells, this is not exclusive and it is also
found in pancreatic duct cells, retinal progenitor cells, megakaryocytes and
haematopoietic cells. Its expression is greatest during periods of active
angiogenesis, such as during development, in the uterus during the
menstrual cycle, and in tumour cells during cancer growth. The majority of its
angiogenic actions are as a result of binding with VEGFA, but it also binds
processed forms of VEGFC and VEGFD[66]. It binds VEGFA with 10 fold
less affinity compared with VEGFR1. VEGFR2 signal transduction mediates
all the processes required for vascular development and regeneration, such
as proliferation, migration, survival and permeability. Signalling cascades
activated by VEGFR2 are numerous and complex. Upon binding of VEGFA,
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secondary signalling molecules attach at their respective tyrosine
phosphorylation sites on VEGFR2 and this results in the activation of
downstream mediators, which include phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3-K), mitogen-activated protein kinase (MAPK) and protein
kinase C (PKC) [66]. The importance of VEGFR2 in angiogenesis and
vascular development has been highlighted in animal models. Mice
holoinsufficient for Flk-1 (Flk-1-/-) die at E8.5-9.5 due to a failure of
development of vasculature and haematopoietic progenitors, therefore
indicating the crucial role of VEGFR2 in vasculogenesis [74]. Other models
with more targeted manipulation of VEGFR2 reveal important tyrosine
phosphorylation sites; for example, mice with a phosphorylation resistant
mutation affecting tyrosine 1173 have a similar phenotype to Flk-1-/- mice
[75]. A complete review of the VEGFR2 action and signalling is beyond the
scope of this introduction; for an excellent review see Koch et al [66].
1.2.4.3 VEGFR3
VEGFR3, or Flt4 in the mouse, seems to be important in lymphatic cell
development and this is highlighted in patients with hereditary lymphoedema,
who carry mutations in VEGFR3. A point mutation in VEGFR3 rendering the
kinase inactive results in the Chy mouse, which develops chylous ascites
[66]. It also appears to play a crucial role in blood vessel development
however, perhaps via heterodimerisation with VEGFR2, or binding of VEGFC
and thereby modulating VEGFR2. This role has been revealed, again, via
genetic studies. Mice holoinsufficient for VEGFR3 (Flt4-/-) die at E10.5 due to
failure of vascular development [76], whereas mice with knockout of VEGFC
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and VEGFD, the main ligands for VEGFR3, retain normal blood vessel
development [77]. The importance of VEGFR3 to the angiogenic process has
been reinforced with recent work suggesting a critical role in tip cell function,
independent of its canonical ligand binding function [58].
1.3 Endothelial progenitor cells
Although, vascular regeneration is the primary concern of this project, there
is a complex overlap with the process of vascular repair. Vascular repair is a
term generally used to denote the process by which re-endothelialisation of
injured vessels occurs. Important in maintaining vascular homeostasis,
vascular repair occurs following endothelial injury from direct trauma incurred
during clinically relevant procedures such as arterial stenting, and also injury
from pathological processes, including atherosclerosis. Until recently it has
been generally accepted that all endothelial repair occurs via the migration of
adjacent, resident healthy endothelial cells, and indeed there is a body of
work that would appear to corroborate this [37-39]. This paradigm, however,
is not entirely accepted and there is data to suggest that bone marrow
derived progenitor cells do incorporate into areas of injured vascular
endothelium [78]. Work published by Asahara et al gave new weight to the
consideration that vascular repair could be aided by circulating endothelial
precursors in a process akin to postnatal vasculogenesis. They described
‘putative progenitor cells’, which were derived after ex vivo expansion of
human peripheral blood mononuclear cells expressing the haematopoietic
stem cell marker CD34. These cells, or those expressing the VEGF receptor
2 (KDR/Flk-1), augmented angiogenesis in rabbit and murine models of
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hindlimb ischaemia. Furthermore, these infused cells were found to
incorporate into capillary like structures when tissue was harvested after six
weeks [36]. These data have been extrapolated to suggest that such
circulating cells, co-expressing CD34 and KDR, represent ‘endothelial
progenitor cells’ capable of augmenting vascular repair and regeneration
[79]. However, it is known that mature endothelial cells, which might also be
expected to express these markers, can be shed from the vessel wall in to
the circulation. In light of this, circulating CD133+/CD34+/KDR+ have been
proposed to more accurately represent endothelial progenitor/precursor
populations [80]. Although there is no doubt that the relative abundance of
these cells correlates independently with vascular risk [81], it is not clear
exactly what role these cells have in vivo. For these reasons, this population
of cells are better referred to as ‘circulating progenitor cells’ or CPCs.
1.3.1 CPC biology
Until recently, it has been the generally accepted dogma that blood vessel
development occurs via distinct mechanisms, depending on the stage of
development. In utero, new blood vessels are derived via a process termed
vasculogenesis, which involves the coalescing of angioblasts to form new
vessels. After birth, to meet the demands of growth and pathological
processes, it has long been thought that native endothelial cells divide and
migrate to form new vessels. The seminal work of Asahara has led to a
paradigm shift and the consideration of a role for circulating progenitor cells
in post-natal vasculogenesis. It is thought that these bone marrow derived
cells respond to stimuli that trigger mobilisation from the bone marrow and
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migrate to sites of vascular injury, hypoxia and inflammation. Here they may
have a pro-angiogenic action via the secretion of mediators that promote
neovascularisation, as well as acting as ‘building blocks’ to form new
endothelial cells, aiding vessel growth.
The mobilisation of CPCs is triggered by processes such as ischaemia and
inflammation. Growth factors, including vascular endothelial growth factor
(VEGF) and stromal derived cell factor (SDF), released by ischaemic tissue,
lead to up-regulation of eNOS activity in bone marrow stromal cells [82],
which in turn increase MMP-9 activity and results in the cleavage of c-kit
ligand, which releases CPCs from the osteoblastic region to the vascular
zone [83]. The CPCs then respond to chemotactic stimuli, via receptors such
as VEGFR2 and CXCR-4, and home to sites of ischaemia [84] where they
facilitate vascular repair and regeneration [85, 86] possibly by direct
incorporation into the endothelium [78], or via paracrine effects.
Figure 1-4. Schema demonstrating mobilisation of CPCs from bone marrow.
Ischaemic tissue produces growth factors such as VEGF and SDF, which
upregulates eNOS
activity and the cleavage of cKit ligand. This releases the CPC to the
vascular zone, and from here it
Abbreviations: VEGF; Vascular endothelial growth factor, SDF; Stromal
derived factor, MMP; Matrix metalloproteinase, CPC; Circulating progenitor
cell.
1.3.2 EPC classification
The in vivo study of circulating progenitor cells is difficult
and there is still no universally accepted definition of what constitutes a
circulating endothelial progenitor cell, or even whether such a lineage exists.
Based on extrapolation of
initially defined as cells co
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activity in the bone marrow. In turn, this induces MMP
localises to the area of ischaemia.
due to their rarity,
Asahara’s initial work, circulating ‘EPCs’ were
-expressing endothelial and haematopoietic cell
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surface markers, namely CD34, CD133 and VEGFR2. The problem with this
definition is that none of these markers are restricted to such ‘EPCs’ and are
variously expressed by mature endothelium, and haematopoietic
stem/progenitor cells [87]. Because of these difficulties, and the low
abundance of circulating progenitors, studies of these cells with regards their
effect on vascular repair, relies on ex vivo expansion of circulating cells. This
results in an entirely different population, generally referred to as EPCs.
The study of EPCs involves cell culture based manipulation of circulating
peripheral blood mononuclear cells (PBMCs). The term EPC can refer to
more than one cell type, and by culturing PBMCs in specific cell culture
media, three distinct cell types have been described. ‘Early outgrowth
endothelial progenitor cells’ or EEPCs refers to two cell populations. If
PBMCs are plated and cultured for approximately four days this gives rise to
so called ‘circulating angiogenic cells’ or CACs. These spindle shaped cells
are capable of augmenting vascular repair and angiogenesis, but have a
limited proliferative capacity and do not incorporate directly into vascular
structures [88]. Methods to identify and define these cells include
assessment of the capacity of cultured cells to absorb acylated LDL and bind
Ulex europaeus agglutinin-1 lectin (UEA-1). This method is fraught with
limitations due to the fact that monocytes (present abundantly in PBMCs)
also absorb acylated LDL and bind UEA-1. Furthermore, platelets
contaminating the mononuclear fraction release platelet fragments
expressing non-specific endothelial markers, such as CD31, which can be
phagocytosed (and then pseudo-expressed) by monocytes [89]. Flow
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cytometric analysis can also be used to identify cell surface markers (such as
CD31) but many of these are not endothelial-specific [87]. It is now widely
accepted that this subset of EEPCs are indeed of monocytic lineage.
Nevertheless, much work has shown that these cells promote vascular
regeneration, for example in murine models of critical limb ischaemia [90].
Any effect they have on vascular repair and regeneration is considered to be
as a result of paracrine action [87], consistent with data demonstrating that
EEPCs release an array of pro-angiogenic growth factors, including VEGFA,
VEGFB, IGF-1 and SDF-1 [91].
If initially non-adherent PBMCs are cultured for approximately four to nine
days, a population of cells form colonies. These cells are called ‘colony
forming unit – Hill cells or CFU-Hill cells. Although CFU-Hill cells express
endothelial markers, and the abundance of these colonies has been to
shown to correlate with Framingham risk score [92], and they can enhance in
vitro angiogenesis[93], it has been demonstrated that these cells are in fact
T-lymphocytes [94, 95]. These CFU clusters have a gene expression profile
indistinguishable from CACs [87], do not directly form blood vessels in vivo,
and in keeping with their leukocytic lineage, possess non-endothelial
functional characteristics [96].
If PBMCs are subjected to more prolonged culture over seven to twenty-one
days, colonies of ‘late outgrowth endothelial progenitor cells’ (LEPCs), also
referred to as outgrowth endothelial cells, are seen to develop [93]. These
cells from tubules on Matrigel and directly contribute to blood vessels when
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implanted in vivo in collagen/fibronectin matrices [96]. They have also been
shown to incorporate into vascular endothelium in murine models of vascular
disease [93]. When considering their proliferative capacity, it has been
shown that cells within a LEPC colony display a heterogeneous mix of
proliferative capacity. Some single cells have low proliferative potential and
do not form secondary colonies when re-plated; others form small
aggregates of 2-50 cells, whilst others have high proliferative potential
forming colonies of >2000 cells [97]. These cells express endothelial markers
(CD31, CD141, CD105, CD146, CD144, VWF, Flk-1), but not leukocyte
markers (e.g. CD45 or CD14). They therefore possess the functional
features one may expect from an endothelial cell, together with a proliferative
capacity indicative of progenitor hierarchy. Therefore, LEPC possess many
of the properties one might expect an EPC to possess, and as such have
been mooted to have therapeutic potential [98].
Although the role and classification of ‘EPCs’ is still debated, experimental
data over the last 10-20 years have provided insight. It is generally accepted
that ‘early outgrowth EPCs’ do not incorporate long term into injured or newly
developing endothelium. They do, however, promote vascular repair and
regeneration and exert their pro-angiogenic effect in a local paracrine
fashion. The cell that most closely resembles the originally conceived ‘EPC’
is probably the late outgrowth EPC. These cells have been shown to
incorporate into vascular endothelium and are in fact almost indistinguishable
endothelial cells [99], although it is important to note that it remains unclear
whether they form spontaneously in vivo.
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1.4 Vascular regeneration and insulin resistance
1.4.1 Metabolic syndrome (MetS)
Insulin resistance is present in a number of related disorders including
diabetes, pre-diabetes and obesity. It is well established that diabetes is
associated with impaired vascular regeneration, with animal studies
demonstrating defects in angiogenesis using wound healing and hindlimb
ischaemia models [100, 101]. Human studies also correlate diabetes with
impaired collateral vessel formation in ischaemic myocardium [102].
Diabetes is also associated with defects in progenitor function and abnormal
progenitor production and mobilisation have also been described [103]. As
mentioned, a cluster of conditions tend to occur along with diabetes and
other insulin resistant states. This heterogenous group of disorders occur
with varying degrees of severity and depending on the levels of abnormality
found, and the guidelines that are applied, this cluster of conditions is termed
the metabolic syndrome [104]. The metabolic syndrome is essentially defined
as the presence of varying combinations of central obesity plus hypertension,
dyslipidaemia and evidence of impaired glucose handling [104]. Although
many of the facets of the metabolic syndrome are associated with reduced
indices of vascular regeneration, the impact insulin resistance per se has is
less established. The following discussion will focus on the impact that each
facet of the metabolic syndrome may have on vascular regeneration.
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Figure 1-5. The clustering of cardiovascular risk factors in the metabolic
syndrome. From: Mercer et al Int J Clin Pract. 2012 Jul;66(7):640-7
1.4.2 Hypertension
Rodent studies have demonstrated a reduction in the number of circulating
progenitor cells in hypertensive animals, in addition to impaired EPC
function, such as migration [105]. Oxidative stress was implicated
mechanistically in this progenitor dysfunction. This correlation between
hypertension and impaired progenitor function is paralleled in human studies.
Blood from hypertensive men yields fewer early EPC (EEPC) colonies [106].
EEPCs from men with essential hypertension exhibit impaired migration and
adhesion compared with those derived from healthy volunteers. Moreover,
these cells augmented vascular repair to a lesser degree when used in a
murine model of vascular injury [107]. Drawing conclusions on the isolated
impact of hypertension in these studies is complicated by differences in
baseline profiles of the two groups with non-significantly higher levels of LDL-
cholesterol, triglycerides and lower levels of HDL-cholesterol. All these
changes are also associated with perturbations in aspects of progenitor
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function. Hypertensive rats have also been shown to exhibit impaired
reperfusion in response to hindlimb ischaemia compared with normotensive
animals. Perfusion was augmented by the infusion of EEPC from control
animals to a greater degree than was observed with EEPCs from the
hypertensive littermates [108]. Increased oxidative stress from the endothelin
A (ET(A)) / Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase
pathway was implicated in this progenitor cell dysfunction. Current data from
both human and animal studies suggests that hypertension has a deleterious
effect on both progenitor function and markers of angiogenesis, with
oxidative stress playing a key role (see later). There is conflicting evidence
however, with a key mediator of hypertension, aldosterone, being shown to
enhance vascular regeneration in murine hindlimb ischaemia studies and co-
treatment with spironolactone (aldosterone receptor antagonist) or valsartan
(Angiotensin-2 receptor antagonist) abrogating this pro-angiogenic effect
[109].
1.4.3 Dyslipidaemia
The characteristic lipid profile of elevated triglycerides, elevated small dense
low density lipoprotein (LDL) cholesterol, reduced high density lipoprotein
(HDL) cholesterol and elevated apolipoprotein (apo)-B is often found in
patients with MetS [110]. Increased levels of LDL cholesterol correlate with
reduced abundance of EPCs, measured by formation of colony forming units
[111]. Oxidised LDL (OxLDL), an important cardiovascular risk factor, has
been shown to significantly impair in vitro EEPC function, with impaired
survival, adhesion, migration, proliferation and tube forming capacity seen in
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cells treated with OxLDL [112, 113]. OxLDL treatment of EEPCs led to a
reduction in Akt phosphorylation and eNOS mRNA expression [112]. Animal
models of hypercholesterolaemia have demonstrated a negative impact on
vascular regeneration [114-116]. This impairment is associated with reduced
T-lymphocyte infiltration, increased oxidative stress and reduced EPC
numbers. The reduced vascular repair seen in hypercholesterolaemic mice is
reversed in NADPH oxidase isoform (Nox)2-/- mice, together with an increase
in EPC number, implicating oxidative stress as a key molecular mechanism
[116].
Lower levels of HDL cholesterol are associated with a reduction in
abundance of EPCs [111, 117]. HDL treatment of EPC in vitro has been
shown to increase eNOS expression and reduce apoptosis, potentially
explaining the relationship between circulating HDL and EPC abundance
[117]. EPC function is also improved with HDL treatment, with enhanced
adhesion and proliferation being demonstrated [118]. Furthermore, HDL
treatment can enhance both in vitro and in vivo angiogenesis. Improved limb
perfusion is seen in murine models of hindlimb ischaemia following HDL
administration. This beneficial effect was abrogated by the concomitant
administration of a PI3K inhibitor, or in eNOS knockout mice [119]. HDL
increases EPC tube formation and can also reverse the deleterious effects of
LDL on their survival [120].
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1.4.4 Inflammation
Obesity is associated with a chronic, indolent inflammatory state, evident
both on a systemic and tissue level, with increased circulating levels of pro-
inflammatory cytokines [121]. Increases in the abundance and activation
state of inflammatory cells are also noted [121]. Inflammation denotes a wide
variety of processes, and notably ‘inflammatory’ cells also play an important
role in hypoxia induced angiogenesis and vascular renewal by releasing
proangiogenic molecules, which increase vascular permeability and degrade
the basement membrane [122]. Animal studies have shown that acute
inflammatory stimuli are associated with enhanced EPC mobilisation [123].
Human studies seem to concur with this finding, for example, enhanced EPC
mobilisation is observed in response to acute myocardial infarction [124]. In
conflict with this is the apparent detrimental effect of chronic systemic
inflammation, with in vitro studies demonstrating decreased EPC number
and increased apoptosis after exposure to TNF alpha and C-reactive protein
exposure respectively [125, 126]. Conditions associated with chronic
inflammation in humans, such as rheumatoid arthritis and heart failure, are
associated with a reduction in circulating progenitors [127, 128]. The
evidence-base suggests that although inflammation and the resulting cellular
responses are required for normal vascular renewal, chronic low grade
inflammation much like that seen in obese states is associated with
deleterious effects on progenitor cells, and may be detrimental to vascular
repair.
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1.4.5 Adipokines
It is accepted that adipose tissue does not merely serve as storage depot for
excess lipids, but also acts much like an endocrine organ. A long list of
signalling molecules produced in adipose tissue (adipokines) have been
found to be important in maintaining energy homeostasis by affecting
signalling cascades in diverse target tissues [129]. As is the case with
dyslipidaemia in the metabolic syndrome, there is a typical derangement in
the levels of the adipokines seen. The vast majority of these are found in
greater levels with increasing adiposity, with the most notable exception
being adiponectin [129]. This insulin sensitising factor is found in reduced
concentrations in the metabolic syndrome, and has been reported to induce
anti-inflammatory, anti-apoptotic and pro-angiogenic changes [129, 130]. The
majority of other adipokines exhibit a positive correlation with indices of
adiposity, and these molecules have been shown to induce inflammation and
inhibit adiponectin signalling [129].
With regard to adipokines and vascular regeneration, adiponectin is probably
the most studied. Data show that adiponectin augments angiogenesis in
animal models[131, 132] via mechanisms including promotion of AMP-
activated protein kinase signalling [131, 132] and increased PI3K/Akt/eNOS
signalling [132]. Adiponectin has also been shown to exert positive effects on
both EPC number and function [133, 134].
Leptin has been shown to have beneficial effects on human EPC function at
low concentration, but paradoxically impairs function at higher
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concentrations, with reduced tube formation and migration noted [135].
Animal studies have also mirrored this effect, with pre-incubation of human
EPC with leptin resulting in enhanced adhesion and vascular repair [136].
Leptin has also been shown to have a positive effect on vascular
regeneration [137, 138].
Resistin is found in higher concentrations with increasing adiposity and has
been shown to augment in vitro tubule formation, endothelial cell proliferation
and aortic sprouting [139] and [140]. PI3K/Akt signalling and NF-kB activity
has been implicated in this pro-angiogenic effect [140].
Visfatin has been shown to have detrimental effects on EPC function and its
levels are increased in obesity and insulin resistant states [141], but has also
been shown to augment angiogenesis and vascular regeneration [142].
Other data show that visfatin enhances endothelial cell function (HUVECs)
and augments in vitro and in vivo angiogenesis [143].
It is difficult to comment on the net effect that the adipokine profile seen in
obese and insulin resistant states has on vascular regeneration. The
available data suggest that some features of the obese adipokine profile will
have negative effects on angiogenesis whilst others could have beneficial
impact on EPC function and re-vascularisation.
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1.4.6 Hyperglycaemia
The insulin resistance seen in the metabolic syndrome generally progresses,
and is accompanied by compensatory hyperinsulinaemia, but eventually
pancreatic beta cell failure ensues. These processes lead to sustained
hyperglycaemia, and are central to the diagnosis of diabetes. This section
will look at the effect of hyperglycaemia on EPC function and vascular
regeneration. EPC are grown less readily from patients with type 1 diabetes;
moreover these EPC have reduced indices of function, with the cells less
able promote endothelial tubule formation [144]. Similar findings are
observed in studies of patients with type 2 diabetes [145]. It is difficult to
dissect out and quantify the impact of hyperglycaemia versus insulin
resistance on EPC function in these studies. It is clear however, that type 1
diabetes is associated with a lesser degree of insulin resistance than type 2
diabetes. Also, EPC number has been shown to inversely correlate with
glycosolated haemoglobin levels in patients with type 2 diabetes. It is
therefore reasonable to surmise that hyperglycaemia has a significant impact
on EPC biology. Data from in vitro studies support this conclusion, and
highlight the negative impact hyperglycaemia has on both EPC number and
function. Incubation in a high glucose environment leads to reduced early
and late outgrowth EPC number, increased senescence, decreased
migration and decreased tubule formation. This was independent of any
osmotic effect and mechanistically, reduced PI3K/Akt signalling and NO
bioavailability was implicated [146].
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In vitro studies have demonstrated that hyperglycaemia results in abnormal
angiogenesis. Spheroid assays utilising endothelial and smooth muscle cells
cultured in control and high glucose environment revealed an increase in
fragile, thin endothelial sprouts that was a result of increase Jag1 activity,
and resultant down regulation of Notch signalling [147].
Animal models of type 1 diabetes mellitus include mice with streptozotocin
induced pancreatic injury. These animals exhibit impaired limb perfusion
recovery in hindlimb ischaemia studies [148] and this has been associated
with a reduction in progenitor cell number, and attributed to an increase in
reactive oxygen species (ROS) [149]. This defect in limb perfusion recovery
was reversed by the administration of an antioxidant, or reducing the
production of ROS via genetic manipulation of NADPH oxidase [149].
Impaired vascular regeneration is also seen in murine models of type 2
diabetes. Leptin deficient mice are obese, with fasting hyperglycaemia and
hyperinsulinaeima [150]. These mice also demonstrate impaired limb
perfusion recovery in hindlimb ischaemia experiments [101]. Interestingly,
animal studies utilising type 1 and type 2 diabetes models as comparators
demonstrate that although both had impaired indices of vascular renewal
following hindlimb ischaemia, the defect was more marked in the type 2
diabetes model [151] - i.e. insulin resistant diabetes is associated with a
more marked defect in vascular regeneration than insulin deficiency.
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Recent work has highlighted the potential role of PGC-1α on angiogenic 
processes. PGC-1α is a transcription factor that regulates metabolism in 
numerous tissues and is up-regulated in both type 1 and type 2 diabetes,
suggesting hyperglycaemia rather than insulin resistance is responsible for
this. Sawada et al found that overexpressing PGC-1α in the endothelium of 
mice resulted in impaired endothelial cell migration, impaired vascular repair
in a wire injury model, and impaired vascular regeneration in a hindlimb
ischaemia model. They postulated that PGC-1α mediated up-regulation of 
Notch activity, with resultant attenuation of Akt/eNOS signalling, was the
underlying mechanism for this dysfunction [152]. Another recent study has
suggested that hyperglycaemia-related oxidative stress prevents VEGFR2
membrane localisation, thereby leading to VEGF resistance and impaired
angiogenic activity [153].
1.4.7 Abnormal insulin signalling
Discussion thus far has highlighted the complexity of the insulin resistant
phenotype and the difficulty in assessing the impact that each facet of this
phenotype can have on vascular regeneration. When considering the effect
of insulin resistance and abnormal insulin signalling per se on vascular
regeneration, it is important to note that the insulin receptor is found in many
tissues beyond liver, skeletal muscle and fat. The insulin receptor can also
be found in vascular endothelium, cardiac myocytes, leukocytes and many
other cell types. Although few studies specifically address vascular
regeneration, there is much data from murine studies utilising gene-modified
strains with global or tissue specific alteration of insulin signalling.
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The insulin receptor knockout (IRKO) mouse has global haploinsufficiency of
the insulin receptor. This results in mild metabolic insulin resistance with
normoglycaemia and mild hypertension [154]. Work in our lab has
demonstrated that IRKO mice exhibit delayed re-endothelialisation following
femoral artery denudation with an angioplasty wire [155]. Circulating
progenitor cells (CPCs) were less abundant, as were blood derived EEPCs,
and there was impaired CPC mobilisation in response to VEGF. Interestingly,
c-kit+ progenitors infused from wildtype (WT), but not IRKO donors
normalised re-endothelialisation in IRKO recipients following wire injury. C-
kit+ cells from IRKO donors improved vascular repair, but not to the extent
seen with WT cells, implying a defect in both CPC mobilisation and function
[155]. However, the effect of global insulin resistance on vascular
regeneration has not yet been addressed.
Recent work from our lab has also evaluated LEPC derived from South
Asian men, who were relatively insulin resistant, compared with white
European controls. These LEPC had impaired in vitro function, as
demonstrated in tube forming and migration assays. The South Asian LEPC
also did not augment vascular repair to the extent as white European cells
when transfused into mice following femoral artery denuding injury. We
linked these defects with a reduction in Akt/eNOS signalling, and were able
to restore South Asian LEPC functionality via expression of a constitutively
active Akt mutant [156].
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Murine models of cell specific insulin resistance exist, and although few
address vascular repair and regeneration, clues can be found in the existing
literature. The most pertinent study, by Kondo et al, utilised mice with
complete loss of insulin receptor expression in the vascular endothelium
(VENIRKO). These mice exhibited a reduction in retinal angiogenesis in
response to relative hypoxia, which was associated with reduced tissue
VEGF and eNOS expression [157]. This supports the notion that insulin
resistance can negatively impact vascular regeneration. However, the effect
of systemic insulin resistance on angiogenesis in other vascular beds, and in
response to other angiogenic stimuli remains to be clarified.
Other models of tissue specific insulin resistance provide insight with regards
vascular regeneration. A muscle specific insulin receptor knockout model,
which lacks insulin receptor in cardiac myocytes, exhibited a reduction in
cardiac vascular density, both before and after ischaemia. This was
associated with a subsequent reduction in VEGF expression, and suggests
that insulin signalling is key in regulating tissue VEGF expression [158].
1.4.8 Insulin resistance and altered vascular regeneration; Molecular
mechanisms
The preceding discussion has highlighted how different facets of the insulin
resistant phenotype can impact on vascular regeneration. There are
recurring mechanistic themes throughout, and to identify potential
therapeutic targets it is of course vital to understand these. Reduced PI3-
kinase mediated signalling, reduced nitric oxide bioavailability, perturbations
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in growth factor sensing/signalling, and oxidative stress have all been
implicated; the following section will expand on these.
1.4.8.1 PI3 kinase/Akt/eNOS signalling
As already outlined, the PI3-kinase/Akt signalling pathway results in many of
the metabolic actions of insulin, and in the vascular endothelium also induces
NO production. It is widely accepted that signalling via this pathway is
disturbed in insulin resistant states [13]. Examining models of altered PI3-
kinase signalling may therefore provide insight into whether this is relevant to
the diminished vascular repair and regeneration associated with insulin
resistance. PI3-kinase has been shown to mediate VEGF expression and
angiogenesis, with constitutively active PI3-kinase expression resulting in
increased angiogenesis. Conversely, expression of a dominant negative PI3-
kinase construct results in a reduction in angiogenesis [159]. Study of PI3-
kinase-Ɣ knockout mice has demonstrated a homing defect in their EEPCs; 
bone marrow derived progenitor cells from these mice are also less able to
augment angiogenesis when transfused following hindlimb ischaemia
induction, compared with cells derived from WT mice [160]. Akt1 knockout
mice exhibit impaired ischaemia driven angiogenesis, as demonstrated using
the hindlimb ischaemia model [161]. Seemingly eNOS is an important
mediator of this pro-angiogenic function of Akt signalling, as studies in mice
expressing mutant eNOS, resistant to phosphorylation at the site recognised
by Akt1 also demonstrate impaired angiogenesis, which is overcome with the
expression of constitutively active eNOS[162].
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Nitric oxide (NO) bioavailablity (or eNOS signalling) has been shown to play
a critical role in progenitor mobilisation. For instance, Dimmler et al
demonstrated rescue of the defective ischaemia-associated
neovascularisation seen in eNOS knockout mice by infusing wildtype
progenitor cells. They suggested that a lack of eNOS expression in bone
marrow stromal cells, and hence a reduction in NO bioavailabilty, resulted in
a progenitor mobilisation defect that significantly impaired recovery from
hindlimb ischaemia [82]. Our laboratory’s work in insulin resistant South
Asian men has also demonstrated that progenitor mobilisation depends
significantly on NO, with the NOS inhibitor, L-NMMA, abrogating exercise
stimulated CPC mobilisation [163]. These data highlight the important role of
PI3-kinase/Akt/eNOS signalling in angiogenic processes, and given the
defects seen in this signalling cascade with insulin resistance, it is
reasonable to consider this as a likely mechanism underlying associated
disturbances in vascular regeneration.
1.4.8.2 Reactive oxygen species
Reactive oxygen species (ROS) are chemically reactive oxygen based
molecules, produced during normal cellular metabolism. The term ROS
describes a group of molecules that can be divided into free-radicals
(superoxide anion, peroxynitrite) and non-radicals (hydrogen peroxide,
ozone). ROS are produced during oxygen metabolism by mitochondria, and
by enzymes such as lipoxygenase and NADPH oxidases (NOX). NOX are
the most pertinent group of enzymes with regards vascular regeneration as
they are the predominant source of ROS in the vasculature [164]. ROS were
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originally thought to represent the harmful by-product of processes required
for normal cellular function, and indeed some aspects of this statement can
be considered correct. ROS are indeed the by-product of many crucial
cellular processes, most notably the production of energy via the metabolism
of oxygen. It is also clear that ROS can be harmful, and this property is
exploited by macrophages that kill bacteria after phagocytosis using a
‘respiratory burst’ of ROS. At high concentrations ROS can react with DNA,
lipid, carbohydrate and cause impaired function or irreversible damage
[164].However, it has become clear that ROS act in other ways that are
crucial to normal cellular function, for instance as signalling molecules [164].
There are biological systems in place to limit the production and lifespan of
ROS, in order to limit the damage they can cause in excess. The breakdown
of ROS is mediated by enzymes including superoxide dismutase and
catalase, which dismute superoxide anion into hydrogen peroxide and water
and degrade hydrogen peroxide to water and oxygen respectively [164].
Oxidative stress occurs when ROS production outweighs the capacity of the
cell to degrade ROS. Insulin resistant syndromes are associated with an
increase in ROS [165].
As outlined before, it is established that ROS play an important role in normal
cell physiology, but also have the potential to cause cell damage if present in
excess. Intuitively therefore, it would seem that there is a window within
which the concentration of ROS is optimal. There is evidence to suggest that
increased ROS have a detrimental impact on progenitor biology. In vitro
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studies have demonstrated that hydrogen peroxide negatively impacts upon
LEPC proliferative capacity [166]. Another in vitro study, however,
demonstrated an increase in angiogenic processes (migration, proliferation
and tube forming) in bovine endothelial cells treated with lower
concentrations of hydrogen peroxide [167].
Murine studies have also highlighted the necessity of ROS for angiogenesis.
Mice lacking an isoform of NADPH oxidase, NOX1, exhibit reduced
endothelial cell migration and tube formation [168]. Furthermore, mice with
NOX2 knockout have impaired ischaemia and VEGF stimulated
angiogenesis in a hindlimb ischaemia model[169].
NOX4, a source of hydrogen peroxide, has been implicated in vascular
regeneration. NOX4 knockout mice have impaired neovascularisation in
response to hindlimb ischaemia and lung endothelial cells isolated from
these mice form fewer vascular tubules in vitro, possibly due to reduced
expression of eNOS [170].
In addition to the data discussed that highlights the importance of ROS to
physiological angiogenesis, there is data to suggest that excess ROS
negatively impact upon vascular regeneration. Studies show that in
conditions characterised by oxidative stress, such as hypertension, there are
impaired indices of vascular regeneration [171]. Eplerenone, a
mineralocorticoid antagonist and losartan, an angiotensin receptor
antagonist, have been shown to improve recovery from hindlimb ischaemia
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in rats, via an antioxidant effect [105, 172]. Superoxide dismutase inhibition,
and so elevation in superoxide concentrations, results in impaired collateral
artery formation in a rat model of myocardial ischaemia [173]. Oxidative
stress has been implicated as a mechanistic factor central to the impaired
angiogenic response in type 1 diabetic mice post ischaemia [149] as well as
host of other pathologies associated with reduced angiogenesis including
hypercholesterolaemia [116]. In both of these studies the defect in
angiogenesis was reversed by treatment with antioxidants or genetic ablation
of proteins capable of producing ROS.
The apparent profound effect of ROS on angiogenesis has in part been
attributed to its effect on VEGF signalling. Data shows that it impacts on
many facets of VEGF signalling and action, including VEGF receptor
dimerisation and activation, and VEGF mediated endothelial cell migration
and proliferation [174]. For example, signalling pathways involving ROS are
crucial to the action of VEGFR2. In order for the VEGFR2 to function
normally it must be auto phosphorylated and this is regulated by protein
tyrosine phosphotases (PTPs), via dephosphorylation at important sites of
the VEGFR2. PTP activity is inhibited by oxidation, which occurs via
superoxide anion [175] and therefore ROS indirectly regulates VEGFR2
activity. Another study by Warren et al [153], discussed in more detail in the
following section, provides a link between diabetes, oxidative stress and
abnormal VEGF activity and thereby provides a potential mechanistic link
between diabetes and impaired vascular regeneration.
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Evidence suggests that ROS are clearly very important to physiological
angiogenic processes. There is also ample data to demonstrate that
oxidative stress is detrimental to vascular regeneration, and often mediates
the negative impacts on angiogenesis of a number of pathologies that co-
exist in insulin resistant syndromes. On balance current literature supports
the notion that there is probably an ‘optimal zone’ for ROS, and if levels of
ROS fall either above or below this zone it is detrimental to angiogenesis and
vascular regeneration.
1.4.8.3 VEGF signalling
As has been already discussed, VEGF is the chief angiogenic mediator, and
its expression is under the control of hypoxia inducible factors (HIFs).
Interference with this hypoxia sensing mechanism, and subsequent VEGF
signalling, leads to changes in angiogenesis. There is data to suggest that
these systems are affected in insulin resistant syndromes. It has been shown
that monocytes from diabetic patients do not migrate effectively to VEGF;
this was associated with significantly higher plasma levels of VEGFA in these
subjects. However, their monocyte migration to formylMetLeuPhe appeared
intact [176], and mechanistic studies suggested hyperglycaemia induced
ROS inhibited protein tyrosine phosphatases required to terminate signal
transduction. This may lead to constitutive activation of VEGFR1, and so
prevent directed migration toward exogenous VEGF ligands. The authors of
this study suggested that because monocytes lack VEGFR2, the receptor by
which VEGFA-directed migration is chiefly mediated in endothelial cells,
extrapolating these findings to endothelial cells is difficult. The findings do,
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however, raise the concept of VEGF resistance in tandem with insulin
resistance. More recent work supports this notion, with the demonstration
that hyperglycaemia induced ROS results in abnormal VEGFR2
phosphorylation dynamics. This results in reduced VEGFR2 trafficking to the
cell surface and a muted response to VEGFA despite increased circulating
levels [153]. These experiments were done using two murine models of
diabetes; ob/ob mice and streptozotocin induced diabetic mice, in which
results were similar. This therefore implicated hyperglycaemia, rather than
insulin resistance, in the signalling abnormalities and apparent VEGF
resistance. In contrast to this, it is known that insulin can induce VEGF
expression in a PI3K/Akt dependant manner, and when this insulin signalling
is reduced VEGF mRNA levels fall [159]. VEGF production in response to
ischaemia is reduced in diabetic rats [177]. Therefore, both ‘VEGF
resistance’ and impaired VEGF production in response to ischaemia offer
reasonable mechanisms by which the impaired vascular regeneration seen
in diabetes occurs. Although insulin resistance may be implicated by
association, it is not possible to accurately define the link between abnormal
VEGF signalling and insulin resistance.
In addition to the apparent abnormalities in VEGF expression and
responsiveness in insulin resistant syndromes, there is data to suggest
significant crosstalk between insulin and VEGF signalling pathways. It is
therefore conceivable that defects at certain levels of the insulin signalling
cascade could modulate VEGF signalling. Evidence for this is provided by
Senthil et al who demonstrated that insulin receptor substrate 1 (IRS1) is
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phosphorylated in response to VEGF exposure in mouse kidney epithelial
cells and rat heart endothelial cells [178]. Al-Mahmood et al also
demonstrated that IRS-1 is upregulated in angiogenic conditions, and that by
reducing the expression of IRS-1 with an antisense oligonucleotide, in vivo
and in vitro, angiogenesis is reduced [179]. Data is also available to show
that important cross talk occurs at the PI3-K signalling node. PKC activation,
as seen in diabetic states, has been shown to phosphorylate the p85 subunit
of PI3-K at Thr86 [180]. This modification is inhibitory, and results in
decreased PI3-K/Akt activation in response to not only insulin exposure, but
also to VEGF exposure, and therefore highlights another important node of
the insulin signalling cascade that is shared with the VEGF signalling
pathway.
1.5 Cell therapy
As insulin resistant syndromes become increasingly prevalent, novel
treatment strategies have been sought to address the associated excess
cardiovascular mortality and morbidity. One such therapeutic modality that
has received recent attention is cell-based cardiovascular repair. The
following discussion will focus on cell therapy, rather than other novel
strategies, as it informs some of the work that has been conducted as part of
this project.
Therapeutic strategies utilising cells of various lineages have been, and
continue to be, evaluated in human clinical trials and animal studies. One
such human study injected EEPCs or bone marrow derived cells into the
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coronary arteries of patients that had recently had a myocardial infarction.
They found a modest improvement in cardiac dysfunction, which was most
pronounced with the use of bone marrow derived cells [181], recreating the
findings of earlier studies [182, 183]. Although these studies are generally
relatively small, 5 year follow up in the TOPCARE-AMI trial suggests that
transfusion of bone marrow derived cells is a relatively safe procedure, and
improvements in ejection fraction are maintained [184]. The REPAIR-AMI
study, also showed a reduction in death, recurrent myocardial infarction and
revascularisation at 1 year [185]. One study has failed to show any benefit
with the transfusion of autologous bone marrow derived cells [186], but the
methods used to store cells prior to use may have had negative effects on
SDF-1 signalling. Encouraging results have been described in the SCIPIO
trial where c-kit+ myocardium derived cells where injected into the coronary
arteries of patients with ischaemic cardiomyopathy post bypass surgery.
Patients receiving the c-kit+ cells had an 8% absolute increase in ejection
fraction (EF), compared with no change in EF in the control group [187].
Similar results have been observed with the intracoronary delivery of
cardiosphere derived cells [188], although both studies were not powered to
assess anything other than safety measures. The balance of evidence
remains unclear, and further work, powered to look at ‘hard’ outcomes, is
required to address this. Furthermore, a recent meta-analysis has added to
this lack of clarity, with the authors questioning the quality of the evidence
base and highlighting a correlation between the number of discrepancies in a
study and the magnitude of effect on left ventricular ejection fraction [189]. It
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should be noted that some success has also been observed with the use of
adult stem cells in the setting of peripheral arterial disease [190].
In particular relevance to work that will be carried out as part of this project,
human LEPC have been used in pre-clinical animal models. LEPCs have
been used in a murine hindlimb ischaemia model and were found to enhance
neovascularisation; this effect was enhanced if the cells were co-injected
with EEPCs [191]. They have also been used in models of porcine
myocardial infarction, with the intra coronary injection of LEPC being
associated with an increase in neovascularisation, and improvements in left
ventricular remodelling, versus mesenchymal stem cells or vehicle [192].
Human studies so far encourage cautious optimism with regards cell therapy,
although none have specifically recruited patients with insulin resistance or
diabetes. One important consideration from the preclinical data outlined
earlier is that these disorders appear to negatively impact upon progenitor
cell function. It is therefore likely that autologous cell-based therapies in
patients with insulin resistance or diabetes will require ex vivo
pharmaceutical or genetic manipulation of cells in an attempt to improve their
function.
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1.6 South Asian ethnicity and cardiovascular risk
1.6.1 South Asian ethnicity
Novel strategies, such as cell-based therapies, may offer a means by which
cardiovascular events can be prevented in high risk patients, such as those
with diabetes. Another group at high risk for cardiovascular disease, and
associated insulin resistant disorders, are those of South Asian ethnicity;
published data from our group suggest progenitor cell dysfunction is also
present in this population. Before discussing these issues in more detail, it is
important to first define South Asian ethnicity. Ethnicity encompasses a
person’s religion, diet, culture, language and geographical heritage [193].
Biomedical research often assigns subjects to a particular ethnic group
based on their geographical heritage. This method has its limitations as it
fails to address other aspects of ethnicity that could impact on biology, and
result in significant heterogeneity within these groups. There is no overriding
consensus in how to address this, but for the purposes of this discussion,
South Asian ethnicity represents those with Indian, Pakistani, Bangladeshi,
Sri Lankan or Napalese heritage, unless stated otherwise.
1.6.2 South Asian ethnicity and cardiovascular risk
1.6.2.1 Epidemiology
Epidemiological studies conducted in the United Kingdom (UK) have
consistently shown that South Asian ethnicity is associated with an increased
risk of cardiovascular disease (CVD) [194, 195]. Cross-sectional analysis of
UK mortality data identified an excess mortality from ischaemic heart
72
disease, compared with the UK average, of approximately 70% in South
Asians in 1970, and 50% in 1990. When looking at cerebrovascular disease,
the difference in mortality was more marked, with South Asians having
standardised mortality ratios of 240 in 1970, and 150 in 1990.
Table 1. Prevalence of CVD/IHD/IHD or stroke, by age within minority ethnic
group and sex. From: Health Survey for England 2004: The Health of
Minority Ethnic Groups
Age: 55+ Indian
(%)
Pakistani
(%)
Bangladeshi
(%)
Chinese
(%)
Carribean
(%)
Gen
Pop
(%)
IHD Male 23.9 35.1 18 7.2 12.8 17.9
Female 14.7 13.7 12.7 8.2 6.3 4.1
IHD or
Stroke
Male 26.9 41.1 24.2 8.7 20.1 21.6
Female 18.9 17.6 18.2 9 10.8 5.8
Data collected during the Health Survey for England in 2004 [196] again
demonstrated the increased burden of cardiovascular disease in those of
South Asian ethnicity. Table 1 shows data for both men and women over the
age of 55. The highest prevalence of ischaemic heart disease (IHD) and
stroke were seen in men of Pakistani heritage, with the prevalence of both
IHD and stroke being elevated in men and women originating from Pakistan,
India and Bangladesh.
This high prevalence of cardiovascular disease in UK South Asians is
mirrored in other settings. Epidemiological data from the USA demonstrates
this, with studies from 1996 quoting a three-fold increase in prevalence of
angina or myocardial infarction in Asian Indian men, compared with the
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general population; this was despite lower levels of cigarette smoking and
obesity [197]. Other data point toward higher rates of ischaemic heart
disease in urban, compared with rural, India. A systematic review carried out
in 2005 used ECG criteria to define ischaemic heart disease, and concluded
that the prevalence of IHD in urban areas was approximately double that
seen in rural areas [198]. These findings, along with data from migrant
populations in Western countries, imply that migration and the adoption of an
urban or ‘Western’ lifestyle is important when considering the increased IHD
risk seen in South Asian populations. Along with increased prevalence, there
is evidence to suggest South Asian patients have more severe disease, with
a tendency to suffer earlier and larger myocardial infarctions (MI) than those
from other ethnic groups [199]. Recent angiographic studies in men of South
Asian ethnicity in the US demonstrate that this group has much higher rates
of 3 vessel coronary artery disease (CAD) than their Caucasian counterparts.
South Asian men in this cohort had significantly higher levels of co-existing
diabetes, hypertension, obesity and dyslipidaemia, but the Caucasian cohort
contained more smokers. There was a strong trend towards South Asian
ethnicity being an independent risk factor for the presence of 3 vessel
disease CAD [200]. South Asian ethnicity has itself been mooted to be an
independent risk factor for cardiovascular disease, with the excess risk not
simply being explained by differences in conventional CVD risk factors,
compared with Caucasian populations[199].
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1.6.2.2 Pathogenesis
Some published data suggest that the increased CVD risk in South Asian
populations can be accounted for by conventional risk factors such as
hypertension, smoking and hyperlipidaemia [201]. However, there is also
data to counter this that demonstrates that, in fact, excess CVD cannot
completely be explained by an increase in conventional CVD risk factors
[202]. When considering the impact of migration and the adoption of a
‘western’ lifestyle on vascular disease patterns it is interesting to note that
other migrant populations, for example, Chinese immigrants in the UK, do
not experience an increase in vascular disease, and in fact, have lower rates
of IHD than the general population [203]. This suggests that the increased
CVD risk in UK South Asians is therefore unlikely to solely be accounted for
by migration and the adoption of a ‘Western’ lifestyle and that other factors
play a significant role in the development of the observed CVD.
1.6.2.2.1 Socioeconomic factors and healthcare provision
The impact of socioeconomic status on the health of ethnic minority
populations may also be important. A recent population study in Finland
provides a good example of the impact socioeconomic deprivation can have,
with higher socioeconomic status correlating with a favourable
cardiovascular risk profile, and a slower rate of progression of carotid
atheroma [204]. UK census data from 1991 showed that although there were
higher rates of CVD in South Asian populations, these were proportionally
spread across socioeconomic classes comparably to the general population.
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This suggests that the higher rates of CVD seen in UK South Asians are not
related to socioeconomic factors [205].
Recent data suggest that access to healthcare, and appropriate investigation
and treatment, is not affected by ethnic status or socioeconomic status [206].
This conflicts with earlier work that suggested that thrombolysis occurred
less frequently in UK South Asians [207]. Differences have also been seen
historically in less acute settings, with data from the early 1990s
demonstrating a longer time from experience of first angina symptoms to
referral for secondary care input. The authors of this work suggested that
language barriers, or perhaps referral bias on the part of general
practitioners, could have been potential factors [208]. Subsequent work with
South Asian focus groups acknowledges that language barriers play a part
when considering access to health services [209]. Another study in 2002
concluded that although South Asian patients were less likely than white
patients to receive revascularisation, despite being deemed appropriate
candidates, this was not due to physician bias [210]. Available data has
identified that socioeconomic factors do indeed impact on cardiovascular
risk, but the impact this has on cardiovascular risk on UK South Asians, at
least, is not disproportionate in comparison to the general population. On
balance, although socioeconomic factors and access to healthcare have
been shown to affect UK South Asians, it is probably not a major determinant
of the excess CVD seen in this population.
76
1.6.2.2.2 Classical CVD risk factors
When considering CV risk in UK South Asians, or any other population, it is
important to consider the presence of classical CV risk factors, such as
hypertension, smoking, hyperlipidaemia and diabetes, and comparisons of
risk profiles between populations may help to define reasons for inter-ethnic
differences. In keeping with the heterogeneity of South Asian ethnic groups,
tobacco use rates vary widely within the population. Studies can be found
quoting lower overall rates of smoking [197], and smoking in Indian women is
not commonly encountered [211]. A cross-sectional study of South Asian
immigrants in the UK found that smoking prevalence was comparable to
white Europeans, except for the Punjabi Sikh group, whose smoking rates
were much lower [212]. Available data suggests that total cholesterol levels
are broadly similar in South Asian and Caucasian populations. It is noted that
south Asians do generally have lower levels of HDL cholesterol and higher
triglycerides than other ethnic groups [197]. Furthermore, there are often
higher levels of small, dense LDL cholesterol [213]. Interestingly, this pattern
is reflective of the typical lipid profile seen in insulin resistant syndromes and
the metabolic syndrome. Although this hints at the presence of insulin
resistance, which could certainly contribute to the elevation of CVD rates in
this ethnic group, and will be discussed further, differences in circulating
lipids are not stark and it suggests that hyperlipidaemia per se is probably
not the only mechanism by which CVD risk is elevated in South Asians. The
Health Survey for England in 2004 found that levels of systolic blood
pressure in those of South Asian origin were lower than the general
population, and therefore cannot explain the increase in CVD seen, at least
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in UK South Asians. UK census data again provide valuable insight to the
prevalence of diabetes in those of South Asian ethnicity, reporting marked
increases in rates of DM in those of South Asian origin, compared to the
general population.
Table 2 Prevalence of type 2 Diabetes Mellitus within minority ethnic group
and sex. From: Health Survey for England 2004: The Health of Minority
Ethnic Groups
Age:
55+
Indian
(%)
Pakistani
(%)
Bangladeshi
(%)
Chinese
(%)
Carribean
(%)
Gen
Pop
(%)
Type
2 DM
Male 24.3 25.3 29.9 16.1 24.8 9.3
Female 20.5 44.4 13.5 13.1 25.7 6.9
1.6.2.2.3 Obesity and Insulin resistance
It is clear that the high prevalence of diabetes in South Asian populations is
likely to be a major contributor to their increased CVD risk. Interestingly,
given the close links between obesity, insulin resistance, and diabetes, this
hugely elevated diabetes risk in South Asians is seen with body mass indices
(BMIs) comparable to the general population. Evidence suggests, however,
that despite having ‘normal’ BMI, South Asian populations have different
body compositions to Caucasian counterparts, with increased body fat, and
in particular visceral adiposity. Moreover, data produced using the gold
standard test of insulin resistance, hyperinsulinaemic euglycaemic clamping,
suggest a majority of healthy South Asian men are insulin resistant [214].
Similar data has been reproduced in UK cohorts, where despite similar BMI,
UK South Asians are insulin resistant relative to Caucasian counterparts.
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Again, this work provided evidence of differing body composition, with a
propensity towards central adiposity seen in the South Asian group [215]. As
a result of this apparent increased diabetes risk at ‘normal’ BMI levels, the
International Diabetes Federation now recommends the application of
ethnicity-specific thresholds for waist circumference when diagnosing the
metabolic syndrome [104].
The aetiology of this central adiposity, increased visceral fat distribution, and
resultant insulin resistance seen in South Asians migrating to urban/Western
areas has been linked to the so-called thrifty phenotype phenomenon.
Originally described with respect to the metabolic syndrome by Hales and
Barker, this theory suggests that exposure to environmental factors in utero
can lead to ‘foetal reprogramming’, and permanent adaptive changes that
can influence the risk of developing disease in later life [216]. In the case of
obesity and diabetes that are seen in migrant South Asian populations, it is
postulated that in utero under-nutrition (e.g. during periods of famine) leads
to adaptations which conserve metabolic homeostasis via induction of insulin
resistance. It is suggested that these initially adaptive metabolic changes can
become maladaptive in later life, if challenged by caloric excess and physical
inactivity, resulting in the manifestation of obesity and frank diabetes. This
theory is supported by the observations that birth weight in South Asian
populations is amongst the lowest in the world, and this remains the case in
babies born in the UK to parents of South Asian origin [217].
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The fact that insulin resistance (or diabetes) is one of the few consistent
differences in the cardiovascular risk profiles of UK South Asian groups,
versus the general population, suggests that it is an important pathogenic
factor in the development of CVD in this group, and this suggestion is
supported by the findings of the Southall study, where diabetes or insulin
resistance accounted for 70% of Q wave ECG abnormalities in migrant
South Asians [218]. There are established mechanisms that link insulin
resistance and endothelial dysfunction, the antecedent of atherosclerosis
[10]. Perturbed insulin signalling in the vascular endothelium leads to a
reduction in nitric oxide (NO) bioavailability [154], a hallmark of endothelial
dysfunction. Diabetic humans have been shown to exhibit endothelial
dysfunction [219], and this has also been demonstrated in animal models of
insulin resistance [154]. Furthermore, there is evidence to show that young
South Asian men have endothelial dysfunction, manifest by impaired flow
mediated dilatation [220]. This impairment was, however, found to persist
despite adjustment for insulin resistance as well as other common CVD risk
factors, and perhaps implicates genetic differences, altered risk factor
sensitivity or novel risk factors. The reasons for the endothelial dysfunction
seen in young South Asians are not fully understood. A possible explanation
is oxidative stress mediated reduction in NO bioavailability [221]; as
highlighted in previous sections, many facets of the metabolic syndrome are
characterised by oxidative stress. Also, the actions of insulin on the
endothelium include the production of NO via Akt/PI3-K/eNOS signalling
[222] and this could have implications in South Asian populations with insulin
resistance. Whatever the cause(s) of such endothelial dysfunction, a
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decrease in NO results in the reduction of, or loss of, its beneficial anti-
coagulant, anti-inflammatory and vasodilatory properties and is a significant
step in the development of overt atherosclerotic disease.
A common theme throughout this discussion is that a number of factors often
combine to result in an observed phenotype. This is also the case with
insulin resistance, and insulin resistance per se is unlikely to exclusively
account for inter-ethnic differences in CVD risk. This is highlighted by studies
in people of African origin. Despite exhibiting high levels of diabetes and
insulin resistance [223], this population experiences low rates of CVD,
something that is demonstrated in UK population studies (see Table 1).
Further observations of this study were a lack of central adiposity despite the
presence of insulin resistance and the presence of a favourable lipid profile
in comparison to European counterparts [223]. It may be extrapolated
therefore, that South Asian groups cluster more features of the metabolic
syndrome; an atherogenic lipid profile along with insulin resistance for
example, and it is this coming together of factors that increases CVD risk. In
addition, physical inactivity and other factors that are more difficult to define,
such as diet, are likely to play an important environmental role in the
development of insulin resistance, indeed a sedentary lifestyle, possibly
related to migration and urbanisation, has been shown to be a potential
contributor to insulin resistance in British Asians [224]. The markedly
increased rates of type 2 diabetes and CVD seen in UK South Asians is
undoubtedly due to a combination of factors, the impact of which cannot be
assessed individually. Genetic, intra-uterine and environmental factors
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combine to result in physiological and anatomical differences, and differing
body fat distribution. The culmination of these factors is ultimately insulin
resistance, and this, along with a cluster of other factors, results in
endothelial dysfunction; the first pathological step to overt atherosclerotic
disease.
1.7 South Asian ethnicity and progenitor cell dysfunction
Work carried out in our lab already has demonstrated impairment in
progenitor cell mobilisation, abundance and function in healthy South Asian
volunteers. CPC mobilisation in response to exercise is impaired in healthy
South Asian subjects [163]; this correlated with impaired flow mediated
dilatation (FMD), and hence endothelial dysfunction. In further experiments,
L-NMMA, the nitric oxide synthase inhibitor, abrogated CPC mobilisation; this
is suggestive of reduced NO bioavailibity in the South Asian group leading to
the CPC mobilisation defect [163]. This echoed findings of previous work
demonstrating a reduction in basal CPC number and function, along with
endothelial dysfunction, in apparently healthy, but relatively insulin resistant,
UK South Asian men [225].
A further study in our lab used 12 healthy South Asian and white European
volunteers to study the biology of late outgrowth endothelial progenitor cells
(LEPCs). All baseline characteristics were comparable, except that the South
Asian cohort was relatively insulin resistant, as measured by the HOMA-IR
index.
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LEPCs derived from the South Asian cohort grew less readily, formed fewer
vascular networks on Matrigel, had impaired migration to VEGF and were
more senescent. When infused in a murine vascular injury model, they did
not encourage re-endothelialisation beyond that seen by vehicle alone, yet
the white European cells did. These in vitro and in vivo functional deficits
were associated with a reduction in Akt, eNOS, pAKT and peNOS levels, key
components of the insulin signalling cascade. The defect in Akt expression
was then corrected by lentiviral expression of a constitutively active Akt1
mutant (E17KAkt) in the south Asian LEPCs. All experiments were then
repeated and E17KAkt expressing South Asian LEPCs were found to
augment re-endothelialisation to a level comparable with white European
LEPC [156]. This work suggests a link between South Asian LEPC
dysfunction and metabolic insulin resistance, although did not specifically
address insulin resistance in LEPC per se. It also shows that by modulating a
critical node of insulin (amongst many others) signalling cascade rescues the
capacity of these cells to augment vascular repair. However, it is yet to be
elucidated whether South Asian LEPCs can augment vascular regeneration
in the context of tissue ischaemia.
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Chapter 2. Aims and Hypotheses
A body of work, including work done in our lab, demonstrates that South
Asian ethnicity is associated with defects in progenitor cell function and our
lab has demonstrated that LEPC from healthy South Asian subjects do not
augment vascular repair. It is not known however, how LEPCs from this
group affect vascular regeneration, an important question as these cells are
potentially important therapeutic tools in the management of ischaemic
disorders. South Asian populations are a group that has been shown to
exhibit insulin resistance and are also at relatively high risk of cardiovascular
disease. But, as has been highlighted in the introduction, dissecting and
defining the impact of ethnicity from insulin resistance on biological
processes such as vascular repair is difficult. We will attempt to investigate
this further by assessing the impact of critical insulin signalling node
modulation in LEPCs on vascular regeneration and we will do this by
manipulating late outgrowth endothelial progenitor cells (LEPCs) from South
Asian men. This aspect of the project will therefore set out to answer these
questions:
1. Does the ability of LEPCs from South Asian men to augment
angiogenesis in vivo differ from the ability of LEPCs from white
European men to do so?
2. If LEPC from South Asian men do not augment angiogenesis to the
extent of those from white European men, can modulation of a critical
insulin signalling node (Akt) improve their angiogenic function?
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As mentioned earlier, separating the impact of ethnicity from insulin
resistance in human studies is difficult. Therefore, another set of studies will
be undertaken to determine the impact that insulin resistance per se has on
vascular regeneration. As discussed during the introduction, diabetes, a
major global health problem, is a leading cause of premature death and
much of this is driven by cardiovascular disease and ischaemic disorders. A
body of evidence demonstrates that diabetes is associated with defective
angiogenesis, but what is less clear, however, is the impact that insulin
resistance per se has on angiogenesis. Occult insulin resistance is present
long before the onset of diabetes, and importantly it has been shown that
these patients also experience increased cardiovascular morbidity and
mortality. An interventional target with potential to reduce the CVD burden
seen in patients with insulin resistant syndromes could therefore be revealed,
if the impact that insulin resistance has on vascular regeneration could be
clarified. In order to investigate this we have planned a series of experiments
that will aim to answer the following questions:
3. Does isolated insulin resistance impair vascular regeneration in
response to ischaemia in vivo?
4. Does insulin resistance impair VEGF driven angiogenesis in vitro?
5. If insulin resistance is associated with impaired angiogenesis, what
are the mechanisms responsible and how does this modulate VEGF
action?
These questions translate into four key hypotheses that will be addressed
within two major sub-sections of the results chapter. Firstly aims 1 and 2 will
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be addressed with studies utilising LEPC derived from South Asian and
Caucasian men. The null hypotheses for this section are:
1. LEPCs from South Asian men augment angiogenesis in a similar
fashion to LEPCs from Caucasian men.
2. Modulating Akt signalling in LEPCs from South Asian men does not
improve their vascular regenerative function.
Further sub-sections of the results chapter will address questions 3, 4 and 5
with a series of in vivo and in vitro assays, using murine and cell culture
based models of insulin resistance. The null hypotheses for this section are:
1. Insulin resistance does not impact upon vascular regeneration.
2. Insulin resistance does not modulate VEGF action.
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Chapter 3. Materials
3.1 Demographic and biochemical assessment
 Human insulin ELISA (Mercodia #10-1113-10)
 Syphygmomanometer (Omron MX3 Plus)
 Blood analyses performed in the laboratories of Leeds General
Infirmary:
o Full blood count
o Urea and Electrolytes
o Liver function tests
o Plasma glucose
o Lipid profile
3.2 LEPC derivation and culture
 Phosphate buffered saline (Sigma)
 Ficoll Paque PLUS (GE Healthcare)
 Biocoat fibronectin coated plastic culture vessels in 6-well, 24-
well, T25 flask and T75 flask format (Becton Dickinson)
 EGM-2 culture medium ± EBM2 Singlequots growth factor
supplements (Lonza)
 Foetal calf serum (Biosera)
 Trypsin/EDTA 0.025% solution (Gibco BRL)
 Cryomedium ( Cryo-SFM) (Promocell)
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3.3 Lentiviral transduction
 QuickTiterTM Lentivirus Titer Kit #VPK – 107 (Cell Biolabs)
 Akt Kinase assay kit #9840 (Cell signalling)
3.4 Hindlimb ischaemia and Murine femoral artery injury
 Microscopes
o Nikon SMZ1500 Stereo microscope for dissecting tissue
o Olympus SZ61 with up to 45x magnification with QiCam
Olympus digital camera
 Fluovac anaesthetising chamber with gas scavenging system,
Harvard apparatus
 Compact anaesthesia system AN001 (Vet Tech Solutions Ltd,
UK) Fluovac system, Harvard apparatus
 Isoflurane key fill applicator AN003B
 Heating plate (Vet Tech Solutions Ltd, UK)
 Thermal cage (HE-011(Vet Tech Solutions Ltd, UK))
 Light source (Schott KL 1500 LCD)
 Guide wire 0.014” – Hi-Torque Cross-IT 200XT
(AbbotVascular, USA)
 Micro serrifine curved (Inter Focus #18055-05)
 Forceps type clip applicator (Inter Focus #18057-14)
 Needle holder (World Precision Instrument #14109)
 Forceps and scissors:
o Vannas scissors for arteriotomy (World Precision
Instrument #501778)
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o Vannas scissors for cleaning vessels (Inter Focus
#91501-09)
o Fine Iris scissors for skin incision (Inter Focus #14094-
11)
o Tweezers Dumont (World Precision Instrument
#500339)
o Tweezers Dumont (World Precision Instrument
#500234)
 Syringes
o Insulin syringe 0.3ml with needle 29G x 13mm (Terumo)
o Insulin syringe 0.5ml with needle 27G x 13mm (Terumo)
o Insulin syringe 1ml with needle 29G x 13mm (Terumo)
 Surgical sutures
o VICRYL absorbable surgical suture, 6-0, ETHICON
(Johnson & Johnson)
o VICRYL absorbable surgical suture, 8-0, ETHICON
(Johnson & Johnson)
 Microscope slide (Cell Path)
 Microscope Coverslip 22 x 22mm (SLS)
 Others
o Cotton tips
o Gauze
o Hair removal cream (Veet)
o Adhesive tape
 Reagents
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o Isoflurane-Vet (Merial Animal Health Ltd, Essex, UK)
o 4% paraformaldehyde (Fisher)
o Rodent No.1 maintainence diet (Specialist Diet Service,
UK)
o Evans Blue (Fluka)
o Buprenorphine (Alsatoe Animal Health, UK)
 Serum free protein block (DAKO, UK)
 Tissue-Tek OCT compound (Sakura, Netherlands)
 rabbit polyclonal antibody to mouse/human CD31 - ab28364
(Abcam,UK)
 goat polyclonal anti-rabbit conjugated to Chromeo642 -
ab60319 (Abcam, UK)
 DAPI-Fluoromount-G (Southern Biotech, AL, USA)
 Laser Doppler analysis (Moor LDI2-HR, Moor systems, UK)
 LSM 700 laser scanning confocal microscope (Zeiss)
3.5 Akt Kinase activity assessment and Western Immunoblotting
 Akt Kinase assay Kit (Nonradioactive) (Cell signalling)
 Tris-Buffered saline with Tween-20
 Dried skimmed milk (Marvel)
 Bovine serum albumin (Santa Cruz Biotechnology)
 NuPAGE® LDS sample buffer (Invitrogen)
 NuPAGE® Sample reducing agent (Invitrogen)
 MES SDS Running Buffer (Invitrogen)
 4-12% Bis-Tris Gels 1.5mm 10 well (Invitrogen)
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 Precision Plus Protein Western C Standards (Bio-Rad)
 Precison Strep Tactin HRP Conjugate (Bio-Rad)
 Immobilon Western Chemiluminescent HRP Substrate
(Millipore)
 Syngene G box imaging system
 Akt Rabbit Antibody (New England biolabs)
 Phospho-Akt Ser 473 Rabbit Antibody (New England biolabs)
 eNOS Mouse Antibody (BD Biosciences)
 Phospho-eNOS Ser 1177 Mouse Antibody (BD Biosciences)
 ERK 2 Mouse Antibody (Santa Cruz Biotechnology)
 Phospho-ERK Tyr 204 Mouse Antibody (Santa Cruz
Biotechnology)
3.6 In vitro Angiogenesis, Boyden chamber migration assays and
Invasion studies
 Growth factor reduced BD Matrigel™ matrix (Becton
Dickinson)
 Human Recombinant Vascular Endothelial Growth Factor 165
(Peprotech)
 Biocoat fibronectin coated plastic 24-well culture vessels
(Becton Dickinson)
 Polycarbonate Boyden chamber inserts with 8µm pore size
(Becton Dickinson)
 Boyden chamber inserts with 8µm pore size, pre-coated with
Matrigel (Corning)
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 L-NMMA (Calbiochem)
 Olympus CKX41 Flourescence microscope with ‘Cell F’
software
 Haemotoxylin and Eosin (Sigma)
3.7 Murine aortic ring assay
 Phosphate buffered saline (Sigma)
 Opti-MEM + GlutaMAX-I (Gibco)
 Foetal calf serum (Biosera)
 Dulbecco’s modified Eagle’s medium (Gibco)
 Penicillin-streptomycin (Gibco)
 Collagen type I, rat tail (Millipore)
 Human Recombinant Vascular Endothelial Growth Factor 165
(Peprotech)
 Triton X-100 (Sigma)
 Protein block, serum free (Dako)
 BS1 lectin-FITC (Sigma)
 LSM 700 laser scanning confocal microscope (Zeiss)
3.8 Senescence
 Image J software - National Institutes of Health, USA
 Senescence β-Galactosidase Staining Kit (Cell signalling) 
 Olympus CKX41 Flourescence microscope with ‘Cell F’
software
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3.9 Survival studies
 Recombinant human tumour necrosis factor (TNF) – alpha (R&D
systems)
 Hydrogen peroxide (Sigma)
 Lactate dehydrogenase (LDH) activity kit (Sigma)
 MRX TC 2 microplate reader (Dynex technologies)
3.10 Akt silencing
 Lipofectamine RNAiMax (Invitrogen)
 Akt1 (GCGUGACCAUGAACGAGUUTT, siRNA ID: s659) and
control scrambled siRNA (Invitrogen)
 Opti-MEM serum free media (GIBCO)
3.11 Quantitative PCR
 Trizol reagent (Sigma)
 Isopropanol (Sigma)
 PTC Pellier thermal cycler (MJ Research)
 ABI prism 7900 HT thermal cycler (Applied Biosystems)
 Nano drop machine
 Reverse transcriptase kit (Applied Biosystems)
 Taqman PCR probes (Applied Biosystems)
3.12 PEC isolation
 anti-mouse PECAM-1 antibody (CD-31) (BD Biosciences)
 anti-mouse ICAM-2 antibody (CD-102) (BD Biosciences)
 anti-rat IgG Dynabeads (Invitrogen)
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 Magnetic Particle Concentrator (MPC) (BD Biosciences)
 DMEM (Gibco)
 Collagenase/Dispase (C/D) (Roche)
 Cell strainer 70 μm nylon (Becton Dickinson) 
 14G Cannula (BD Biosciences)
 10ml Syringes (BD Biosciences)
 Petri dishes (Nuncon)
 MACSmix™ Tube Rotator (Miltenyi Biotec)
 Scalpel blades (Swann-Morton)
 Bovine serum albumin solution (Gibco)
 Gelatin from Bovine skin (Sigma)
3.13 Scratch wound assay
 Sterile, non-coated, cell culture treated 24 well plate (BD Falcon)
 Olympus CKX41 Flourescence microscope with ‘Cell F’ software
 Mitomycin C from Streptomyces caespitosus (Sigma)
3.14 Proliferation assay
 LSM 700 laser scanning confocal microscope (Zeiss)
 Click-iT® EdU Alexa Fluor® 488 Imaging Kit (Life technologies)
 Phosphate buffered saline (Sigma)
 4% paraformaldehyde (Fisher)
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Chapter 4. Methods
4.1 LEPC derivation
4.1.1 Subject selection
Posters seeking healthy volunteers were displayed within the university
campus after seeking appropriate ethical approval. Subjects were given
written information prior to providing written consent. Ethical approval was
provided by the Harrogate and district, and Leeds Central, NHS research
ethics committees (06/Q1107/32 and 11/YH/0030). Ethnicity was defined by
subjects from a list used in UK healthcare monitoring [226]; those selecting
‘Asian or British Asian’ were allocated to the South Asian cohort and those
selecting ‘White’ were allocated to the white European cohort.
Subjects were required to be male, aged 18-40, and other exclusion criteria
included; smoking within the past year, obesity (BMI>30), diabetes,
hypertension (>160/90mmHg), hypercholesterolaemia (Total cholesterol
>7mmol/L) and not taking regular medications. These criteria were chosen to
minimise variability not related to ethnicity. Subjects were screened for the
above criteria with a questionnaire, clinical exam and blood testing. Twelve
white European and twelve South Asian men were recruited.
Blood pressure, body mass index, waist-hip ratio, full blood count, urea and
electrolytes, liver function tests, fasting lipid profile, fasting insulin and fasting
glucose were all measured in each recruit. All blood tests were analysed by
the laboratory at the Leeds General Infirmary, with the exception of fasting
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plasma insulin levels. This was measured in house with the use of an ELISA
as per manufacturer’s instructions. HOMA-IR, the index of insulin resistance,
was calculated as fasting insulin x fasting glucose/22.5 [227].
4.1.2 LEPC derivation
Blood samples were taken and stored in EDTA coated tubes. 30mls of blood
was mixed with an equal volume of phosphate buffered saline (PBS) and
layered on top of Ficoll Paque PLUS prior to density gradient centrifugation
(30mins, 300G, 22ºC, brake off). Peripheral blood mononuclear cells
(PBMCs) were aspirated from the buffy layer and washed in 50mls of PBS
and re-centrifuged at 400G for 10 minutes. The cell pellet was washed once
more in 50mls of PBS at 400G for 10 minutes. The resultant cell pellet was
re-suspended in 6mls of supplemented EGM2 media before being split, in
equal volumes, into 3 wells of a fibronectin coated 6-well plate. Non adherent
cells were removed daily for the initial 7 days of culture with a full culture
media change and PBS wash. Half media changes were then performed on
alternate days. Colonies of late outgrowth endothelial progenitor cells, with
typical cobblestone morphology, were identified at approximately days 21 to
28 of culture (see Figure 4-1). These populations were then expanded via
serial passage. After 2 passages the cells were detached from the culture
vessel using 0.025% Trypsin/EDTA and centrifuged at 400G for 10mins. The
LEPCs were re-suspended in 1 ml of cryo-medium in order to be stored in
liquid Nitrogen for use at a later date. Prior to placement in liquid Nitrogen,
cells were placed in a -80ºC freezer inside a freezing container containing
isopropyl alcohol for 24 hours. This results in slow cooling, lowering the
temperature by 1ºC per minute, which is necessary for cryopreservation of
cells.
Figure 4-1: Example of LEPC colony and subsequent expansion. Scale bars
denote 500µm.
4.1.3 Lentiviral transduction
As discussed previously, work in our lab has already identified dysfunction
the LEPC from healthy south Asian men and associated this with down
regulation in the Akt/eNOS signaling axis. This dysfunction was reversed by
over expressing Akt and this method was repeated for my studies to assess
any effect on South Asian
protocol.
Recent reports have identified a somatic mutation of Akt1
breast, ovary and colorectal cancers. This mutation results in the substitution
of lysine for glutamic acid a
mutation alters the pleckstrin homology domain (PHD) of the protein and
results in constitutive
the plasma membrane Akt is readily phosphorylated at serine 473 and
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LEPC performance in a hindlimb ischaemia
t amino acid residue 17 (E17K)
localization to the plasma membrane. Once localized at
in
found in human
[228]. This
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threonine 308. This mutation therefore renders Akt constitutively active. A
lentivirus (pHVSLS2) was used to deliver this constitutively active form of
Akt1 to the South Asian LEPCs. Lentiviral delivery (pSINCSGWdlNot1) of
enhanced green fluorescent protein (EGFP) to matched LEPC samples was
performed as a control to account for the effect of viral infection on the
function of the cells.
pSINCSGWdlNot1 was a kind gift of Dr. Yashiro Idea (Mayo Clinic,
Minnesota, USA). The EGFP cassette of pSINCSGWdlNot1 was replaced by
E17KAkt to generate pHVSLS2. The SIN-lentiviral vectors were generated in
accordance to established protocols [229]. Production of the lentivirus and
subsequent cell transduction was performed by Dr Sam Stephen. Viral
titration work was carried out by Dr Hema Viswambharan.
The lentiviral vectors were titred using QuickTiter™ Lentivirus Titer Kit
(Lentivirus-Associated HIV p24 ELISA kit [Cell Biolabs]) in accordance with
manufacturer’s protocol. The method is as follows. 100µl of inactivated
lentiviral sample or p24 standard was added to a p24 antibody coated plate
and incubated for 1 hour at 37ºC. After washing the plate with provided
buffer 100µl of FITC-conjugated anti-p24 antibody was added to each well.
This was agitated at room temperature for 1 hour and then washed 3 times
with the provided wash buffer. These were repeated with a HRP-conjugated
anti-FITC antibody in place of the FITC-conjugated anti-p24 antibody.
Provided substrate solution (100µl) was added to each well and the plate
was left for a further 30 minutes at room temperature. 100µl of stop solution
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was then added to each well and absorbance at 450nm was measured
immediately with a plate reader. According to the manufacturer’s instructions,
the results were used to calculate the concentration of lentiviral particles.
LEPCs were then infected with differing amounts of virus to infer the
appropriate ratio of virus particles to LEPCs (multiplicity of infection, or moi)
required to increase Akt activity by the desired amount; one moi of virus was
used to increase Akt activity by a factor of 3 (as defined in pilot studies for a
previously conducted project).
Prior to use in experiments semi-confluent second passage LEPC were
transduced at one multiplicity of infection (moi) of appropriate lentiviral vector
for use 4 days later.
4.2 LEPC transfusion studies
4.2.1 Preparation of cells for transfusion
On the day of hindlimb ischaemia induction, LEPCs were prepared in the
following manner. Cells were labelled with CMDil cell tracker to enable
subsequent in vivo tracing studies; this was done by reconstituting one vial of
CMDil cell tracker (containing 50µg of CMDil) with 50µl of DMSO. This
solution was then added to 50mls of complete EBM2 (supplemented with
bullet kit and 10% FCS). Media was aspirated from the LEPCs and replaced
with 2mls per well (6well plate) of the CMDil/EBM2 mixture and cells were
placed in the incubator for 5 minutes. Cells were then detached from the
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plate using Trypsin/EDTA solution and enumerated with a haemocytometer.
3x105 LEPCs were used for each injection, and these cells were
resuspended in 300µl of complete EBM2 media. The cells were aspirated
into a 0.5ml syringe with a 27G needle attached and transported on ice to the
animal facility to be transfused following surgery.
4.2.2 Hindlimb ischaemia
CD1 Immunodeficient mice were used to assess the capacity of LEPC to
augment angiogenesis in vivo; this was done with a hindlimb ischaemia
protocol. 24-72 hours prior to femoral artery ligation hair removal was
undertaken. This was done after anaesthetic induction with 5% inhaled
isoflurane in an anaesthetic chamber. Anaesthesia was maintained with 1-
2% inhaled isoflurane delivered via face mask. Appropriate anaesthesia was
confirmed by loss of withdrawal reflexes in the paw. Hair was carefully
removed with clippers to the naval level, front and back. To remove residual
hair, depilation cream was applied and gently removed with water and tissue
paper. The mice were then recovered in a controlled manner and left until the
following day, when cutaneous inflammation had resolved, and they were
ready for the surgical procedure.
Anaesthesia was carried out as described above for the femoral artery
ligation, along with an intraperitoneal injection of buprenorphine (0.25mg/Kg).
An incision was made over the right inguinal ligament and the femoral
vessels were identified and dissected. The femoral artery was ligated
proximally at the inguinal ligament and distally at the bifurcation giving rise to
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the popliteal and saphenous vessels. The ligated section of femoral artery
was then removed and the wound was closed. Laser Doppler was performed
2 hours post-operation to confirm induction of hindlimb ischaemia.
Six hours following the induction of hindlimb ischaemia 3x105 pre-prepared
CMDil tracked LEPCs in EBM2, or vehicle alone as negative control, were
injected into the contralateral femoral vein at the time of sham surgery.
Following the sham procedure assessment of limb perfusion was performed
via laser Doppler analysis.
4.2.3 Laser Doppler
Laser Doppler was undertaken to confirm ischaemia and to monitor recovery
of perfusion 14 days later. Laser Doppler measurement was performed
under anaesthesia. Before Doppler analysis, the machine was calibrated with
the kit provided by the manufacturer. Mice were anaesthetised using 5%
inhaled isoflurane (in Oxygen) for induction and maintenance was achieved
with 1-2% inhaled isoflurane. Mice were gently immobilised with tape by the
front paws in a supine position. The hindlimbs were gently extended and
externally rotated and held in place by a 3-5mmx2mm section of double
sided tape to allow visualisation of the appropriate section of hindlimb. The
limbs were then imaged by the laser Doppler and limb perfusion was
calculated by analysing signal flux below the ankle with the software
provided. The flux arising from the injured limb was divided by the flux from
the non-injured limb, after correction for the area that was measured, to give
an ischaemic/non-ischaemic flux ratio. The mouse was then woken and
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placed back with its litter mates, typically in cages of 2-4 mice. Mice were not
housed alone unless fighting between siblings occurred. Mice were
euthanised on day 14 after contucting repeat laser Doppler analysis.
Adductor and gastrocnemius muscle was harvested from both limbs at this
point for use for histological analysis. See Figure 4-2 for representative
image following laser Doppler.
Figure 4-2: Laser doppler imaging; pre and post hindlimb ischaemia
induction. Red indicates areas of high flux and therefore areas with
increased perfusion. Conversely, blue is indicative of low flux and low or
absent perfusion. Green represents areas with intermediate flux/perfusion.
4.2.4 Histological analysis
On day 14 post-surgery, perfusion fixation with 4% paraformaldehyde was
carried out under isoflurane anaesthesia. Ischemic and contralateral-limb
gastrocnemius muscle was then harvested and embedded in OCT, prior to
snap freezing in liquid nitrogen and cryosectioning at 10µm thickness on to
glass slides pre-coated with polylysine. Specimens were then blocked with
serum free protein block (Dako) and incubated for 2 hours at room
temperature with a rabbit polyclonal antibody to mouse/human CD31 (1:500
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dilution) and washed with PBS. This was followed by a 1 hour incubation with
a goat polyclonal anti-rabbit conjugated to Chromeo642 (1:100 dilution) then
mounted on slides with DAPI to define nuclei. Confocal microscopy (Zeiss
LSM 510 META Axioplan 2) was used to count engrafted LEPC, defined by
nuclei with peripheral DiI and Chromeo642 fluorescence, per mm2.
4.3 Transduced LEPC functional studies
4.3.1 Tubule formation
The required number of wells of a non-coated 24-well plastic cell culture
plate were coated with 200µl of standard concentration, growth factor
reduced, Matrigel and placed in a 37ºC incubator for 30 minutes. To render
the cells quiescent, they were incubated in EGM-2 with 1% foetal calf serum
for 4 hours. After this, cells were detached from the culture vessel with
trypsin and enumerated using a haemocytometer. LEPCs (5×104 cells in 1ml
of EGM-2 with 1% foetal calf serum with or without 50ng/ml VEGFA165) were
seeded in triplicate then cultured for 24 hours; in a subset of experiments
0.1mmol/L L-NG-nitro-l-arginine methyl ester (L-NMMA), a nitric oxide
synthase antagonist, was also added to culture medium. After 24 hours the
plates were imaged with a phase contrast microscope (4 images per well at
pre-defined positions, to avoid bias) and analysed. Tubules were defined as
contiguous structures (see Figure 4-3: Representative image of tubules on
Matrigel. Scale bar denotes 2500µm. x40 magnification.Figure 4-3 for
example of contiguous structure) and a mean number of tubules was
calculated per sample by calculating the mean number of tubules per high
power field from the 3 wells, i.e. 12 images
magnification)).
Figure 4-3: Representative image of tubules on M
2500µm. x40 magnification.
definition of all contiguous structures within that field of view.
4.3.2 Migration studies
LEPC were serum starved for 4 hours in EGM2 supplemented with 1% FCS
prior to being treated with Trypsin to aid detachment from the culture plate
and enumeration. 4×10
FCS, without other additives)
modified Boyden chamber apparatus. The lower compar
basal EGM2 medium
Vascular Endothelial Growth Factor (VEGF
were fixed in 70% ethanol before mechanical removal of cells on the upper
surface, and Haematoxylin/Eo
in 10 high power fields (HPF: 1430x1060µm).
in triplicate. See Figure
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(HPF: 7150x5300µm (x4
atrigel. Scale bar denotes
The panel on the right demonstrates the
4 LEPC, suspended in basal EGM2 medium (1%
, were placed in the upper compartment of
with 1% FCS, with or without (control)
A165). After 24 hours
sin staining; migrant LEPC were enumerated
Experiments were conducted
4-4 for a representative image.
0
tment contained
50ng/ml
, membranes
104
Figure 4-4. Representative image of Boyden chamber experiment x200
magnification. Scale bar denotes 500µm.
4.3.3 Senescence
Sub-confluent 3rd passage LEPCs were studied using a senescence-
associated β-galactosidase staining kit. Cells were washed with PBS before 
treatment with the provided fixative solution. After 15 minutes the cells were
washed two further times with PBS before adding the provided β-
galactosidase staining solution and incubating overnight at 37ºC in ambient
air. Senescent cells were identified by observing those cells that had
developed a deep blue colour. Senescent EPCs were counted using Image
J software and expressed as % of total cells. See Figure 4-5 for a
representative image.
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Figure 4-5. Representative image of senescence experiment x200
magnification. Cells with a deep blue colour were identified as being
senescent.
4.3.4 Survival studies
An assessment of cell survival was carried out in LEPCs from South Asian
donors transduced with E17KAkt or EGFP. This was done using a toxicology
assay kit purchased from Sigma. This previously published method [98],
measures LDH release from cells, a surrogate marker for cell membrane
damage and cytotoxicity. 1x105 LEPCs (transduced with EGFP or E17KAkt)
were plated per well in 24w plate and allowed to adhere for 4 hours.
Confluence was confirmed, and media was prepared to simulate an ‘infarct
environment’, in order to ‘stress’ the cells and induce cytotoxicity. This was
done by adding 0.5% heat inactivated (to denature LDH) FCS, 20ng/ml TNF-
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alpha, and 500µM hydrogen peroxide, to basal EBM2. The cells incubated in
the infarct environment media were then placed in a 1% O2, 5% CO2
incubator at 37°C for 24 hours. Half of the conditioned media (450µl) was
collected from each well from the plate and transferred into Eppendorfs, and
then centrifuged to remove cellular debris. 50µl of the supernatant was taken
and added to a separate 96 well plate in duplicate; as a control, we also
added infarct environment media in 2 wells to confirm low background LDH
activity. 50µl of the provided LDH assay lysis solution was added to each
well of the 24 well plate, which was then placed in a standard cell culture
incubator for 45 minutes, agitating every 15 minutes. During these 45
minutes a reaction mixture was prepared according to manufacturer’s
instructions by combining equal volumes of assay substrate solution, assay
cofactor preparation, and assay dye solution.
After 45 minutes, all of the lysed cell conditioned media was aspirated and
into Eppendorfs and centrifuged to pellet the debris. 50µl of the supernatant
was then added to a 96 well plate in duplicate. 100µl of the prepared reaction
mixture added to each well of a 96 well plate. This plate was then stored in
the dark for 25 minutes prior to stopping the reaction by adding 15µl 1M HCl
to each well of the 96 well plate. A plate reader was used to measure 490nm
and 690nm absorbance (the latter to normalise plate-related absorbance
differences). LDH activity was then inferred using the normalised absorbance
(490nm-690nm). We measured LDH activity in the conditioned medium from
the cells exposed to the infarct environment and normalised to total cellular
LDH.
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4.3.5 Invasion studies
Invasion assays were carried out in an identical manner to the migration
studies described in section 4.3.22, other than using Boyden chamber inserts
pre-coated with Matrigel (Corning), to define VEGF-directed invasion, versus
vehicle control.
4.4 LEPC Akt knockdown studies
4.4.1 Akt knockdown
confluent OEC were transfected with 20nM Akt1 siRNA
(GCGUGACCAUGAACGAGUUTT, ID: s659) or control, scrambled Sub-
siRNA (Invitrogen) using Lipofectamine RNAiMax (Invitrogen), according to
the manufacturer’s instructions. Confirmation of Akt1 knockdown, and
functional studies, were conducted 48 hours later. In brief the method used
was as follows; the cells were ready to use when 60-80% confluency was
reached. The siRNA and Lipofectamine were both diluted in Opti-MEM
media and mixed in a 1:1 ratio. This mixture was incubated for 5 minutes at
room temperature and then added to the cells. The cells were incubated for
24 hours at 37oC, 5% CO2, for 24 hours and then washed before adding
standard growth media. Knockdown was confirmed at 48 hours by western
blotting for total Akt1 in cell lysates. All functional studies were conducted at
this point.
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4.4.2 Femoral artery injury studies using transfected LEPCs
CD1 Immunodeficient mice were used to assess the reparative capacity of
the LEPCs from white European volunteers following Akt1 silencing. Mice
were anaesthetised using isoflurane before three 1.5cm passes of a 0.014-
inch-diameter angioplasty guidewire was used to denude the endothelium
from the femoral artery. The contralateral artery underwent sham operation,
without arteriotomy or wire injury. Animals received buprenorphine
0.25mg/Kg analgesia. Six hours following this wire-induced injury, equal
numbers (3x105) of cell tracked LEPC in EBM2 were injected into the
external iliac vein. After 4 days, 50µl of 0.5% Evans blue dye was injected
into the inferior vena cava and the mice were perfusion fixed with 4%
paraformaldehyde. Areas staining blue represented persistent denuded
endothelium. See Figure 4-6 for representative images. Conversely, re-
endothelialisation was defined as the region of absent Evan’s blue staining in
relation to a total area of a 5mm long section of vessel, commencing 5mm
distal to the aortic bifurcation. Vessels were then blocked (Serum free
protein block) and incubated for 2 hours at room temperature with a rabbit
polyclonal antibody to mouse/human CD31 (1:500 dilution), this was
followed by a PBS wash step. Samples were then incubated for 1 hour at
room temperature with a goat polyclonal anti-rabbit antibody conjugated to
Chromeo642 (1:100 dilution), washed with PBS and then mounted en face
on slides with DAPI to define nuclei. Confocal microscopy (Zeiss LSM 510
META Axioplan 2) was performed on the intima of femoral artery specimens
and adherent, fluorescently labelled cells that co-stained for CD31 and
CMDiI cell-tracker were enumerated to define the abundance of LEPCs
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incorporated into the endothelium. All murine studies and analysis were
performed blinded to ‘treatment’ allocation.
Figure 4-6. Representative image of explanted femoral arteries stained with
Evan’s blue. Blue areas represent areas that have yet to re-endothelialise. In
each panel there are two vessels from the same mouse; on the left is the
uninjured vessel and on the right is the injured vessel. The vessel in the
panel on the right demonstrates increased Evan’s blue staining, and
therefore delayed endothelial regeneration, in comparison with the vessel in
the left panel. Scale bar denotes 5mm.
4.5 Animal Husbandry
4.5.1 Insulin receptor knockout mice
Insulin receptor knockout mice (IRKO) were originally developed at the
National Institutes of Health, Bethesda, USA [230]. IRKO mice have global
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hemizygous null mutations of the insulin receptor. These mice were created
by targeting the insulin receptor gene in a manner that results in a null allele.
Gene inactivation is achieved by first constructing a targeting vector that will
introduce a sequence including a neomycin resistance cassette and a
premature termination chain. Genes were transferred via electroporation into
embryonic stem cells. Stem cells were allowed to grow and colonies
containing the mutant gene sequence were selected on the basis of
neomycin resistance and expanded before being injected into day 3.5 murine
embryos and implanted into female mice resulting in chimaeric offspring.
Chimaeric males, determined by coat colour, were mated with C57Bl6
females, and the presence of germline mutation in the insulin receptor was
confirmed via southern blotting. Offspring were used to establish colonies.
Mice homozygous for the null allele (IR-/-) develop normally but quickly
develop hyperglycaemia and die after 48-72 hours of ketoacidosis. Mice
heterozygous for the null allele (IR-/+ or IRKO) exhibit apparently normal in
utero development, and are insulin resistant without demonstrating overt
hyperglycaemia [231]. The IRKO model has been chosen for this project so
that the effects of insulin resistance, rather than hyperglycaemia, on vascular
regeneration can be observed. Genetic manipulation was not undertaken as
part of this project, as breeding colonies were already established at the
University of Leeds at the outset. Mice were originally bought from the
Jackson laboratory stock and bred with C57Bl6 females.
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4.5.2 Breeding conditions
Breeding trios were set up to continue the colony. This comprised of 1 male
and 2 females. Only the male ever carried the null allele and all mice were on
a C57Bl6 background. Mice used for breeding were at least 6 weeks of age
and preferably under 6 months of age. Access to food and water was not
restricted.
4.5.3 Nude Mice
Nude mice were first discovered by Dr. N. R. Grist in 1962 at the virus
laboratory at Ruchill hospital, Glasgow. They are hairless, hence the ‘nude’
nickname, but also have a genetic mutation resulting in the deletion of the
FOXN1 gene, which consequently results in the absence of a thymus gland.
Due to the lack of a thymus gland these mice are unable to produce mature
T lymphocytes and the result of this is impairment in an array of immune
responses. A particularly useful characteristic, in terms of research, is the
inability to reject donor material and this has led to widespread use in tumour
research. We chose this mouse as it will not reject human donor cells,
namely LEPCs.
9-13 week old (weight 25-33g) male immuno-deficient CD1 nude mice
(Charles River Labs) were utilized for the hindlimb ischaemia experiments
required for in vivo assessment of human LEPC function.
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4.5.4 Housing and experimental conditions
All experiments were conducted in full accordance with Home Office UK
regulations, as mandated by the Experimental Animals (Scientific
Procedures) Act 1988. Mice were housed in the animal facility at the
University of Leeds under standard laboratory conditions in humidity (55%)
and temperature (21ºC) controlled conditions with a 12-hour light-dark cycle.
Animals were fed a standard chow diet and normal drinking water. Access to
food and water was not restricted. Offspring were weaned at approximately
3-4 weeks onto a standard chow diet and at this point the mice were
separated from their parents into male and female cages. Ear notching was
performed in conscious mice at age 3-4 weeks, to allow identification, and to
provide tissue for genotyping. Mice were housed in cages, irrespective of
genotype, with a maximum of 5 mice per cage. Housing of single animals
was avoided wherever possible. Only male animals were used to exclude the
potential effects of cyclical variation in oestrogens. Mice were aged 8-12
weeks when taken for experiments. When mice were euthanised this was
done via exposure to rising concentrations of CO2 in a commercially sourced
cabinet. This was done over a 10 minute cycle after which death was
confirmed via cervical dislocation. The exception to this was when
experiments required euthanasia with terminal anaesthesia.
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4.5.5 Genotyping
4.5.5.1 DNA extraction
DNA extraction was performed using ear notches and incubating them in
100µl of 25mM NaOH/0.2mM EDTA solution for 20 minutes at 95ºC. After 20
minutes 100µl of 40mM Tris-HCL was added and the sample was vortexed.
4.5.5.2 PCR
PCR was performed in 25µl reaction volumes consisting of 2.5µl PCR buffer
(containing 750mM Tris-HCl, 200mM (NH4)2SO4, 0.1% Tween 20), 2µl of
MgCl (25mM), 0.5µl of dNTP, 0.5µl of primers, 0.2µl of Taq enzyme,17.3µl of
water and 1µl of sample. Three primers were obtained commercially
(Invitrogen) and sequences were as follows: TTA AGG GCC AGC TCA TTC
CT CC (forward), AGC TGT GCA CTT CCC TGC TC AC (forward) and TCT
TTG CCT GTG CTC CAC TCT CA (reverse). After mixing DNA samples with
the reaction mix, tubes were placed in a thermal cycler. After completion of
31 amplification cycles (94ºC for 4 mins; 94ºC for 1 min, 62ºC for 1 min, 72ºC
for 1 min and 72ºC for 4 mins) the products were identified by
electrophoresis on a 1% agarose gel containing 3 µl of ethidium bromide
(10mg/ml) (Sigma). Imaging of bands was performed by fluorescent imaging
using a 100 base pair reference ladder and compatible software
(ChemiLmager 5.5). The WT allele product is 232 base pairs, the null allele
gives a product that is 255 base pairs in length. See Figure 4-7 for
representative image of imaged gel.
Figure 4-7 Representative
mice. IRKO; Insulin receptor knockout, WT; Wildtype
4.6 Western blotting
Cell lysates were generally produced when cells were approximately 95%
confluent in 6 well plates
serum free, unsupplemented media for 4 hours,
basal state or following stimulation with insulin or VEGF
done as follows: they were first washed twice with ice cold PBS in attempt t
arrest any cellular processes. 70
and phosphotase inhibitors,
used to detach and disrupt cells before lysates were aspirated and decanted
into 1.5ml Eppendorf tub
whilst being mixed intermittently to facilitate complete cell lysis. Samples
were then centrifuged at 13000rpm for 15 minutes at 4
supernatant was then aspirated and decanted into clean
tubes. The remaining pellet was discarded.
Before beginning western blotting, protein quantification was undertaken to
allow for the same amount of protein to be loaded for each sample in
subsequent electrophoresis and to ultimately allow
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image of gel used to genotype IRKO and WT
.
. Following quiescence of cells, by incubation in
cells were lysed in their
. L
µl of ice cold RIPA buffer, including protease
was added to the cells and a cell scraper was
es. Cell lysates were then left on ice for 30 minutes
º
accurate comparison.
ysis of cells was
o
C. The resultant
1.5ml Eppendorf
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Protein quantification was done using a commercially acquired bicinchoninic
acid (BCA) assay. The method used was as follows: samples were diluted
1:8 with distilled water and were mixed before being pipette into a 96 well
plate (25µl per well). 9 different, known concentrations of bovine serum
albumin (BSA) were also placed (25µl per well) into the 96 well plate. All
samples and protein standards were set up in duplicate. 200µl of BCA
reaction mix, containing BCA reagent A and BCA reagent B (50:1 ratio) was
then added to each well and the plate was covered with sealing tape and
incubated for 30 minutes at 37ºC. Absorption spectra were measured at
562nm and Protein quantification was done in reference to the known
concentrations of BSA and correction for the initial 1:8 dilution.
When the protein concentration was known, 30µg of sample was taken and
mixed with loading dye to achieve a (1:4) dilution and reducing buffer (1:10)
dilution. RIPA buffer was added to make the total volume 50µl. Each sample
was then heated to 95ºC for 5 minutes. Samples were loaded into the wells
of a pre-cast 4-12% polyacrylamide gel. One well was loaded with a protein
reference ladder. The gel was placed in a tank and 500ml of running buffer
was added (25ml MES SDS running buffer, 475mls distilled water). Samples
were then electrophoresed at 160V for 1 hour.
Following electrophoresis, the gel was then left to soak in transfer buffer
along with filter paper, sponges and a PVDF membrane. Before soaking the
PVDF membrane was first washed with methanol and rinsed with distilled
water. A sandwich was then assembled before protein transfer that consisted
of: sponge, filter paper, gel, PVDF membrane, filter paper, sponge and held
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firmly in a plastic cassette. The cassette was then placed in a transfer tank in
the correct orientation (gel closest to centre of tank) to allow protein transfer.
A mixer was then placed in the tank and it was filled with transfer buffer. An
ice pack was also placed in the tank before the lid was connected to a power
pack (100V for 45minutes).
Following protein transfer the PVDF was air dried prior to immunostaining for
the protein of interest and then washed with methanol and rinsed with
distilled water. The membranes were ‘blocked’ using milk buffer (containing
1.25g milk powder in 25ml of TBS tween) for 1 hour. The antibody of interest
was then added to a pot containing the membrane and left to roll overnight at
4ºC. The antibodies were prepared in milk buffer and diluted according to the
manufacturer’s guidance, which differed depending on the antibody. The
antibodies used and the dilution are indicated in Table 3.
Table 3 Antibodies used for Western blotting
Antibody target Antibody type Manufacturer Dilution
eNOS Monoclonal
mouse
BD 1:1000
Phospho-eNOS
(Ser 1177)
Monoclonal
mouse
BD 1:1000
Akt Monoclonal rabbit Cell Signalling 1:1000
Phospho-Akt
(Ser 473)
Monoclonal rabbit Cell Signalling 1:1000
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ERK 1/2 Monoclonal
mouse
Santa cruz 1:500
Phospho-ERK
1/2
Monocloal
mouse
Santa cruz 1:500
Beta actin Monoclonal
mouse
AbCam 1:3000
HRP conjugated
2º antibody
Mouse/Rabbit Dako 1:1000
After being left overnight the membrane was then washed 3 times with TBS
tween for 10 minutes. A secondary, HRP conjugated antibody directed at
either mouse or rabbit, was then prepared in milk buffer and the membrane
was incubated with this for 1 hour at room temperature. The membrane was
then washed once with TBS tween for 10 minutes, once with TBS tween +
1:25000 Precison Strep Tactin HRP Conjugate for 10 minutes and finally
once more in TBS tween for 10 minutes. The membrane was then incubated
for 5 minutes with Immobilon Western Chemiluminescent HRP Substrate and
sandwiched between 2 acetate films and imaged using the Syngene G box
imaging system.
Once imaged the resultant bands were quantified into arbitrary units via
densitometry using Image J software.
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4.7 Akt activity
Akt activity was determined via a nonradioactive immunoprecipitation-kinase
assay protocol as per the manufacturer’s instruction. Cell lysates were made
as per the western blotting protocol outlined above. Cell lysis buffer provided
in the kit was used in place of RIPA buffer. Prior to centrifugation to remove
cellular debris the samples were sonicated on ice. Beads, conjugated with
Akt primary antibody were provided. Prior to use, they were slowly defrosted
on ice to lower the viscosity of the buffer in which they were suspended. After
protein quantification, 30µg of protein was made up to 200µl by adding lysis
buffer. 20µl of the antibody/bead slurry was then added to the sample and
this mixture was left agitating on a roller for 2 hours at room temperature.
The lysates/antibody/bead mixture was then centrifuged at 14000G for 30
seconds and the pellet was washed twice with ice cold lysis buffer. The
samples were kept on ice during the wash steps. The pellet was then
washed twice more with kinase buffer, provided in the kit, before the pellet
was suspended in 40µl of kinase buffer, and ATP and GSK-3 fusion protein
were added. This reaction mixture was then incubated for 30minutes at
30ºC. After 30 minutes the reaction was terminated by the addition of SDS
sample buffer. The sample was then used in a western blot protocol exactly
as described above and immunostaining for phospho-GSK-3 was done using
an antibody provided in the kit. The phosphorylated product that was
measured was produced in a reaction catalysed by Akt present in the original
cell lysates and is therefore indicative of the Akt activity of the sample.
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4.8 In vivo assessment of angiogenesis in the IRKO mouse
4.8.1 Hindlimb ischaemia protocol
Hindlimb ischaemia was undertaken in IRKO and WT mice in the same
manner that has been described in section 4.2.2. Conditions did not differ but
no cells were administered in this subset of experiments.
4.8.2 Laser Doppler
Laser Doppler was undertaken as described in section 4.2.3, although was
conducted every 7 days for 3 weeks after the initial assessment on day 0 to
confirm appropriate induction of hind-limb ischaemia.
4.8.3 Histological analysis
On day 21 post-surgery, perfusion fixation with 4% paraformaldehyde was
carried out under isoflurane anaesthesia. Ischemic and contralateral-limb
gastrocnemius muscle was then harvested and snap frozen in liquid nitrogen
and embedded in paraffin prior to sectioning at 5µm thickness on to glass
slides pre-coated with polylysine. Specimens were then blocked with serum
free protein block (Dako) and incubated for 2 hours at room temperature with
a rabbit polyclonal antibody to mouse/human CD31(1:500 dilution) then
washed with PBS. A further 1 hour incubation at room temperature with a
goat polyclonal anti-rabbit conjugated to Horse Radish peroxidase (1:100
dilution) followed. The specimens were then incubated with DAB substrate
and mounting on slides was completed with the addition of a coverslip
following staining with Haemotoxylin and Eosin. Brightfield microscopy was
used to count capillaries
between myocytes.
Figure 4-8. Representative image taken
gastrocnemius muscle harvested following hindlimb ischaemia. X400
magnification. Scale bar denotes 250
4.8.4 Quantitative PCR
Gastrocnemius and adductor muscle were harvested following hindlimb
ischaemia for analysis of VE
PCR. The methods used are described below.
4.8.4.1 RNA Extraction
Prior to RNA extraction tissue samples were placed in a 1.5ml Eppendorf
tube containing 1ml of Trizol reagent (Sigma) and lysed using a mechanical
tissue lyser. The resultant mixture was centrifuged at 10,000g for 10 minutes.
The supernatant was transferred to a fresh tube and 200ul of phenol
chloroform was added. The tubes were shaken vigorously for 15 seconds
and left to settle for 3 minutes before an
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. These were identified as brown structures running
See Figure 4-8 for a representative image.
following histological analysis of
µm.
GF expression, which was done via quantitative
other centrifugation step (12,000g for
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15 minutes). The resulting clear layer was carefully removed with a pipette
and decanted into a clean tube. 500µl isopropanol was added before being
gently mixed and left at room temperature for 10 minutes. The samples were
placed in the centrifuge and span at 12,000g for 10 minutes, the resulting
supernatant was discarded and the pellet was mixed 1ml of 75% ethanol and
span at 7,500g for 5 minutes. The supernatant was carefully removed and
the samples were left to air dry for 10 minutes. Samples were mixed with
20µl of RNase free water and placed on ice for 20 minutes. RNA
concentration was then measured using a nanodrop system and relevant
software. Samples were stored at -80ºC until needed.
4.8.4.2 Reverse transcriptase PCR
Before performing quantitative PCR, RNA obtained from the extraction
process was converted to complimentary DNA (cDNA). 1µg of RNA was
added to a mastermix, containing water, random primers, dNTPs, multiscribe
enzyme (reverse transcriptase) and buffer. The RNA was diluted in water (10
µl total volume) and this was added to the mastermix to give a final reaction
volume of 20µl. This was then placed in a thermal cycler (25ºC for 10
minutes, 37ºC for 2 hours 85ºC for 5 minutes) and then either used for
quantitative PCR or stored at 4ºC.
4.8.4.3 Quantitative PCR
Quantification of RNA expression was done using cDNA obtained as outlined
above. The PCR reaction was performed in a thermal cycler (ABI Prism
7900HT, Applied Biosystems) using Taqman as the fluorescent probe to
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detect PCR products. Samples were analysed in triplicate and an average of
the 3 readings was used to calculate the relative expression using the
comparative Ct method. Reaction volumes were 19 µl and made up as
follows; water 8µl, Taqman 10µl, primer 1µl. Beta-actin was used as the
house keeping gene for normalisation and the sequence was as follows:
forward TTCTACAATGAGCTGCGTGTG and reverse
GGGGTGTTGAAGGTCTCAAA. The insulin receptor primers used had the
following sequence: forward TGCCACCAACCCCTCTGT and reverse
CGGAGGGTGGTTTCCACTT. Other primers used included an 18s Taqman
probe; product code Mm02601777-g1, and a VEGFA Taqman probe; product
code Mn01281449-m1.
4.9 PEC Isolation
This previously described method [232] was used to isolate pulmonary
endothelial cells (PECs) from murine lungs. The endothelial cells cultured
were then use in an array of in vitro functional assessments and signalling
studies.
4.9.1 PECAM bead preparation
Prior to obtaining tissue for pulmonary endothelial cell (PEC) isolation
antibody/bead solutions were prepared. 200µl of magnetic bead solution was
aliquoted into a 1.5ml Eppendorf tube. This was then loaded onto a magnetic
column and left for 1 minute. The supernatant was then removed and the
magnetic beads were washed four times with a 0.5% BSA/PBS mixture. The
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beads were then resuspended in 500µl of 0.5% BSA/PBS and mixed with
10µl of anti cd-31 (anti PECAM). This mixture was agitated overnight at 4ºC.
The antibody/Bead solution was then loaded onto the magnetic columns and
washed with 0.5% BSA/PBS four more times in the manner described above.
The antibody/bead solution was finally re-suspended in 200µl of 0.5%
BSA/PBS and stored at 4ºC for up to two weeks. The above steps were
repeated in the same manner to prepare the anti CD102 (anti ICAM)/bead
mixture. This mixture was stored at 4ºC for up to two weeks also.
4.9.2 PEC Isolation
Mice were euthanized at ages 8-12 weeks by exposure to a rising
concentration of CO2. Death was confirmed via neck dislocation.
Subsequently, the lungs were carefully dissected and transferred into Hank’s
buffered salt solution (HBSS) and kept on ice until ready to process further.
In a cell culture hood, the lungs were placed into 10cm Petri dishes and
minced with two scalpel blades until the lungs were cut into approximately
1mm3 cubes. Minced lungs were then mixed with 10mls of a
collagenase/dispase solution (1mg/ml prepared in Dubellcos modified eagle
medium (DMEM)) and agitated for 45 minutes at 37ºC. The mixture was then
passed through a 70µm cell strainer and the collagenase/dispase was
neutralised with complete endothelial cell media containing 10% FCS. The
solution was then triturated with a 14G cannula and 10ml syringe in an
attempt to achieve a single cell suspension. The solution was then
centrifuged for 8 minutes at 400g. The cell pellet was re-suspended in 3mls
of a 0.5% BSA/PBS mixture before the addition of 20µl of PECAM/Magnetic
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bead slurry. The solution was agitated for 15 minutes at room temperature
before proceeding with the magnetic separation of endothelial cells. The
cell/bead mixture was split into three 1.5ml sterile Eppendorf tubes and
loaded onto the magnetic columns. After 1 minute the supernatant was
removed and the cells were washed with 1ml of 0.5% BSA/PBS. The cells
were then loaded onto the magnetic column again. This process was
repeated five times and then the cells were suspended in 10mls of
endothelial cell growth media and plated onto T75 cell culture flasks that
were pre-coated with 2% Gelatin. After twenty-four hours the media was
completely replaced and thereafter half the media was replaced on alternate
days. Clusters of cells then began to grow and when 70% confluency was
achieved, typically after 10-14 days, a second bead separation was
performed. The cells were detached from the flasks using a 0.5%
Trypsin/EDTA solution. When detached from the flask the Trypsin was
neutralised with endothelial cell growth media and the solution was
centrifuged for 8 minutes at 400g. The cell pellet was then re-suspended in
2mls of a 0.5% BSA/PBS mixture and 10µl of the ICAM/Bead slurry was
added. This mixture was agitated at room temperature for 15 minutes. The
solution was then split into two 1.5ml Eppendorf tubes and loaded onto the
magnetic columns. The cells were washed as describe with the first bead
isolation and then re-suspended in 10mls of media once more. These cells
were plated onto a T75 flask pre coated with 2% Gelatin and allowed to grow
to confluency, typically taking approximately 5-7 days. The cells were then
passaged without a bead separation into 3 T75 flasks and allowed to grow to
confluency. At this point they were use for an array of in vitro studies.
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4.9.3 Characterisation of murine PECs
Methods used to confirm the endothelial nature of the cells isolated from
murine lungs included immuno-fluorescence based imaging techniques and
western blotting to confirm the presence of eNOS.
4.9.3.1 Immunocytochemistry
Initially PECs were seeded onto fibronectin coated coverslips and were
allowed to recover and incubated as normal in standard growth media
overnight. The cells were fixed using ice cold acetone for 10 minutes at room
temperature. The use of acetone also permeabilised the cell whilst
preserving membrane bound antigens. The cells were washed twice with ice
cold PBS prior to the blocking stage. Cells were incubated in 1% BSA in
PBSTween for 30 minutes to block subsequent non specific binding of the
antibodies. Cells were incubated with antibody overnight. The antibody used
was an anti-VE Cadherin rabbit polyclonal antibody or a Rabbit IgG Isotype
Control. The cells were washed 3 times with PBS, at each wash step the
PBS was left for 5 minutes. The secondary antibody, again diluted in 1%
BSA in PBSTween, was then added and the cells were incubated for 1 hour
at room temperature in the dark. The secondary antibody was an Alexa
Fluor® 647 Goat Anti-Rabbit IgG (H+L) Antibody. The cells were then
washed a further 3 times (for 5 minutes) in PBS before they were counter-
stained with DAPI for 1 minute. The cells were rinsed again with PBS and
imaged using a confocal microscope. Negative control samples were
processed identically, other than omitting the addition of the primary VE-
Cadherin antibody (See Figure 4-99 for a representative image). This
confirms the presence of VE Cadherin in the anticipated pattern
their endothelial phenotype
eNOS in bead purified samples
Figure 4-9 Panel A
following immune-staining with nuclear stain, DAPI in blue, and Alexa Flour
647 isotype control antibody in Red (Negative control). Panel B
Representative confocal microscopy image of PECs following immune
staining with nuclear stain, DAPI in blue, and VE
Alexa Flour 647 secondary anti rabbit IgG antibody, in Red.
Figure 4-10. Western blot of PEC lysates. Lane A from a lysates made
using PECs derived without two step bead purificatio
lysates made from the PECs derived by the method used for this thesis.
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. Western blotting confirmed the
(See Figure 4-1010).
: Representative confocal microscopy image of PECs
Cadherin antibody with
n. Lane B is from a
, supporting
enrichment of
:
-
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4.10 In vitro assessment of angiogenesis in the IRKO mouse
4.10.1 Aortic ring sprouting assay
Mice were culled at age 8-12 weeks by exposure to a rising concentration of
carbon dioxide; subsequently death was confirmed via dislocation of the
neck. Aortae were harvested into ice cold Opti-MEM media. A dissecting
microscope was used to facilitate the removal of peri-vascular fat and
trimming of side branches. After cleaning, the aortae were gently flushed with
1 ml of Opti-MEM media using a 1ml syringe and 27G needle. The aortae
were cut into approximately 20 rings of approximately 1mm thickness. These
rings were then incubated overnight in serum free Opti-MEM at 37°C in 5%
CO2. The following day (day 0), each ring was placed in individual wells of a
96-well plate and embedded in a plug consisting of DMEM and 1mg/ml rat
tail collagen. The 1mg/ml collagen DMEM mixture was prepared on ice and
75µl volumes were aliquoted quickly into each well of a 96 well plate. Only 5
wells were aliquoted at a time to prevent premature polymerisation prior to
embedding of the aortae. The rings were placed so the lumen of the aorta
was in a vertical orientation. Aortic rings from IRKO and WT littermates were
exposed to either Opti-MEM media containing 2.5% FCS alone, or 2.5% FCS
plus 50ng/ml of VEGFA165. Penicillin-streptomycin was added to the media to
prevent the development of infection. Media was replaced on day 3 and the
rings were fixed and stained on day 5 in preparation for analysis on day 6.
On day 5 all wells were washed with PBS and then incubated for 30 minutes
at room temperature with 4% paraformaldehyde. The fixative was removed
prior to 2 further 15 minute incubations with PBS plus 0.25% Triton-X 100.
Each well was then incubated with 1 drop of DAKO protein blocker for
30mins at 37°C. The rings were then incubated overnight with PBS plus
0.1% Tween-20 and 0.1mg/ml of BS
well was imaged using a laser scan
laser scanning confocal microscope
complete visualisation of the ring and endothelial sprouts.
for representative images
longest sprouts and counting the number of sprouts per ring. Data from the
rings of one mouse was collated and a mean value (mean number of
sprouts, mean sprout length) was calculated for each mouse.
was counted as it emerged from the base of the ring before it had branched.
Data was compared between groups using an unpaired students t test and
statistical significance defined as p<0.05.
Figure 4-11. Panel A: Rep
rings following lectin staining. Scale bar denotes 500
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-1 lectin-FITC. The following day each
ning confocal microscope
). Tiled images were taken (3x3) to allow
See
. The data was analysed by measuring the 3
resentative confocal microscopy imaging of aortic
µm. X200 Magnification.
(Zeiss LSM700
Figure 4-111
Each sprout
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Panel B: Method used to determine sprout length; 3 longest sprouts and
measures taken are shown. Panel C: Identification of sprouts for
enumeration; sprouts were counted prior to branching.
4.10.2 Tubule formation
Murine pulmonary endothelial cells (PECs) were isolated as described and
used at passage 3 to assess tubule formation capacity. Prior to cell seeding,
Matrigel coated plates were prepared. Tube forming experiments were
performed as described as described in section 4.3.1, except that 2x105 cells
PECs were used per well. Prior to seeding the cells were suspended in basal
media containing 1% FCS +/- 50ng/ml of VEGFA. Wells were set up in
triplicate for each condition and imaging was performed
4.10.3 Migration assay (Boyden chamber)
Murine PECs were isolated as described and identified for use in a Boyden
chamber assay at passage 3. Boyden chamber experiments were done as
described in section 4.3.2, except that 5x104 PECs were used per well.
4.10.4 Migration assay (scratch wound)
The capacity for WT and IRKO PECs to migrate was assessed with a scratch
wound assay. Cells were plated in triplicate for each condition on to 24 well
plates that were pre-coated with 2% Gelatin and allowed to grow until
confluent. Prior to plating, a line perpendicular to the intended scratch wound
was drawn underneath the plate to aid localisation during imaging. When
confluent, a proportion of cells were incubated for 12 hours in complete
endothelial cell growth media containing 1
prevent cell division
A horizontal scratch wa
the centre of the plate. Each well was then imaged using phase contrast
microscopy (x40
Mitomycin C previously
studies indicated that after 16 hours
not completely, so this duration was used in all presented data.
each well was imaged again and the plate was discarded. Images were
analysed using Ima
reduction calculated (
hours).
Figure 4-12. Representative image of scratch wou
pictures) and 16 hours (right pictures). Scale bar denotes 500
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µg/ml Mitomycin C in order to
, hence allowing study of migration without proliferation
s then made using a p-200 Gilson pipette tip across
magnification). Cells that had been incubated with
, remained in this media during scratch clo
the wound had closed
ge J software and the percentage of wound area
See Figure 4-122 for representative images at 0 and 16
nd assay at 0 hours (left
.
sure. Pilot
substantially, but
At this stage,
µm. X40
131
magnification. Bottom panels demonstrate the quantification of wound area
at 0 and 16 hours.
4.10.5 Proliferation assay
Assessment of the proliferative capacity of murine PECs was performed via
a commercially available kit. The Click-iT® EdU cell proliferation assay (Life
technologies) utilises EdU (5-ethynyl-2´-deoxyuridine), a modified nucleoside
which is incorporated into the DNA of actively dividing cells. This EdU is then
detected with Click-iT™ EdU Alexa Fluor® azide reagent, and imaging
identifies proliferating cells. Reagents required for the assay were prepared
as per the manufacturer’s instructions. The detailed method is as follows.
PECs were plated onto a twenty-four well micro clear imaging plate and
allowed to grow until approximately 75% confluent. Half of the media was
then replaced with media containing EdU at a concentration of 20µM to
achieve a final concentration of 10µM. The cells were then incubated for two
hours in standard conditions (37ºC, 5%CO2) before proceeding to fixation
and staining. The media/EdU solution was removed from the cells and 1ml of
4% Formaldehyde was added to each well and left at room temperature for
15 minutes. The fixative was removed and the cells were washed twice with
1ml of a 3% BSA/PBS mixture. Cells were then permeabilised for 20 minutes
at room temperature with 1ml of 0.5% Triton X-100 in PBS in each well. The
permeabilisation buffer was removed and each well was washed twice with
3% BSA/PBS. A reaction cocktail was prepared as per manufacturer’s
instructions and 0.5ml of this Click-iT® reaction cocktail was added to each
well. The plate was left in the dark for 30 minutes at room temperature. All
wells were then washed with 1ml of 3% BSA/PBS
nuclear counterstaining. Nuclear staining was undertaken with a Hoechst
stain provided with the kit
5µg/ml Hoechst in PBS solution
BSA/PBS mixture and stored in the dark at 4ºC until ready to image. Imaging
was performed using laser scanning confocal microscopy.
was identified via the nuclear staining
the percentage of
representative image
Figure 4-13. Representative confocal microscopy image of PECs following
EdU proliferation assay. Nuclei are stained with
blue. Proliferating cells have incorporated the EdU and therefore appear
green.
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before proceeding with
(30 minutes in the dark at room temperature with a
). The cells were then washed again with 3%
Total
; proliferating cells were expressed as
total in each field of view (See Figure
).
Hoechst stain and appear
cell number
4-133 for a
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4.10.6 Apoptosis assay
Apoptosis was inferred in PECs from IRKO and WT mice using Western
blotting. A kit containing antibodies against total Caspase 3 and cleaved
Caspase 3, along with positive and negative controls were used. Caspases
are central regulators of apoptosis; once activated, initiation Caspases
cleave and activate effector Caspases, one of which is Caspase 3, and in
turn these proteins cleave other targeted cellular proteins, initiating apoptosis
[233]. Hence, higher levels of cleaved Caspase 3 suggest a higher degree of
apoptosis. Western blotting was carried out as described in section 4.6.
4.11 PEC signalling studies
PECs were isolated as has been described and were plated into gelatin
coated 6 well plates at passage 2. Cells were serum straved to render them
quiescent by incubating them in MV2 only + 1% FCS for 4 hours. Cells were
then stimulated with VEGF (50ng/ml) and lysed at 0, 10, 15 and 30 minutes.
Western blotting of lysates was performed as has been described. Proteins
that were quantified included: enos, phospho enos S1177, Akt, phospho Akt
S473, ERK1/2, phospho ERK1/2, and beta actin was measured to use as the
house keeping protein by which protein levels were normalised.
4.12 Statistics
All data are displayed as mean ± SEM; p<0.05 is denoted by *. Comparative
analysis between groups was performed using the unpaired student t test.
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Statistical significance was taken as P<0.05. Statistical analysis was
performed using Microsoft Excel 2007 software.
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Chapter 5. Results: Part 1
Experiments were carried out to evaluate the ability of LEPCs from WE and
SA donors to augment vascular regeneration. A group of 12 WE and 12 SA
men were recruited to provide blood samples to allow the derivation of
LEPCs. As highlighted in Table 4, these volunteers were well matched for all
classical CVD risk factors. However, the SA group had a significantly higher
fasting plasma insulin level and relative insulin resistance, as demonstrated
by a higher HOMA-IR score.
Table 4: Demographic and cardiovascular risk profile (work carried out in
conjunction with Dr Richard Cubbon and Dr Vivek Baliga)
South Asian White
European
p value
Age (years) 30.9 (1.2) 29.7 (1.1) NS
Body Mass Index (Kg/m2) 24.1 (0.7) 22.4 (0.5) NS
Waist-Hip ratio 0.85 (0.01) 0.84 (0.01) NS
Systolic Blood Pressure (mmHg) 116 (2.3) 116 (2.5) NS
Diastolic Blood Pressure
(mmHg)
70 (1.6) 69 (1.6) NS
Total Cholesterol (mmol/L) 4.6 (0.1) 4.7 (0.1) NS
Triglycerides (mmol/L) 1.1 (0.1) 1.2 (0.1) NS
Glucose (mmol/L) 4.8 (0.1) 4.6 (0.1) NS
Insulin (mu/L) 5.6 (0.8) 2.9 (0.3) 0.009
HOMA-IR 1.2 (0.2) 0.6 (0.1) 0.008
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5.1 LEPC transfusion studies
Previous work in our lab has demonstrated that SA LEPCs have an impaired
capacity to augment endothelial regeneration after vascular injury. This was
associated with impaired indices of in vitro function also; SA LEPCs formed
fewer vascular networks on Matrigel and displayed impaired migration
towards VEGF and IGF-1 [156]. In an attempt to build on these data, we first
assessed the capacity of SA LEPCs to augment vascular regeneration in
comparison to LEPCs from WE donors. We began with an in vivo model,
hindlimb ischaemia, and the results are presented below. As discussed in the
introduction to this thesis, the impaired function, previously observed in our
lab, was associated with reduced abundance of Akt and eNOS protein [156].
Restoration of Akt activity in SA LEPCs rescued their endothelial
regenerative capacity [156], and this finding forms the basis for many of our
experiments, the results of which, are presented in this chapter.
5.1.1 Hindlimb ischaemia laser Doppler
Transfusion studies were carried out following the induction of hind limb
ischaemia in mice as described in section 4.2.1. WE LEPCs significantly
enhanced recovery of limb perfusion (WE 66% [3] vs. SA 49% [2] vs. vehicle
50% [2] Ischaemic/Non-ischaemic Flux ratio, p=0.002 for WE vs. SA). The
SA LEPCs, however, did not enhance reperfusion, at day 14 post operation,
above the level observed with vehicle control (basal medium): Figure 5-1.
Representative laser Doppler imaging is presented in Figure 5-2. Hindlimb
ischaemia surgery was performed by Dr N Yuldasheva.
Figure 5-1. Limb blood flow, whilst comparable post
on day 14 in mice receiving WE LEPC than those receiving vehicle or SA
LEPC (n=5 per group)
Figure 5-2. Representative laser Doppler imaging 14
ischaemia induction and transfusion of vehicle control, WE LEPC and SA
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-operatively, is greater
days following hindlimb
LEPC. Red areas represent areas with increased blood
areas with lesser blood flow.
5.1.2 Hindlimb ischaemia histological analysis
Histological analysis was performed on muscle blocks taken at the end of the
experiment as described in section
assessed by confocal microscopic imaging of muscle sections. The findings
of reduced Doppler measures of tissue perfusion were supported by this
histological data, and the number o
co-expressing CD-31, was significantly higher in mice that had received WE
LEPCs (WE 80.9 [16.9] vs
See Figure 5-3.
Yuldasheva. Confocal microscopy was performed
Figure 5-3. LEPC eng
more abundant in the muscle of mice receiving WE LEPC
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flow;
4.2.4. Engraftment of LEPCs was
f engrafted fluorescently tracked
. SA 44.6 [5.2] LEPCs per mm
Histological preparation was performed
with Dr R Cubbon.
raftment following hindlimb ischaemia. LEPCs were
.
blue represents
LEPC,
2, p=0.048, n=5).
with Dr N
Figure 5-4. Representative confocal microscopy images of ischaemic
gastrocnemius muscle. Increased
tracker) from WE donors is evident. These cells also co
(yellow – Chromeo642)
5.1.3 Lentiviral transduction of South Asian LEPC
Previous findings from our lab of reduced protein levels
SA LEPC led to the targeting of Akt as a means of restoring
capacity. The rationale for this was both the upstream location of Akt to
eNOS, and published literature identifying these molecules as key
angiogenic mediators
activity using a lentiviral vector as described in section
chosen to increase
aiming to achieve a level comparable to that seen in the WE LEPCs.
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engraftment of LEPC (red
-express CD31
. Scale bar denotes 50µm.
of Akt and eNOS
[82, 161, 234]. We chose to augment SA LEPC Akt
4.1.3
SA LEPC phospho-Akt S473 content by a factor of three,
– CMDil cell
in
reparative
. Viral titres were
E17KAkt expressing SA
content and Akt activity as measured using a cell free GSK phosphorylation
assay; Akt activity in EGFP expressing and native SA LEPC was
comparable. E17KAkt expressing SA LEPC also demonstrated increa
total and phospho
transduction of LEPCs was performed by Dr S Stephen and Dr H
Viswambharan.
Figure 5-5. : E17
(S473), eNOS, peNOS
LEPC.
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LEPC exhibited increased phospho
-eNOS S1177. See Figure 5-5. Handling of virus and
KAkt expressing SA LEPC had higher levels
(S1177) and Akt activity than EGFP expressing
-Akt S473
sed
of pAkt
5.1.4 Hindlimb ischaemia following
LEPC: laser Doppler
Hindlimb ischaemia experiments were repeated with SA LEPC exp
either E17KAkt or
promoting capacity of SA LEPCs
LEPCs. EGFP expression had no effect on limb perfusion recovery a
was no difference seen betwe
control (basal medium)
ischaemic Flux ratio, p=0.02, n=5
representative laser Doppler images.
performed by Dr N Yuldasheva.
Figure 5-6: Representative laser Doppler images taken 14 days post hind
limb ischaemia induction and transfusion of WE LEPC,
expressing SA LEPC or EGFP
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transfusion of E17KAkt expressing
EGFP. Augmenting Akt activity restored the
to an extent comparable to th
en the EGFP expressing cells and vehicle
(E17KAkt 63 [1.2] vs. EGFP 48 [3.3] Ischaemic/Non
). See Figure 5-7. See
Hindlimb ischaemia surgery was
SA LEPC, E17KAkt
-expressing SA LEPC. It is evident that mice
ressing
reperfusion
at seen in WE
s there
-
Figure 5-6 for
-
-
receiving E17KAkt transduced SA LEPC had limb reperfusion comparable to
the level seen in mice receiving WE LEPCs.
Figure 5-7: Mice receiving E17KAkt expressing LEPCs displayed improved
limb perfusion recovery at day 14 in comparison to those receiving EGFP
expressing LEPCs.
5.1.5 Hindlimb ischaemia following
LEPC: histological analysis
The findings of increased Doppler measures of tissue perfusion with the
transfusion of E17KAkt expressing SA LEPCs were supported by histological
data. The number of engrafted fluorescently t
CD31, was significantly higher in mice th
SA LEPCs, compared with EGFP expressing SA LEPCs
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transfusion of E17KAkt expressing
racked LEPC, co
at had received E17KAkt expressing
-expressing
(E17KAkt 111.4
[15.3] vs. EGFP 36.7 [4.1] EPCs per mm
Histological preparation
microscopy was performed
Figure 5-8: Engraftment of LEPC into
hindlimb ischaemia
E17KAkt, versus EGFP
5.2 E17KAkt expressing LEPC:
In order to gain further insight into the impact of modulating Akt activity in SA
LEPCs on vascular reparative capacity,
Previous work from our lab, as outlined, had identi
function of SA LEPCs in comparison to WE LEPCs. Specifically, defects in
growth factor directed migration,
and premature senescence
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2, p=0.001, n=5).
with performed by Dr N Yuldasheva
with Dr R Cubbon.
gastrocnemius muscle following
is significantly increased in SA LEPC expressing
.
in vitro studies
in vitro studies were performed.
fied deficits in the
angiogenic tubule formation on Matrigel
, were noted.
See Figure 5-8.
. Confocal
in vitro
,
5.2.1 Tubule formation
SA LEPCs were transduc
Constitutively activating Akt in SA LEPCs, resulted in increased vascular
tubule formation on Matrigel
per field (x40), p=0.03, n=4
abrogated by the addition of L
inhibitor, thereby causally implicating Akt/eNOS signalling
production, in the improved angiogenic function seen with E17KAkt
expression.
Figure 5-9. Mean number of vascular tubules formed by E17KAkt and EGFP
expressing SA LEPCs.
5.2.2 Migration
Migration towards VEGF was assessed as described in section
using SA LEPCs transduced with E17KAkt or EGFP. Increasing Akt activity
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ed to express either E17KAkt or EGFP.
(E17KAkt 9.6 [1.4] vs. EGFP 5.8 [0.7] Tubules
). See Figure 5-9. The formation of tubules was
-NMMA, a nitric oxide synthase (NOS)
, and increased NO
1034.3.2
did not alter the chemotactic response to VEGF
that migrated to the lower aspect of the
using both E17KAkt and EGFP expressing SA LEPCs
vs. EGFP 34.8 [3.5], p=0.2, n=4)
Figure 5-10. Mean number of migrated
(x100).
5.2.3 Senescence
Previous work has highlighted increased levels of senescence in SA LEPCs
in comparison to those derived from WE subjects
of levels of senescence was undertaken in SA LEPCs expressin
E17KAkt and GFP. There was no demonstrable difference in senescence
between E17KAkt and EGFP expressing cells at passage number
(E17KAkt 73.2% [5.8] vs EGFP 73.8% [3.7] % senescent cells, p=0.95, n=4)
See Figure 5-11.
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since the number of cells
Boyden chamber was similar
(E17KAkt 25.3 [6.2]
. See Figure 5-10.
LEPCs per high powered field
, and therefore assessment
when
g both
3
.
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Figure 5-11. Percentage of senescent LEPCs at passage 5.
5.2.4 Survival studies
The effect of increased Akt activity on cell survival was assessed by
simulating an ‘infarct environment’. Lysates from E17KAkt expressing SA
LEPCs had higher levels of total LDH (E17KAkt 1.51 [0.21] vs EGFP 0.78
[0.11] Total cell LDH (AU), p=0.045, n=4), a marker of cell survival, where as
analysis of conditioned media demonstrated increased levels of released
LDH (E17KAkt 0.13 [0.02] vs EGFP 0.35 [0.04] LDH release (AU), p=0.003,
n=4), a marker of cytotoxicity, in the EGFP expressing SA LEPCs. See
Figure 5-12 and Figure 5-13.
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Figure 5-12. Levels of total LDH were elevated in lysates made from
E17KAkt expressing cells compared with the EGFP expressing cells.
Figure 5-13. LDH release was higher from the EGFP expressi
than from the E17KAkt expressing SA LEPCs.
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ng SA LEPCs
5.2.5 Invasion studies
Assessment of invasion was performed on LEPCs from SA and WE donors.
There was no difference observed between the groups
22.7 [2.8] Invaded cells, p=0.67, n=5)
Figure 5-14. WE and SA LEPCs invade through a layer of Matrigel similarly
5.3 LEPC Akt knockdown studies
5.3.1 Akt knockdown
In order to strengthen our pro
in SA LEPC dysfunction
LEPCs were transfected with scramble
to decrease Akt expression
blotting, with approximately 50% Akt knockdown being
0.93 [0.12] vs. Akt siRNA
Figure 5-15. Transfection of LEPCs was performed
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(SA 25.2 [4.9] vs WE
. See Figure 5-14.
posed causal role for reduced
, we went on to silence Akt1 in WE LEPCs. WE
d siRNA as a control
. Akt knockdown was confirmed
achieved
0.48 [0.08] Total Akt (AU), p=0.002, n=4)
with Dr A Bruns.
.
Akt1 expression
, or Akt1 siRNA
using western
(Scrambled
. See
Figure 5-15. Demonstration of effective Akt knockdown in WE LEPCs using
western blotting (including representative blots)
5.3.2 Femoral injury studies
WE LEPCs transfected with scramble
mice following femoral arterial injury to assess endothelial regenerative
capacity. WE LEPCs transfected with Akt
regeneration to a lesser degree than those transfected with scramble
(Scrambled siRNA
regeneration, p=0.002, n=6)
with previous work from our lab demonstrating decreased augmentation of
re-endothelialisation with SA LEPC com
149
.
d or Akt1 siRNA were tran
1 siRNA augmented endothelial
40.2% [2.0] vs. Akt1 siRNA 24.0% [1.6] endothelial
. See Figure 5-16. These findings are in keeping
pared with WE LEPCs
sfused into
d siRNA
, and also the
augmented re-endothelialisation seen with SA LEPC
E17KAkt. Moreover, these findings
reduced Akt1 activity
performed by N Yuldasheva.
Figure 5-16. Augmentation of endothelial regeneration was reduced in WE
LEPCs transfected with Akt1 siRNA compared with those transfected with
scrambled siRNA.
This difference in endothel
examining the incorporation of
artery samples. This was done using confocal microscopy, and
demonstrated a reduction in the number of
received Akt1 silenced WE LEPCs
with scrambled siRNA
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when expressing
further strengthen the
in SA LEPC dysfunction. Femoral injury surgery was
ial regeneration was recapitulated when
LEPCs into the intima of explanted femoral
engrafted cells in mice that had
, compared with WE LEPCs transfected
(Scrambled 2214.1 [168.3] vs Akt knockdown 924.8
causal role of
[122.0] engrafted LEPCs per mm
microscopy was perfo
Figure 5-17. Number of LEPCs engrafting in murine femoral artery intima
following femoral arterial denudation and LEPC transfusion. There were
fewer engrafted WE LEPCs in mice that had
compared with cells transfected with scrambled siRNA
5.3.3 Migration
WE LEPCs transfected with scrambled or Akt
aspect of a Boyden chamber membrane when exposed to a VEGF
concentration gradient. Akt sil
(Scrambled siRNA
powered field (x100), p= 0.01, n=4
keeping with previous work from
chemotactic response to VEGF in SA LEPCs compared with WE LEPCs.
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2, p=0.002, n=6). See Figure
rmed with Dr R Cubbon.
received Akt silenced cells,
.
1 siRNA migrated to the lower
encing reduced the number of migrat
28.4 [5.8] vs. Akt siRNA 10.8 [3.3] migrated cells per high
). See Figure 5-18. These findings are in
our lab demonstrating an impaired
5-17. Confocal
ing cells
Figure 5-18. Migration of cells to VEGF in WE LEPCs transfected with
scrambled siRNA or Akt1 siRNA
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Chapter 6. Results Part 2
6.1 Vascular regeneration is impaired in the IRKO mouse: In vivo data
6.1.1 Hindlimb ischaemia; laser Doppler
To assess vascular regeneration in response to ischaemia
limb ischaemia was used. Hindlimb ischaemia was induced in both W
IRKO mice as described in section
out on day 0, day 7, day 14 and day 21. Representative laser Doppler
images are presented below. Red areas
increased blood flow
ischaemia surgery was performed by Dr N Yuldasheva.
Figure 6-1. Representative laser Doppler images taken from WT and IRKO
mice in a supine
operatively and 14 days post operatively. The IRKO mouse has delayed
recovery of blood flow in the ischaemic (mouse’s left) limb.
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, a model of critical
4.2.3. Laser Doppler analysis was carried
indicate higher flux and represents
, whereas blue indicates the opposite
position immediately post operatively, 7 days post
T and
. Hindlimb
Experiments were carried out in 14 IRKO mice and 13 WT. Laser Doppler
analyses confirm a delay in the return of limb perfusion in the IRKO mice in
response to critical limb ischaemia in comparison to WT mice. Ischaemia
was confirmed post operatively in both genotypes with a similar is
non-ischaemic ratio being observed
p=0.25). At days 7
[5.4] vs. IRKO 57.4% [5.1], p=0.02)
[7.1], p=0.04) there is increased ischaemic:
the WT mice in comparison to the IRKO mice
Figure 6-2. Limb perfusion recovery is blunted in the IRKO mouse following
hindlimb ischaemia inducti
day 14, and day 21.
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(WT 9.8%[1.3] vs.
(WT 47%[3.5] vs IRKO 36.4%[4.7}, p=0.04)
and 21(WT 82.2% [5.6] vs
non-ischaemic
. See Figure 6-
on with a significant difference evident at day 7,
chaemic:
IRKO 7.7%[1.2],
, 14 (WT 76%
. IRKO 62.2%
limb flux ratio in
2.
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6.1.2 Hindlimb ischaemia histological analysis
Muscles were analysed 21 days following hindlimb ischaemia induction. This
demonstrates a strong trend towards a reduction in capillary density in the
ischaemic gastrocnemius muscle from IRKO mice (WT 57.9 [3.3] vs IRKO
46.7 [6.3] Capillaries per HPF, n=9). This finding correlates with the perfusion
defect seen at day 21 in the IRKO mice (r2 0.254, p=0.037, see Figure 6-3 for
scatter plot) and suggests that this is, at least partly, due to a defect in
capillary formation and therefore angiogenesis.
Figure 6-3. There was a trend towards a reduction in capillary density within
the ischaemic gastrocnemius of IRKO mice.
6.1.3 Hindlimb ischaemia quantitative PCR data
Muscles from both the ischaemic and non
from mice 3 days post hindlimb ischaemia induction. These tissue specimens
were used for quantitative PCR analysis, which was
Stacey Galloway. Levels of VEGF mRNA in non
were similar in IRKO and WT mice
of18S expression, p=0.47, n=4)
were significantly higher in the ischaemic adductor muscles of IRKO mice
compared with WT mice however
18S expression, p=0.04, n=4)
there is higher expression of VEGF in response to ischaemia in the
musculature of IRKO mice despite perfusion recovery being delayed in this
group when compared with WT littermates.
Figure 6-4. Basal levels of VEGF expression in adductor muscle is similar in
IRKO and WT mice.
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-ischaemic legs were explanted
conducted by Mrs
-ischaemic adductor muscle
(WT 1.67% [0.34] vs. IRKO 1.35% [0.26]
. See Figure 6-4. Levels of VEGF mRNA
(WT 9.8% [2.5] vs. IRKO 31.4% [6.7] of
. See Figure 6-5. This therefore indicates that
Figure 6-5. VEGF expression in ischaemic adductor muscle is increased in
the IRKO mouse.
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6.2 Angiogenesis is impaired
6.2.1 Aortic ring sprouting angiogenesis
As described in section
sprouting from segments
explanted from WT
identified by BS-1 lectin staining.
confocal microscopy are presented below.
Figure 6-6: Representative confocal micros
aortic rings following immunostaining. Endothelial sprouts from the aortae of
IRKO mice are smaller and less abundant.
Experiments were
mice. Mean sprout length in the rings cultu
were significantly longer than those from
vs. IRKO 846.51µm
Sprout length in rings from WT and IRKO mi
not significantly different (WT 553.8µm [62.13] vs
p=0.10). Although there is a trend to diminished sprout length in the IRKO
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in the IRKO mouse: In vitro data
4.10.1, this assay looks at ex vivo
of aorta, in response to VEGF. Aortic rings
and IRKO mice formed vascular endothelial sprouts,
Representative images obtained from
copy images of WT and IRKO
conducted using aortae form 8 WT mice and 8 IRKO
red with VEGF from WT mice
IRKO mice (WT 1037.46µm
[37.98], p=0.003; n = 8 IRKO, 8WT). See
ce not cultured with VEGF was
. IRKO 419.63µm [30.23],
endothelial
[38.58]
Figure 6-7.
compared with WT in conditions without significant growth factor addition, t
difference is only statistically different
Figure 6-7. Mean length of endothelial sprouts, from aortic rings cultured in
VEGF, is greater in WT compared with IRKO mice.
This difference in response to VEGF exposure is repeated when observing
the number of endothelial sprouts present in aortic rings from WT compared
with IRKO mice (WT 29.93 [2.19] vs
per ring, p=0.03). (n = 8IRKO, 8WT)
emerging from rings cultured in media without addition of VEGF was
comparable between WT and IRKO mice (WT 12.53 [1.38] vs
[0.92] endothelial sprouts per ring, p=0.84).
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during exposure to VEGF.
. IRKO 21.82 [2.42] endothelial sprouts
. See Figure 6-8. The number of sprouts
he
. IRKO 12.18
Figure 6-8. Mean number of endothelial sprouts, from aortic rings cultured in
VEGF, is higher from WT compared with IRKO mice.
6.2.2 Tubule formation
PECs isolated from WT and IRKO formed tubular structures when seeded
onto Matrigel and
form cell-cell contacts. PECs from IRKO mice formed fewer tubu
structures in comparison to
structures per 40x microscopic field, p=0.004). (
6-9.
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cultured with VEGF, by extending cellular processes to
WT PECs (WT 27.6 [2.1] vs IRKO 14.5 [2.4]
n= 7IRKO, 4WT)
lar
. See Figure
Figure 6-9. Tubule formation is reduced in PECs from IRKO compared with
WT mice.
6.2.3 Migration assay (Boyden chamber)
Further studies were done to identify functional deficits that may contribute to
the reduction in angiogenesis seen in the IRKO
PECs isolated from both WT and IRKO mice exhibited migration in response
to vehicle (EBM + FCS 1%) solution and VE
migratory response to VEGF, data was corrected on an individual
basis for the migratory activity of cells exposed to vehicle solution alone.
Migration towards VEGF was reduced in PECs isolated from IRKO mice
7.5 [1.7] vs. IRKO 2.2 [1.1] cells per 100x high power field,
5IRKO vs 4WT). See
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PEC during
GF. In order to assess specific
Figure 6-10.
in vitro studies.
sample
(WT
p= 0.048; n=
Figure 6-10. Migration to VEGF is reduced in PECs from IRKO
compared to WT.
6.2.4 Migration assay (scratch wound)
PECs isolated from both WT and IRKO mice exhibited migration in response
to the formation of a scratch wound. Cells were cultured in standard media
supplemented with Mitomycin C (1
proliferation. There was no difference in the degree of wound closure
achieved by WT cells compared with IRKO cells
67.4% [9.1] % wound closure, p=0.9:
Similarly, there was no difference in the absence of Mitomycin C
[7.5] vs. IRKO 60.5 [1.9] % woun
Figure 6-12.
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Figure 6-11. There was no difference in the degree of wound closure
achieved by WT cells compared with IRKO cells
Mitomycin C.
Figure 6-12. There was no difference in the degree of wou
achieved by WT cells compared with IRKO cells in the absence of Mitomycin
C.
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6.2.5 Proliferation assay
The proliferative activity
assessed by observing EdU uptake, as described in section
passage number 3. The proliferative state of the PECs was comparable
between genotypes
proliferating cells, p=0.77:
6-13.
Figure 6-13. The proliferative state of the PECs was comparable between
genotypes.
6.2.6 Apoptosis assay
The degree of apoptosis
was assessed by measuring the levels of caspase 3 and cleaved caspase 3
present in cell lysates using western blotting,
kit. The kit also provided control samples. The abundance of
cleaved caspase 3 in PEC lysates was similar
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of PECs isolated from WT and IRKO mice was
(WT 0.1 [0.03] vs IRKO 0.09 [0.03] fraction of
Figure 6-13) (n=11IRKO vs 7WT)
present amongst WT compared with IRKO PECs
using a commercially
in cells from WT and IRKO
4.10.5 after
. See Figure
available
caspase 3 and
mice (WT 0.51 [0.05] vs
n=3IRKO vs 3WT). See
caspase 3 in any of the PEC lysates, an important finding, as it suggests that
any differences in the functional performance of the cells is not
due to cell death. Representative western blots are presented in
Figure 6-14. Representative western blot of
positive (staurosporine treated) controls provided with the purchased kit.
Abbreviations: L; Ladder, WT; Wildtype, TG; Transgenic, C; Control.
Figure 6-15. The abundance of caspase 3 and cleaved caspase 3 in PEC
lysates was similar in cells from WT and IRKO mice.
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. IRKO 0.50 [0.04] Caspase 3/B actin (AU),
Figure 6-15. In fact, there was no detectable cleaved
PEC lysates and negative and
p=0.87;
likely to be
Figure 6-14.
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6.3 PEC signalling studies
Stimulation of PECs was carried out as described in 4.11. Preliminary data
suggests subtle differences in signalling responses to VEGF between PECs
from WT and IRKO mice. With experiments being carried out in 4 WT and
4IRKO samples a trend is emerging with higher basal levels of Akt
phosphorylation (S473) being evident in the PECs from IRKO mice. This
difference is reversed after 15 minutes of exposure to VEGF, with Akt
phosphorylation being increased in WT PECs. See Figure 6-17. Basal levels
of eNOS phosphorylation (S1177) were similar between genotypes, but there
was increased eNOS phosphorylation seen in the WT PECs compared with
those from IRKO mice after 15 and 30 minutes of exposure to VEGF. See
figure Figure 6-16. None of the differences observed are statistically
significant. Further experiments will be conducted, and although interesting,
the results should be interpreted as preliminary.
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Figure 6-16. A trend towards reduced eNOS phosphorylation in response to
VEGF exposure in IRKO PECs when compared with WT cells. (n=4 WT,
4IRKO).
Figure 6-17. There is a trend towards increased Akt phosphorylation in IRKO
PECs when compared with WT cells in basal, quiescent, conditions. There is
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a trend towards reduced eNOS phosphorylation in response to VEGF
exposure in IRKO PECs when compared with WT cells. (n=4 WT, 4IRKO).
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Chapter 7. Discussion
7.1 Summary of key findings
This thesis presents a broad assessment of the impaired capacity of LEPCs
derived from apparently healthy, but insulin resistant, SA men to augment
vascular regeneration. Moreover we present a strategy to rescue their
function, and in doing so causally implicate reduced Akt1 activity. As has
been extensively discussed in the introduction, separating ethnicity from
insulin resistance, as well as other potentially contributory factors, is difficult.
In an attempt to address this issue, went on to characterise the adverse
impact of insulin resistance in an animal model. The overall observations of
the thesis will now be summarised.
Our cohorts of SA and WE men were well matched for classical CVD risk
factors, including blood pressure, smoking status, lipid profile and BMI. The
only apparent difference between the two groups was an elevated fasting
plasma insulin level, and as a result an increased HOMA-IR score, in the SA
group. We have demonstrated that, when transfused following hindlimb
ischaemia induction, SA LEPCs are not able to augment vascular
regeneration in the manner that WE LEPCs do. This data builds on an
existing body of work, already carried out in our lab, demonstrating the
impaired ability of these cells to facilitate re-endothelialisation of injured
arteries. On the basis of previous findings from our lab showing reduced Akt
phosphorylation in SA LEPC, we elected to assess whether increasing Akt1
activity in SA LEPCs, using lentiviral transduction of a constitutively active
mutant, could rescue their angiogenic function. Indeed, this was the case in a
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murine limb ischaemia model, with the level of regenerative function being
comparable to non-manipulated WE LEPCs. In vitro, vascular network
formation on Matrigel was significantly improved in SA LEPC expressing
E17KAkt, and could be entirely abrogated by eNOS antagonism. Previous
work from our lab highlighted an important reduction in total Akt, total eNOS,
and their respective phosphorylated forms, in SA LEPC. By restoring Akt
activity, and rescuing vascular regenerative function, we have causally
implicated reduced Akt1 activity in SA LEPC dysfunction. The finding of
relative insulin resistance in the South Asian group is also an important
finding to bear in mind, since this is associated with reduced insulin mediated
vascular Akt/eNOS phosphorylation in murine models. The subset of
experiments demonstrating abrogated tubule formation in the presence of L-
NMMA further implicates abnormal Akt/eNOS signalling and NO
bioavailability in this observed SA LEPC dysfunction. Furthermore, by
silencing Akt in WE LEPCs, we were able to recreate the dysfunction seen in
SA LEPCs; Akt silenced WE LEPCs did not augment re-endothelialisation in
a murine model of femoral arterial injury. In vitro dysfunction was also
demonstrated with an impaired migratory response to VEGF evident in Akt
silenced WE LEPCs when compared with control WE LEPCs. These data,
again, strengthen the implication that impaired Akt1 signalling is important in
the dysfunction seen in SA LEPCs.
Although we have identified that defective Akt1 signalling has important
consequences for the vascular regenerative capacity of LEPCs derived from
SA men, it is difficult to define the contribution of ethnicity or insulin
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resistance to this dysfunction. We did, however, go on to perform further
experiments to investigate the fundamental impact insulin resistance can
have on vascular regeneration. Our in vivo studies in the IRKO mice,
haploinsufficient for the insulin receptor, suggest that insulin resistance does
indeed negatively impact vascular regeneration. Laser Doppler data
gathered following the induction of hindlimb ischaemia suggest that limb
perfusion recovery is delayed in the setting of insulin resistance. This defect
in limb perfusion is associated with a reduction in capillary density when
assessed at 21 days post ischaemia induction. Mechanistic insight is gained
from quantitative PCR data obtained from the analysis of ischaemic
musculature from both IRKO and WT mice. It is apparent that despite
increased VEGF-A expression in the ischaemic adductor muscle of the IRKO
mouse compared with the WT mice, perfusion recovery is impaired. This
raises the possibility that functional resistance to the actions of VEGF-A are
playing a role in the observed phenotype. These findings are also supported
by preliminary data from western blots of lysates made from PECs following
VEGF stimulation. These data suggests that the phosphorylation of key
angiogenic mediators, Akt and eNOS, is blunted in endothelial cells isolated
from IRKO mice when exposed to VEGF.
Findings from an array of in vitro studies complement our in vivo data;
reduced VEGF mediated angiogenesis was evident in an aortic ring
sprouting angiogenesis model, and IRKO PECs formed fewer vascular
networks on Matrigel. Functional assays suggest an impaired migratory
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response to VEGF in endothelial cells, a potential contributing mechanism by
which angiogenesis could be impaired.
As outlined in the introduction, many facets of insulin resistant syndromes
are associated with a reduction in angiogenesis and vascular regeneration.
Our data demonstrates impaired function in a population of cells capable of
aiding vascular regeneration, derived from a cohort of individuals with
relative insulin resistance, and at higher risk of CVD. We have causally
implicated decreased Akt1 signalling, a critical node in insulin signalling, in
this dysfunction. We have gone on to demonstrate that insulin resistance per
se is associated with reduced vascular regeneration. These data suggest
that insulin resistance does impair vascular regeneration and that modifying
insulin signalling in certain settings can improve vascular regenerative
function.
7.2 Wider research context
7.2.1 SA LEPC transfusion studies
7.2.1.1 South Asian LEPCs do not augment vascular regeneration
Although a link between SA ethnicity and impaired vascular regenerative
LEPC function has not been made before, there is data that demonstrates a
link between SA ethnicity and dysfunction of other progenitor fractions.
Murphy et al demonstrated a link between endothelial dysfunction in healthy
SA men and a reduction in circulating CD133+/CD34+/KDR+ CPCs [225].
Further work demonstrated a reduced abundance of the same fraction of
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CPCs in healthy SA men, both basally and when assessed following
exercise, along with reductions in CD34+/CD45- CPCs [163]. Importantly, it
is from within this rare latter fraction of cells that LEPC are derived [235], and
newly published data from our lab demonstrates that LEPC colony formation
is indeed reduced in healthy SA men. Furthermore, dysfunction is evident in
LEPC from SA men [236]. In vitro studies demonstrate reduced proliferative
capacity, increased senescence, impaired migration to VEGF and impaired
vascular network formation on Matrigel with SA LEPCs compared with WE
LEPCs. SA LEPCs did not augment re-endothelialisation in in vivo studies.
Although in vivo vascular regenerative dysfunction has not been
demonstrated previously, processes tested by the described in vitro studies,
such as migration and proliferation, are important to angiogenesis and
vascular regeneration, and our finding that SA LEPCs do not augment
vascular regeneration is in keeping with the small existing body of evidence.
The fact that LEPCs are capable of augmenting vascular regeneration is
something that has previously been documented in the setting of murine hind
limb ischaemia [191] and porcine myocardial infarction [192].
7.2.2 Akt signalling and vascular regeneration
The finding of reduced levels of total Akt and eNOS in SA LEPCs from
previous work done in our lab [156] led to us restore Akt activity in SA LEPCs
in an effort to reverse the observed inability to augment vascular
regeneration. As outlined in the results section, modulating Akt1 activity via
lentiviral delivery of a constitutively active Akt1 mutant, E17KAkt, did restore
vascular regenerative function, as measured by an array in vivo and in vitro
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assessments. Previous work by Ackah et al has highlighted the importance
of Akt1 to ischaemia driven angiogenesis. This work identified that mice
homozygous for Akt1 gene deletion had significantly impaired limb perfusion
recovery following hind limb ischaemia, and impaired mobilisation of EEPCs.
They also found that PECs isolated from these mice exhibited impaired
migration to chemotactic stimuli in Boyden chamber experiments. The
authors of this study concluded that, mechanistically, genetic loss of Akt1
resulted in the observed phenotype, due to impaired fibroblast and
endothelial cell migration, reduced EPC mobilisation and reduced NO
release [161]. Although different experimental models are used in this study,
compared with ours, our findings build on the body of literature with regards
the role Akt1 plays in vascular regeneration.
Interestingly, although our lab has previously found impaired SA LEPC
migration to chemotactic stimuli, and impaired migration was noted in Akt1
silenced WE LEPC, we did not observe increased migration in E17KAkt
expressing SA LEPCs. In fact a trend towards reduced cell migration was
seen, compared with EGFP expressing SA LEPC, possibly because
constitutive activation of Akt1 rendered the cells insensitive to further
stimulation by VEGF.
Our finding of increased survival of E17KAkt expressing SA LEPCs offers
potential mechanistic insight. If progenitor cells are to be used in the manner
that has often been proposed, i.e. as a therapy to revascularise ischaemic
tissue, they will have to function in an ischaemic environment that is hypoxic,
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oxidative, and pro-inflammatory. All these factors have the potential to be
cytotoxic, and interventions that infer resistance to these insults may
enhance function. Another study that manipulated human LEPC by
increasing Akt and heme-oxygenase-1 found that survival was enhanced;
this was assessed using the same assay employed during our studies. They
also found that vascular regenerative function of LEPCs was enhanced in a
murine myocardial infarction model [98].
Our in vitro findings of abrogated angiogenesis in the presence of the NOS
antagonist LNMMA, suggest that NO is critical to the beneficial angiogenic
effects of enhanced Akt activity. The finding of increased eNOS expression
in E17KAkt treated cells adds further support to this conclusion. These
findings complement other data, published from our lab previously, that has
demonstrated a reduction in flow mediated dilatation (FMD) [225] and a
reduction in exercise induced CPC mobilisation in healthy SA men [163].
Both of these findings were found to relate to a reduction in NO
bioavailability. Our suggestion, that NO mediates the improvement in LEPC
function that accompanies increased Akt activity, is also supported by other
work. Murohora et al demonstrated that eNOS is a critical mediator of
ischaemic angiogenesis [234], and Sleicher et al demonstrated that the
angiogenic effects of Akt1 are mediated via eNOS signalling by crossing
Akt1 deficient mice with mice with a knock in mutation in a critical
phosphorylation site of eNOS, which mimics phosphorylation (by Akt, for
example). This led to rescue of the defective post-natal angiogenesis
exhibited by Akt1 deficient mice [162].
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7.2.3 Ex vivo modification of cells improves therapeutic function
Our data support the notion that LEPCs can augment vascular regeneration
and be used in a therapeutic manner. It has previously been demonstrated
that progenitor cells can be manipulated to improve their function; one
example is the use of statins, which have been shown to reduce circulating
angiogenic cell apoptosis [237]. Our data however, to our knowledge, are the
first to demonstrate the ex vivo manipulation of LEPCs derived from a group
at high risk of cardiovascular disease, resulting in rescued vascular
regenerative function. Our data, therefore, provides an important proof of
principle because, as discussed in the introduction, many disease states,
including insulin resistant syndromes, are associated with progenitor cell
dysfunction. Therefore, if progenitors such as LEPCs are to be taken from
patients with cardiovascular disease, with a view to being utilised as part of
an autologous cell therapy strategy, it is likely that ex vivo manipulation will
first be necessary. We have demonstrated that this type of manipulation prior
to administration is feasible, although clearly there are many remaining
hurdles in the process of translation to the clinic.
7.2.4 Akt signalling, vascular regeneration and insulin resistance
As discussed in the introduction, insulin resistance is thought to play a major
role in the increased CVD seen in South Asian populations. This, coupled
with our findings of relative insulin resistance in our South Asian cohort,
provides a basis for the inference that insulin resistance may underlie the
abnormalities in SA LEPC function that have been observed. We have
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causally implicated diminished Akt activity by improving SA LEPC function
after increasing Akt activity. This observation is strengthened by our data,
showing that silencing of Akt in WE LEPCs recreates the in vivo and in vitro
dysfunction apparent in SA LEPC. When considering a link between
perturbed Akt signalling and insulin resistance it is important to note that
although Akt signalling is central to a diverse array of cellular processes,
disturbed PI3-K/Akt signalling is a defining characteristic of vascular insulin
resistance [13]. Unfortunately it is not possible to more accurately define the
impact of insulin resistance on SA LEPC dysfunction with our data. Although
human studies are invaluable in terms of clinical relevance and translation to
the clinical setting, a significant obstacle is encountered when probing
mechanisms responsible for observed abnormalities. This is due to the
obvious technical and ethical limitations that are part of scientific study in
humans. It is because of this that we decided to probe the effect of insulin
resistance on vascular regeneration with a murine model and the context of
the findings generated will be discussed further here.
7.2.5 Studies of vascular regeneration in the IRKO mouse
Work carried out in our lab has previously identified that when compared with
WT mice, the IRKO mouse has delayed endothelial repair and regeneration.
This was previously assessed in a femoral arterial injury model, and
demonstrated that insulin resistance is associated with abnormal endothelial
repair [155]. This study also identified that VEGF induced mobilisation of
CPCs is impaired in the IRKO mouse. Although distinct processes, there is a
degree of overlap in the steps required for both endothelial repair and
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vascular regeneration, including endothelial cell migration and proliferation.
Therefore our findings that vascular regeneration is impaired in the IRKO
complement, and significantly expand, previous findings from our lab. The
previous observation that VEGF induced CPC mobilisation is perturbed in
the IRKO is pertinent, and offers a potential mechanism by which vascular
regeneration may be impaired in the IRKO also. The only other available
data that has addressed angiogenesis in insulin receptor knockout models
comes from the work of Kondo et al. These authors found that mice with
holoinsufficiency of the insulin receptor in vascular endothelium had reduced
retinal neovascularisation in retinopathy of prematurity model [157]. This
finding was associated with a blunted rise in angiogenic mediators VEGF,
eNOS and endothelin-1. Again, in one respect, our findings are in keeping
with this data, with angiogenesis in response to ischaemia being diminished,
albeit in a different tissue bed, in different conditions, and in a mouse with
systemic insulin receptor haploinsufficiency rather than holoinsufficiency
confined to the endothelium. However we have found that VEGF expression
is increased, rather than decreased, in the muscle of the IRKO mice, and our
in vitro studies demonstrate that functional responses to VEGF, such as
migration, are also reduced. Western blots also suggest that signalling in
endothelial cells from IRKO mice, in response to VEGF exposure may be
blunted. An explanation for these differences is not obvious, but important
differences between models and methods used in our study and the Kondo
could certainly have profound effects. Specifically, the animal model used by
Kondo et al has a complete lack of insulin receptors in the endothelium,
therefore insulin signalling in every other tissue in this model is preserved.
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They also examined a different tissue bed using different experimental
techniques.
Our in vivo findings of reduced vascular regeneration in the IRKO are
complemented by in vitro data also. VEGF induced angiogenesis was
reduced in the aortic ring endothelial sprouting assay. This assay, whilst
allowing the study of isolated substances, such as growth factors, in relation
to angiogenesis, also allows observation of the interaction between
endothelial cells and supporting cells such as pericytes and fibroblasts,
which are important in maintaining vessel integrity. Kahn et al have
presented data from our lab on aortic rings explanted from IRKO mice
previously [155]. They found in this small sample that there was a very small,
non-significant reduction in mean sprout length from the IRKO mice
compared with the WT mice. We believe that our data enhances this work
because our sample size is bigger, but also our assay is much more refined
and suited for identifying endothelial sprouts. The method utilised in this
thesis, previously published by Baker et al [238], requires staining with the
relatively specific endothelial marker, BS 1 lectin. This is important as it
allows accurate identification of endothelial sprouts. As mentioned, one of
the advantages of this assay is that it involves a heterogenous population of
cells, but without the described staining it is more difficult to define what is an
endothelial sprout versus, for example, fibroblast outgrowth. Our assay also
looked at VEGF stimulated growth, the aortic rings in the study of Kahn et al
were cultured in complete endothelial cell growth medium, which contains
numerous growth factors and a higher percentage of FCS.
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These findings were recapitulated in another in vitro assay, the assessment
of vascular network formation on Matrigel by PECs. Therefore a reduction in
VEGF stimulated angiogenesis has been demonstrated in two in vitro assays
utilising tissue from the IRKO mouse. Further functional assays offer insight
as to potential mechanisms responsible for the reduction in angiogenesis
and vascular regeneration that we have observed. In particular, our
observation that endothelial cells from the IRKO mice display impaired
migratory response to VEGF compared with cells from WT mice, is an
important one. As outlined in the discussion, an appropriate response to
migratory cues is a crucial part of sprouting angiogenesis. It can be
appreciated that an impaired ability to respond adequately to a VEGF
concentration gradient is likely to negatively affect the rate at which
angiogenesis occurs and ultimately could lead to a delay in tissue
reperfusion, as has been demonstrated in our in vivo studies. It is important
to interpret the data from our studies of PEC migration using the scratch
wound method in the context of our dataset as a whole. The other functional
assays that we have utilised observe angiogenic processes in response to
VEGF exposure. In vivo, angiogenesis occurs in response to ischaemia in
the setting of growth factor gradients, with areas of tissue that are most
ischaemic producing more angiogenic mediators, such as VEGF.
Considering, the scratch wound assay is perhaps more representative of the
cell migration required following endothelial injury. In fact, our data
demonstrating a similar capacity for PECs from both WT and IRKO mice to
migrate and ‘heal’ a scratch wound, are compatible with the suggestion of
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Kahn et al, that impaired endothelial regeneration in the IRKO mouse may be
a CPC mediated phenomenon [155].
Our finding of increased VEGF-A expression in the ischaemic adductor
muscle of IRKO in comparison to WT mice is potentially indicative of
functional VEGF resistance. Our data from western blot studies also
suggests VEGF resistance. Functional resistance to VEGF has previously
been demonstrated by Waltenberger et al in monocytes obtained from
patients with diabetes. Migration to VEGF was impaired in these cells, whilst
migration to other chemotactic stimulants was preserved [176]. Recent work
from Warren et al highlights how, mechanistically, VEGF resistance can arise
in the setting of diabetes. They found that post-translational modification of
VEGFR2 by ROS, generated as a result of hyperglycaemia, leads to
impaired VEGFR2 trafficking to the cell membrane and progressively muted
responses to VEGF [153]. Work from Mehra et al also supports the notion of
VEGF resistance accompanying insulin resistance. These authors have
demonstrated that by high fat feeding mice, a recognised method of inducing
insulin resistance in vivo, they can induce VEGF resistance [239]. This was
demonstrated by infusing VEGF into the aortae of both high fat fed and chow
fed mice; eNOS phosphorylation was reduced in the aortae of the high fat
fed mice. They also found that treating endothelial cells with palmitate
rendered them resistant to VEGF. Mechanistically, they found that an
increase in free fatty acids results in VEGF resistance as ceramide induces
Protein phosphatase 2A (PP2A), which in turn dephosphorylates the
molecular substrates of VEGF signalling and results in VEGF resistance. The
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authors were able to restore VEGF signalling in high fat fed mice by
genetically reducing serine palmitoyltransferase expression, the enzyme that
facilitates the conversion of palmitate to ceramide. Our data complements
and advances this growing body of evidence that insulin resistance is
associated with VEGF resistance. Other work has been published that
contrasts these findings however, for instance, Kajiwara et al found that the
levels of expressions of angiogenic factors, including VEGF, were reduced in
the ischaemic muscles of Zucker diabetic rats [177]. Importantly, these data
were obtained from animal models of diabetes, and our observations are the
first in which insulin resistance rather than diabetes, hyperglycaemia and
dyslipidaemia can be implicated.
7.3 Limitations
As with any scientific study, our data has strengths and weaknesses. To fully
understand the implications of our data it is important to appreciate the
limitations of our data.
7.3.1 Defining ethnicity
As highlighted in the discussion, the definition of ethnicity is difficult. Although
the method employed to define ethnicity in our study is typical, and is the
method commonly employed throughout the literature, it is arbitrary and does
not take into account many factors. These factors such as religion, culture
and diet are responsible for the dramatic heterogeneity within ethnic groups
and are also likely to impact significantly on cardiovascular risk. Furthermore,
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with increasing globalisation there is increasing migration and commonly
used ethnic descriptors apply to fewer people. These limitations are not
easily overcome, and we have employed such a method to replicate prior
studies.
7.3.2 Sample size
A factor with potential implications for the study is the relatively small sample
size. Because of this it is important to note that where we have found no
difference, it is not possible to be conclusive in this regard. During this study
we have collected a relatively large amount of data for a small sample size,
which is more effective with regards hypotheses generation, than collecting
small amounts of data from a large sample size. Importantly, funds available
for consumables during this project were finite, and the development and
application of the described assays required significant expenditure of money
and time. Where relevant, we have attempted to identify situations where
sample size may influence our conclusions.
7.3.3 Origin and definition of LEPCs
As highlighted in the introduction of this thesis, difficulty and debate exists
regarding the definition and classification of ‘EPC’s. The possibility exists that
LEPCs can acquire and lose properties during cell culture or even that
LEPCs are a cell that only exist in cell culture. In many ways, at least with
regards to this thesis, this debate is academic, as we, along with other
groups, have shown that LEPCs can augment vascular regeneration. They
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have therefore been demonstrated to possess potential, in terms of
benefitting patients as a ‘cell therapy’.
7.3.4 Lentiviral vector use and oncogenic potential
LEPCs have the potential to proliferate substantially and are capable of
significant expansion. The capacity for LEPCs to partake in tumour
angiogenesis when transfused as a cell therapy is therefore theoretically
possible. This is however, speculation and further evaluation is required.
Increased tumour growth has not been observed where LEPCs have been
utilised in animal studies, but these studies are of course short and longer
periods of follow-up would be required before the safety profile of LEPCs as
a cell therapy can be more accurately defined. This issue is clouded further
when lentiviruses are used to introduce a putative oncogene (E17KAkt) in
order to permanently promote the angiogenic potential of these cells.
Lentiviral vectors do have an advantage over some other methods of gene
delivery as they integrate the target cell genome in a stable fashion, even in
non-dividing cells [240]. The use of these vectors does raise biosafety
issues, namely the risk of insertional oncogenesis, and the risk of
recombination between the transfer vector and packaging constructs to
create a replication competent lentivirus [240]. In an attempt to circumvent
these issues, self inactivating (SIN) lentivectors have been developed [241].
As commented on above, studies utilising animals are short-term and there
is therefore not enough longer term safety data to appraise the potential for
harm when using lentiviral vectors to deliver gene therapy.
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Further problems may be anticipated to arise from persistent constitutive Akt
activation in LEPC. Indeed, there is evidence to suggest that chronic
hyperactivation of Akt signalling can be detrimental, and work by Wang et al
associates excess Akt signalling with increased endothelial cell senescence,
reduced vascular network formation on Matrigel, and reduced proliferation.
They also found that EPC mobilisation was reduced in response to
ischaemia and VEGF stimulation [242]. This relationship between chronic Akt
activation and senescence has been demonstrated by other groups also,
Nishi et al found that endothelial cells with VEGFR1 deletion became
prematurely senescent and they found excess Akt activation to be
responsible for this [243]. Moreover, Akt over expression has been
associated with oncogenesis [244, 245], and as described in the methods
section, the mutation in Akt used in this thesis to augment Akt activity in SA
LEPCs was originally identified in human breast, colorectal and ovarian
cancers [228], this immediately raises concern with regards oncogenesis.
Due to these issues it seems that alternative means of transiently promoting
Akt activity in LEPC will be desirable before conducting clinical trials of
modified LEPC.
7.3.5 Mechanistic insight
The fact that it is difficult to probe molecular mechanisms in human studies
has already been highlighted. Much of the work done to probe signalling
pathways in animal models, involves genetic modification via the production
of gene knock-out/knock-in models, siRNA administration or the
administration of novel drugs or inhibitors. This obviously cannot be done in
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human studies, and the lack of a more precise molecular mechanism is
therefore an unavoidable limitation of this study. It would be beneficial to
ascertain a more precise molecular mechanism for the diminished Akt
activity seen in our SA cohort, and this would perhaps allow us to dissect the
contribution of insulin resistance from ethnicity, or indeed other factors on the
observed SA LEPC dysfunction. If a more detailed molecular mechanism
were known, signalling pathways might be modulated in a more subtle way
than the method that we have employed, and so there may be more potential
for human translation. Potential avenues for future exploration will be
discussed later, and we have also gone on to utilise an animal model to
probe the effects of insulin resistance on vascular regeneration in more
general terms, but issues with human studies that I have outlined cannot be
overcome.
7.3.6 Animal model of insulin resistance
As with all animal models, our murine model of insulin resistance has certain
limitations, and caution should be exercised when extrapolating the findings
to the setting of human insulin resistant syndromes. Insulin resistance seen
in human disease is complex and is acquired via modification of insulin
signalling pathways at multiple levels. This occurs due to the effects of
several co-existing pathological factors, such as hyperglycaemia, lipotoxicity
and inflammation. The murine model used in this project, the IRKO mouse,
has haploinsufficiency of the insulin receptor and thus rendered insulin
resistant. The manner by which insulin resistance is created is not
necessarily analogous to the processes that result in insulin resistance seen
187
in human disease. However, this model also has advantages, we have
demonstrated that it recapitulates ‘prediabetic’ vascular dysfunction [154],
and for this project, the ability to separate the effects of systemic insulin
resistance from hyperglycaemia and observe the impact this has on vascular
regeneration, is important.
7.3.7 Limitations of methods employed
The murine hindlimb ischaemia model is a widely used assay to assess
vascular regeneration. It has benefits and allows the study of arteriogenesis
and collateral recruitment in proximal muscle groups as well as angiogenesis
in distal muscle groups. With the development of laser Doppler imaging it
also allows for the collection of a complete data set over a period of weeks
from one mouse, removing the need for sacrifice at different time points to
allow analysis. One limitation of this assay is the acute nature of ischaemia
induction. Peripheral vascular disease usually progresses chronically in
humans, which allows for the development of collaterals. When assessing
therapies have we have done with SA LEPCs it is important to bear in mind
that the pathological processes resulting in ischaemia are very different.
Although the data obtained from our studies of hindlimb ischaemia are
interesting, it would perhaps be more compelling if other in vivo methods to
assess vascular regeneration and angiogenesis were also utilised. Many
other assays exist and some of these will be discussed in the future plans
section.
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Again, as with most, if not all, of the methods employed during scientific
study, there are limitations in the in vitro assays used to determine the
impact of insulin resistance on angiogenesis. It is important not to take the
results of these in vitro assays in isolation and our data compliment our in
vivo findings. When using cultured and expanded cells, such as PECs, it is
possible that the cellular phenotype could be altered by such processes.
Furthermore, angiogenesis is a complex process requiring the coordinated
function of many different cell types. The tube forming assay used in this
thesis is an assay that highlights these shortcomings. This assay uses one
cell type that is expanded ex vivo and assesses angiogenesis in 2
dimensions only. The limitations of this assay are mitigated in our dataset by
the use of another assay, the aortic ring sprouting assay. This assay allows
the observation of angiogenesis in 3 dimensions, with a mixed cell
population, that have not been expanded ex vivo. Using a number of in vitro
methods to complement our in vivo findings results in a more robust dataset.
Just as with aspects of the data obtained during our SA LEPC studies, the
use of a relatively small sample size in some of the experiments with the
IRKO leads to certain limitations. The scratch wound assay and the
proliferation assay, both of which used PECs from IRKO and WT mice, are
affected by this factor. For example, we found no difference between IRKO
and WT PECs when investigating migration in the scratch wound assay. This
experiment was done using cells from 4 IRKO mice and 3 WT mice. The
findings were almost identical but it is not possible to categorically state that
there is no difference and in order to be entirely confident in this a bigger
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sample would be necessary. This project was subject to time and resource
constraint and it is our opinion that it was more productive to investigate a
larger range of processes rather than focussing time and resources on fewer
experiments, this allowed the observation of a wider range of processes. The
same issue applies to our observation of proliferative capacity in the IRKO
and WT PECs. In order to firmly state that a reduction in endothelial cell
proliferative capacity is not contributing to the phenotype observed in the
IRKO mice a more extensive assessment is probably required. Again, the
sample size is relatively small, and the fraction of proliferating cells that was
observed was surprisingly low in PECs from both the IRKO and WT mice.
Investigation of proliferation at earlier passage, using different stimuli, and
alternative methodologies would therefore be desirable, and this will be
discussed further in the future studies section.
7.4 Future plans
7.4.1 Further work in SA LEPC
As outlined, the manipulation of Akt raises safety concerns when considering
use in humans. Contributors to this concern are the potential negative impact
of chronic Akt activation and potential for oncogenesis. It is for this reason
that future work could be directed to more accurately define the mechanistic
basis for reduced Akt signalling in SA LEPCs. If this were better understood,
there is potential to modulate Akt signalling in a more subtle fashion,
therefore tempering some of the safety concerns raised during discussions
within this thesis. Previous work from our lab has highlighted that although
there was a significant reduction in the level of Akt protein in SA LEPCs
compared with WE LEPCs, mRNA levels of Akt1 were similar, implicating
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translational or post-translational issues in our observations [156]. A possible
explanation for this finding is that Akt is more rapidly degraded in the SA
cells. The regulation of Akt activity and stability involves many complex
signalling pathways [246]. To investigate if and how Akt stability is altered in
SA LEPCs compared with WE LEPCs, it would be necessary to identify any
differences in the levels of molecules that are known to regulate Akt
degradation. There is an exhaustive list of signalling intermediaries that can
affect the stability of Akt. Our strategy for investigating this would be to
evaluate for levels of key mediators of Akt stability, for example, Pin1; a
protein that has been shown to protect Akt from degradation [247]. This
could be quantified by western blotting. Another process known to regulate
protein activity, including kinases such as Akt, is the reversible acetylation
and deacetylation of lysine residues by histone acetyltransferases and
histone deacetylases, respectively [248]. Acetylation of the pleckstrin
homology domain of Akt has been shown to reduce its activity, and
conversely deacetylation by SIRT1 has been shown to increase its activity by
allowing the binding of PIP3 and subsequent membrane localisation, a critical
step in Akt activation [249]. Interestingly, unpublished, pilot work from our
laboratory suggests that reduced levels of the histone deacetylase, SIRT1,
may be a factor in SA LEPC dysfunction. Future work would aim to robustly
quantify SIRT1 levels in SA LEPC with PCR and/or western blotting. If a
decrease in SIRT1 was confirmed in SA LEPC, treatment of cells to increase
SIRT1 could be trialled. One such substance, capable of increasing SIRT1
activity is Resveratrol, a naturally occurring phenol, found in the skin of red
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grapes and other fruits [250]. Manipulation of cells in this manner may carry
with it less safety concern. Currently, however, this is of course speculative.
7.4.2 Further work in the IRKO mouse
Further work to define the role of insulin resistance on vascular regeneration
and angiogenesis is planned. Additional in vivo experiments will be
conducted in IRKO and WT mice. Another in vivo model that will be
developed is the retinal angiogenesis model. This assay, involves the
dissection of mouse pup retinas, and takes advantage of the fact that
vascularisation of the mouse retina occurs post-natally. Further in vivo data
will advance and add strength to our current observations. The retinal
angiogenesis model allows the observation of development angiogenesis, as
opposed to pathological angiogenesis seen in hind limb ischaemia studies. It
also allows the visualisation of neovascularisation in a single plane. This has
advantages with regards to our experimental needs. This assay will allow a
more in depth interrogation of angiogenesis, such as, the observation of
differences in vessel branching, filopodia formation and the recruitment of
mural cells. All these processes are critical to normal angiogenesis, and
although we have established that vascular regeneration is impaired in the
IRKO, with the hindlimb ischaemia data, we cannot comment on these
aforementioned processes. Potentially, responsible mechanisms for the
reduced vascular regeneration observed could include, for example,
abnormalities in mural cell function. This is, of course, speculative but this is
an example of processes that the retinal angiogenesis model can help to
define.
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Other work that would strengthen our current in vivo data would be done to
increase sample size in the scratch wound experiments and the proliferation
experiments. The proliferation experiments will also be carried out at various
time points to be sure that there is no difference in the proliferative state of
endothelial cells from the IRKO mouse compared with WT. It is important to
note that scratch wound experiments were carried out in complete growth
medium. All our functional observations in the PECs from the IRKO have
been made in the context of VEGF exposure. The scratch wound
experiments will be repeated in a similar environment, i.e. in media
containing VEGF only, rather than an array of other growth factors.
We have some interesting preliminary data from western blots but before firm
conclusions can be drawn there is a clear need to increase the numbers of
samples in which these studies are done. We will also look at other proteins,
specifically, total levels of Akt, eNOS, ERK and levels of phospho ERK.
These molecules however, represent a tiny fraction of the potential molecular
candidates responsible for our findings. A method that could be employed to
‘screen’ for candidate molecules of importance is phosphoproteomic
analysis. This method allows the analysis of the entire complement of
phosphorylated proteins within a cell. Therefore, if analysis is carried out
before and after stimulation with a growth factor, in our case VEGF, it may
facilitate the identification of proteins important in relevant signalling
pathways, and that are therefore worthy of further investigation. Ultimately, it
is hoped, that elucidation of an underlying mechanism will yield targets by
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which, we can attempt to reverse the vascular impairment we have seen in
the insulin resistant setting.
Another interesting issue to address is the role that the endothelium has in
the phenotype that we have observed. This could be investigated with the
use of murine models with insulin resistance confined to the endothelium, for
example, using mice haploinsufficient for the insulin receptor in the
endothelium. Indeed work by Kondo et al, involving the study of this mice
with endothelial holoinsufficiency of the insulin receptor (VENIRKO), has
already been discussed in this thesis [157]. This work has demonstrated that
absolute endothelial insulin resistance impacts retinal neovascularisation in a
relative hyperoxia model, a model used to mimic retinopathy of prematurity.
Another murine model with endothelial insulin resistance can be generated
by expressing Thr1134 mutant human insulin receptors, under the control of
the Tie2 promoter/enhancer. This results in the generation of endothelial
specific mutant insulin receptor over expression (ESMIRO) mice [251]. The
ESMIRO mouse has already been studied by our group and therefore for
practical reasons this model is more likely to be used than the VENIRKO
model. Repeating the experiments outlined in this thesis in the ESMIRO
mouse will help to define the role of the endothelium. The systemically insulin
resistant model that we have employed is more analogous to insulin
resistance that is seen in human disease, but it does not separate, for
example, the effects of hepatic insulin resistance from vascular insulin
resistance on vascular regeneration. Another method of assessing the
impact of the endothelium would be to restore insulin sensitivity specifically in
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the endothelium. This could be achieved by crossing IRKO mice with mice
that over express the insulin receptor in the endothelium, the human insulin
receptor endothelial cell over expressing (HIRECO) mouse to create mice
that are resistant to insulin systemically but sensitive to its effects in the
endothelium (IRKO x HIRECO).
7.5 Study implications
As outlined at the outset of this thesis, diabetes and pre-diabetic, insulin
resistant states, are responsible for significant morbidity and mortality
worldwide. Whilst it is not possible to directly translate the findings of this
thesis to the clinical setting, our data is the first to demonstrate LEPC
dysfunction in samples derived from a group at high risk of diabetes and
cardiovascular disease. Furthermore, our data is the first to demonstrate a
critical proof of principle – restoration of the function of these cells ex vivo,
resulting in increased efficacy when transfused into mice as a cell therapy.
There are significant steps to be taken before similar steps are taken in
humans, but nevertheless our findings are important and have the potential
to indirectly impact many patients in the future. Our data demonstrating that
insulin resistance negatively impacts vascular regeneration is also novel.
This fundamental observation is far from being translated into the clinical
arena and directly impacting patient care. It does, however, open an
interesting avenue of investigation that could ultimately lead to the
identification of novel therapeutics. This novel finding, therefore, has the
potential to impact a very large number of patients that experience pre-
diabetes, diabetes and vascular disease.
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7.6 Concluding remarks
At the outset of this project, our initial aim was to assess the capacity of
LEPCs from SA donors to augment vascular regeneration. We have
presented data, confirming that we have met this aim. LEPCs derived from
SA donors do not augment vascular regeneration in the same manner that
those derived from WE donors do. Furthermore we have implicated deficient
Akt signalling in this dysfunction; increasing Akt activity in SA LEPCs
rescued their angiogenic function. This improved function has been
demonstrated with an array of in vivo and in vitro studies. Further in vitro
studies have shown that this improved function with increased Akt activity
may be an NO mediated phenomenon. Interestingly, the dysfunction
exhibited by SA LEPCs was recreated in WE LEPCs by diminishing Akt
expression using siRNA, strengthening the negative association between
impaired Akt signalling and LEPC dysfunction.
Our SA cohort was relatively insulin resistant, an interesting finding, as
insulin resistance is thought to be a key factor underlying the increased
cardiovascular risk seen in this population. Perturbations in the PI3K/Akt
signalling node are also thought to be central to the pathogenesis of insulin
resistance. However, beyond making these observations, it is not possible to
further attribute the SA LEPC dysfunction we have demonstrated to insulin
resistance or to separate the impact of insulin resistance from ethnicity.
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We have gone on to demonstrate, however, that insulin resistance per se
does negatively impact vascular regeneration. We have presented data from
an array of in vivo and in vitro experiments to support this conclusion. Insulin
resistant IRKO mice have impaired limb reperfusion following critical limb
ischaemia, compared with their WT littermates. This is associated with
defective angiogenesis; capillary density was reduced in ischaemic muscle
from the IRKO compared with WT. Moreover, we have demonstrated
impaired in vitro angiogenesis and impaired functional responses to VEGF,
such as, impaired migration. Mechanistically we have data to support a
potential role for VEGF resistance; this is supported by PCR data from
ischaemic muscle demonstrating increased VEGF expression in samples
from the IRKO, which had not translated into superior perfusion or capillary
density compared with the WT. Further support is provided by preliminary
data from western blot studies that suggest impaired Akt and eNOS
phosphorylation in response to VEGF exposure in IRKO PECs.
A critical point to be highlighted from this thesis is that, to our knowledge, our
data is the first to demonstrate that ex vivo manipulation of LEPCs, taken
from a group at high risk of CVD, can restore their function when used as a
cell based therapy. This is an important proof of principle, as manipulation of
cells prior to administration as a therapeutic tool, is likely to be necessary if
cell based techniques for CVD are to enter the clinical arena in the future.
This thesis also presents novel insight into the effects of insulin resistance on
vascular regeneration. Although there is work to be done before these
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findings are of direct benefit to patients with insulin resistant syndromes, our
findings along with future research will help lead to the identification of
therapeutic targets that could eventually aid many patients worldwide.
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